1
|
Lyu SQ, Yang L, Chen L. [The application of artificial intelligence in prehospital treatment of spinal cord trauma]. Zhonghua Yi Xue Za Zhi 2024; 104:991-995. [PMID: 38561294 DOI: 10.3760/cma.j.cn112137-20230906-00406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
The spinal cord trauma induced by production and accidents in the current society has the characteristics of complicated injuries and difficult treatment, which is an important cause of death and disability of the wounded. With the development of computer technology, artificial intelligence (AI) has been widely used in the field of trauma treatment. The application of AI to assist pre-hospital rescue personnel in rapid and accurate identification and emergency treatment of fatal concomitant injuries, the examination of spinal cord function, spinal stabilization, the transport and evacuation of wounded, and supportive treatment can improve the efficiency of spinal cord trauma treatment and reduce the rate of death and disability.
Collapse
Affiliation(s)
- S Q Lyu
- Department of Neurosurgery, Xinqiao Hospital of Army Medical University, Chongqing 400037,China
| | - L Yang
- Department of Neurosurgery, Xinqiao Hospital of Army Medical University, Chongqing 400037,China
| | - L Chen
- Department of Neurosurgery, People's Liberation Army General Hospital, Beijing 100853,China
| |
Collapse
|
2
|
Wang SX, Zheng XZ, Yang L. [The indication of renal biopsy and novel understanding of pathological manifestations in multiple myeloma-related renal]. Zhonghua Nei Ke Za Zhi 2024; 63:337-342. [PMID: 38561278 DOI: 10.3760/cma.j.cn112138-20240129-00080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Affiliation(s)
- S X Wang
- Renal Division, Peking University First Hospital, Renal Pathological Center, Institute of Nephrology, Peking University, Beijing 100034, China Laboratory of Electron Microscopy, Peking University First Hospital, Beijing 100034, China
| | - X Z Zheng
- Renal Division, Peking University First Hospital, Renal Pathological Center, Institute of Nephrology, Peking University, Beijing 100034, China
| | - L Yang
- Renal Division, Peking University First Hospital, Renal Pathological Center, Institute of Nephrology, Peking University, Beijing 100034, China
| |
Collapse
|
3
|
Li J, Yang Y, Xia Y, Luo S, Lin J, Xiao Y, Li X, Huang G, Yang L, Xie Z, Zhou Z. Effect of SIRT1 gene single-nucleotide polymorphisms on susceptibility to type 1 diabetes in a Han Chinese population. J Endocrinol Invest 2024; 47:819-826. [PMID: 37695462 DOI: 10.1007/s40618-023-02190-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/08/2023] [Accepted: 08/25/2023] [Indexed: 09/12/2023]
Abstract
AIMS SIRT1 deficiency has been associated with diabetes, and a variant of the SIRT1 gene has been found to be involved in human autoimmune diabetes; however, it is unclear whether this genetic variation exists in Han Chinese with type 1 diabetes (T1D) and whether it contributes to development of T1D. Therefore, we aimed to explore the association of the SIRT1 gene single-nucleotide polymorphisms (SNPs) rs10997866 and rs3818292 in a Han Chinese population with T1D. METHODS This study recruited 2653 unrelated Han Chinese individuals, of whom 1289 had T1D and 1364 were healthy controls. Allelic and genotypic distributions of SIRT1 polymorphisms (rs10997866 and rs3818292) were determined by MassARRAY. Basic characteristics, genotype and allele frequencies of selected SNPs were compared between the T1D patients and healthy controls. Further genotype-phenotype association analysis of the SNPs was performed on the T1D patients divided into three groups according to genotype. Statistical analyses included the chi-square test, Mann‒Whitney U test, Kruskal‒Wallis H test and logistic regression. RESULTS The allelic (G vs. A) and genotypic (GA vs. AA) distributions of SIRT1 rs10997866 were significantly different in T1D patients and healthy controls (P = 0.039, P = 0.027), and rs10997866 was associated with T1D susceptibility under dominant, overdominant and additive models (P = 0.026, P = 0.030 and P = 0.027, respectively). Moreover, genotype-phenotype association analysis showed the GG genotype of rs10997866 and the GG genotype of rs3818292 to be associated with higher titers of IA-2A (P = 0.013 and P = 0.038, respectively). CONCLUSION SIRT1 rs10997866 is significantly associated with T1D susceptibility, with the minor allele G conferring a higher risk of T1D. Moreover, SIRT1 gene rs10997866 and rs3818292 correlate with the titer of IA-2A in Han Chinese individuals with T1D.
Collapse
Affiliation(s)
- J Li
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| | - Y Yang
- Department of Laboratory Medicine, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Y Xia
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| | - S Luo
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| | - J Lin
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| | - Y Xiao
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| | - X Li
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| | - G Huang
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| | - L Yang
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| | - Z Xie
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China.
| | - Z Zhou
- National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes, Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China
| |
Collapse
|
4
|
Wang Z, Yang L. Natural-product-based, Carrier-free, Noncovalent Nanoparticles for Tumor Chemo-photodynamic Combination Therapy. Pharmacol Res 2024; 203:107150. [PMID: 38521285 DOI: 10.1016/j.phrs.2024.107150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2024] [Revised: 02/22/2024] [Accepted: 03/20/2024] [Indexed: 03/25/2024]
Abstract
Cancer, with its diversity, heterogeneity, and complexity, is a significant contributor to global morbidity, disability, and mortality, highlighting the necessity for transformative treatment approaches. Photodynamic therapy (PDT) has aroused continuous interest as a viable alternative to conventional cancer treatments that encounter drug resistance. Nanotechnology has brought new advances in medicine and has shown great potential in drug delivery and cancer treatment. For precise and efficient therapeutic utilization of such a tumor therapeutic approach with high spatiotemporal selectivity and minimal invasiveness, the carrier-free noncovalent nanoparticles (NPs) based on chemo-photodynamic combination therapy is essential. Utilizing natural products as the foundation for nanodrug development offers unparalleled advantages, including exceptional pharmacological activity, easy functionalization/modification, and well biocompatibility. The natural-product-based, carrier-free, noncovalent NPs revealed excellent synergistic anticancer activity in comparison with free photosensitizers and free bioactive natural products, representing an alternative and favorable combination therapeutic avenue to improve therapeutic efficacy. Herein, a comprehensive summary of current strategies and representative application examples of carrier-free noncovalent NPs in the past decade based on natural products (such as paclitaxel, 10-hydroxycamptothecin, doxorubicin, etoposide, combretastatin A4, epigallocatechin gallate, and curcumin) for tumor chemo-photodynamic combination therapy. We highlight the insightful design and synthesis of the smart carrier-free NPs that aim to enhance PDT efficacy. Meanwhile, we discuss the future challenges and potential opportunities associated with these NPs to provide new enlightenment, spur innovative ideas, and facilitate PDT-mediated clinical transformation.
Collapse
Affiliation(s)
- Zhonglei Wang
- Key Laboratory of Green Natural Products and Pharmaceutical Intermediates in Colleges and Universities of Shandong Province, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu, 273165, P R China; School of Pharmaceutical Sciences, Key Laboratory of Bioorganic Phosphorus, Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, P R China
| | - Liyan Yang
- School of Physics and Physical Engineering, Qufu Normal University, Qufu, 273165, P R China; Beijing National Laboratory for Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
| |
Collapse
|
5
|
Yang L, Liu Y, Li X, Li M, Li W, Wang T, Wang D. Large-Scale, Stretchable, Self-Protective, and Multifunctional Perovskite Luminescent Filament with Ultra-High Stability. Adv Mater 2024:e2400919. [PMID: 38498901 DOI: 10.1002/adma.202400919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2024] [Revised: 03/14/2024] [Indexed: 03/20/2024]
Abstract
Lead halide perovskites possess great application potential in flexible displays and wearable optoelectronics owing to their prominent optoelectronic properties. However, the intrinsic instability upon moisture, heat, and ultraviolet (UV) light irradiation hinders their development and application. In this work, an ultra-stable CsPbX3 (X = Cl, Br, I) perovskite luminescent filament (PLF) with high stretchability (≈2400%) and luminescence performance (photoluminescence quantum yield (PLQY) of 24.5%, tunable emission spectrum, and high color purity) is introduced by a facile environmental-friendly wet-spinning technology via solvent extraction. Benefiting from the in situ encapsulation of the hydrophobic thermoplastic polyurethane (TPU) and the chelation of Lewis base CO in TPU with Lewis acid Pb2+, the CsPbBr3 PLF demonstrates ultra-high photoluminescence (PL) stability when stored in ambient air and high humidity circumstance, annealed at 50 °C, and dipped in water for 30 days, illuminated under ultraviolet light for 300 min, and immersed in organic solvents and solutions with pH of 1-13 for 5 min, respectively. Impressively, it retains 80% of its initial PL after being recycled five times. Overall, the CsPbX3 PLF demonstrates promising prospects in multifunctional applications, including organic dyes and tensile strain sensing, flexible pattern displays, secondary anti-counterfeiting, and hazard warning systems.
Collapse
Affiliation(s)
- Liyan Yang
- Key Laboratory of Textile Fiber and Products (Wuhan Textile University), Ministry of Education, Wuhan, 430200, China
| | - Yunpeng Liu
- Key Laboratory of Textile Fiber and Products (Wuhan Textile University), Ministry of Education, Wuhan, 430200, China
| | - Xiaofang Li
- Key Laboratory of Textile Fiber and Products (Wuhan Textile University), Ministry of Education, Wuhan, 430200, China
| | - Mufang Li
- Key Laboratory of Textile Fiber and Products (Wuhan Textile University), Ministry of Education, Wuhan, 430200, China
| | - Wei Li
- School of Materials Science and Engineering, Wuhan University of Technology, Wuhan, 430070, China
| | - Tao Wang
- School of Materials Science and Engineering, Wuhan University of Technology, Wuhan, 430070, China
| | - Dong Wang
- Key Laboratory of Textile Fiber and Products (Wuhan Textile University), Ministry of Education, Wuhan, 430200, China
| |
Collapse
|
6
|
Chen W, Yang L, Chi G, Zeng J. Ecosystem degradation or restoration? The evolving role of land use in China, 2000-2020. Environ Monit Assess 2024; 196:304. [PMID: 38403777 DOI: 10.1007/s10661-024-12464-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Accepted: 02/17/2024] [Indexed: 02/27/2024]
Abstract
Dramatic land use change in China affects ecosystem degradation and restoration. Identifying the evolving role of land use in ecosystem degradation and restoration in China is essential for sustainable land policy making. However, it is not clear how land use affects ecosystem degradation and restoration over time. Here, we used the revised benefit transfer approach and spatial statistics based on land use data to determine the evolving role that land use plays in ecosystem degradation and restoration in China during 2000-2020. The study results pointed out that the deterioration of the forestland ecosystem during the study period was the main reason for ecosystem degradation, while the conversion of arable land to forestland was the main cause for ecosystem restoration. Every 1% increase of land use intensity in the periods 2000-2005, 2005-2010, 2010-2015, and 2015-2020 resulted in -1.754%, 0.697%, 1.098%, and -0.058% of the changes in ecosystem services, respectively. This study provided important policy implications for future sustainable land use management in China.
Collapse
Affiliation(s)
- Wanxu Chen
- Hubei Key Laboratory of Regional Ecology and Environmental Change, School of Geography and Information Engineering, China University of Geosciences, Wuhan, 430074, China
- Institute of Geographic Sciences and Natural Resources Research, Chinese Academy of Sciences, Beijing, 100101, China
- Key Laboratory of Geospatial Technology for Middle and Lower Yellow River Regions, Henan University, Ministry of Education, Kaifeng, 475004, Henan, China
| | - Liyan Yang
- Hubei Key Laboratory of Regional Ecology and Environmental Change, School of Geography and Information Engineering, China University of Geosciences, Wuhan, 430074, China
| | - Guangqing Chi
- Department of Agricultural Economics, Sociology, and Education, Population Research Institute, and Social Science Research Institute, The Pennsylvania State University, 112E Armsby, University Park, State College, PA, 16802, USA
| | - Jie Zeng
- Hubei Key Laboratory of Regional Ecology and Environmental Change, School of Geography and Information Engineering, China University of Geosciences, Wuhan, 430074, China.
| |
Collapse
|
7
|
Zeng Z, Zhou MF, Lin YJ, Bi XY, Yang L, Deng W, Jiang TT, Hu LP, Xu MJ, Zhang L, Yi W, Li MH. [A real-world study on the features of postpartum hepatitis flares in pregnant women with chronic HBV infection]. Zhonghua Gan Zang Bing Za Zhi 2024; 32:113-118. [PMID: 38514259 DOI: 10.3760/cma.j.cn501113-20231122-00216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 03/23/2024]
Abstract
Objective: To analyze the clinical features of postpartum hepatitis flares in pregnant women with hepatitis B virus (HBV) infection. Methods: A retrospective study was conducted. Patients who met the enrollment criteria were included. Liver function and HBV virology tests were collected from pregnant women with chronic HBV infection at delivery, 6, 24, 36, and 48 weeks after delivery through the hospital information and test system. Additionally, antiviral therapy types and drug withdrawal times were collected. Statistical analysis was performed on all the resulting data. Results: A total of 533 pregnant women who met the inclusion criteria were included, with all patients aged (29.5±3.7) years old. A total of 408 cases received antiviral drugs during pregnancy to interrupt mother-to-child transmission. There was no significant difference in the levels of alanine aminotransferase (ALT, z = -1.981, P = 0.048), aspartate aminotransferase (AST, z = -3.956, P < 0.001), HBV load (z = -15.292, P < 0.001), and HBeAg (z = -4.77, P < 0.001) at delivery in patients who received medication and those who did not. All patients ALT, AST, total bilirubin, direct bilirubin, and albumin showed an upward trend within six weeks after delivery. A total of 231 cases developed hepatitis within 48 weeks after delivery. Among them, 173 cases first showed ALT abnormalities within six weeks postpartum. Conclusion: Hepatitis flare incidence peaked six weeks after delivery or six weeks after drug withdrawal in pregnant women with chronic HBV infection.
Collapse
Affiliation(s)
- Z Zeng
- Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing 100015, China
| | - M F Zhou
- Departmentof Obstetrics and Gynecology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - Y J Lin
- Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing 100015, China
| | - X Y Bi
- Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - L Yang
- Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - W Deng
- Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - T T Jiang
- Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - L P Hu
- Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - M J Xu
- Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - L Zhang
- Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - W Yi
- Departmentof Obstetrics and Gynecology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - M H Li
- Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing 100015, China Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| |
Collapse
|
8
|
Wang Y, Hu D, Liu Y, Yang L, Huang J, Zhou J, Guo L, Fan X, Huang X, Peng M, Cheng C, Zhang W, Feng R, Tian X, Yu S, Xu KF. Sporadic lymphangioleiomyomatosis in a man with somatic mosaicism of TSC2 mutations, a case report. QJM 2024; 117:75-76. [PMID: 37843443 PMCID: PMC10849871 DOI: 10.1093/qjmed/hcad235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2023] [Indexed: 10/17/2023] Open
Affiliation(s)
- Y Wang
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - D Hu
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Y Liu
- McKusick-Zhang Center for Genetic Medicine, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China
| | - L Yang
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - J Huang
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - J Zhou
- Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - L Guo
- Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Center, Beijing, China
| | - X Fan
- Clinical Genome Center, Guangzhou KingMed Diagnostics Group Co., Ltd., Guangdong, China
| | - X Huang
- Clinical Genome Center, Guangzhou KingMed Diagnostics Group Co., Ltd., Guangdong, China
| | - M Peng
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - C Cheng
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - W Zhang
- Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - R Feng
- Department of Pathology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - X Tian
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - S Yu
- Clinical Genome Center, Guangzhou KingMed Diagnostics Group Co., Ltd., Guangdong, China
| | - K -F Xu
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
9
|
Peng R, Tong Y, Yang M, Wang J, Yang L, Zhu J, Liu Y, Wang H, Shi Z, Liu Y. Global burden and inequality of maternal and neonatal disorders: based on data from the 2019 Global Burden of Disease study. QJM 2024; 117:24-37. [PMID: 37773990 PMCID: PMC10849872 DOI: 10.1093/qjmed/hcad220] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Revised: 09/04/2023] [Indexed: 10/01/2023] Open
Abstract
BACKGROUND Maternal and neonatal disorders account for substantial health loss across the lifespan from early childhood. These problems may be related to health inequality. AIM To provide evidence for improvement in health policies regarding maternal and neonatal disorder inequity. DESIGN This was a population-based cross-sectional study based on 2019 Global Burden of Disease data. METHODS Annual cases and age-standardized rates (ASRs) of incidence, prevalence, death, and disability-adjusted life-years (DALYs) in maternal and neonatal disorders between 1990 and 2019 were collected from the 2019 Global Burden of Disease study. Concentration curves and concentration indices were used to summarize the degree of socioeconomic-related inequality. RESULTS For maternal disorders, the global ASRs of incidence, prevalence, death and DALYs were 2889.4 (95% uncertainty interval (UI), 2562.9-3251.9), 502.9 (95% UI 418.7-598.0), 5.0 (95% UI 4.4-5.8) and 324.9 (95% UI 284.0-369.1) per 100 000 women in 2019, respectively. The ASRs of maternal disorders were all obviously reduced and remained pro-poor from 1990 to 2019. In neonatal disorders, the global ASRs of incidence, prevalence, death and DALYs were 363.3 (95% UI 334.6-396.8), 1239.8 (95% UI 1142.1-1356.7), 29.1 (95% UI 24.8-34.5) and 2828.3 (95% UI 2441.6-3329.6) per 100 000 people in 2019, respectively. The global ASRs of incidence, death and DALYs in neonatal disorders have remained pro-poor. However, the socioeconomic-related fairness in the ASR of neonatal disorder prevalence is being levelled. CONCLUSIONS The global burden of maternal and neonatal disorders has remained high, and socioeconomic-related inequality (pro-poor) tended not to change between 1990 and 2019.
Collapse
Affiliation(s)
- R Peng
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| | - Y Tong
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| | - M Yang
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| | - J Wang
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| | - L Yang
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| | - J Zhu
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| | - Yu Liu
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| | - H Wang
- Department of Pediatrics, West China Second University Hospital, Sichuan University, Sichuan, 610041, China
| | - Z Shi
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| | - Ya Liu
- Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, China
| |
Collapse
|
10
|
Yang L, Niu H, Zhang T, Cao Q, Liu M, Liu Y, Yan L, Qi W, Wang T, Liu C, Li L, Xing L, Wang H, Shao Z, Fu R. A nomogram model for predicting the efficacy of cyclosporine in patients with pure red cell aplasia. Ann Hematol 2024:10.1007/s00277-024-05636-9. [PMID: 38308019 DOI: 10.1007/s00277-024-05636-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Accepted: 01/19/2024] [Indexed: 02/04/2024]
Abstract
Pure red cell aplasia (PRCA) is a rare bone marrow disorder characterized by a severe reduction or absence of erythroid precursor cells, without affecting granulocytes and megakaryocytes. Immunosuppressive therapies, particularly cyclosporine, have demonstrated efficacy as a primary treatment. This study aims to develop a predictive model for assessing the efficacy of cyclosporine in acquired PRCA (aPRCA). This retrospective study encompasses newly treated aPRCA patients at the General Hospital of Tianjin Medical University. Diagnosis criteria include severe anemia, and absolute reticulocyte count below 10 × 109/L, with normal white blood cell and platelet counts, and a severe reduction in bone marrow erythroblasts. Cyclosporine therapy was administered, with dose adjustments based on blood concentration. Response to cyclosporine was evaluated according to established criteria. Statistical analysis involved logistic multi-factor regression, generating a predictive model. The study included 112 aPRCA patients with a median age of 63.5 years. Patients presented with severe anemia (median Hb, 56 g/L) and reduced reticulocyte levels. Eighty-six patients had no bone marrow nucleated erythroblasts. Primary PRCA accounted for 62 cases (55.4%), and secondary PRCA accounted for 50 cases (44.6%). Univariate analysis revealed that ferritin, platelet to lymphocyte ratio (PLR), and CD4/CD8 ratio influenced treatment response. Multivariate analysis further supported the predictive value of these factors. A prediction model was constructed using ferritin, PLR, and CD4/CD8 ratio, demonstrating high sensitivity and specificity. The ferritin, PLR, and CD4/CD8-based nomogram showed good predictive ability for aPRCA response to cyclosporine. This model has potential clinical value for individualized diagnosis and treatment of aPRCA patients.
Collapse
Affiliation(s)
- Liyan Yang
- Department of Hematology, General Hospital, Tianjin Medical University, No. 154 Anshandao Road, Heping District, Tianjin, 300052, China
| | - Haiyue Niu
- Department of Hematology, General Hospital, Tianjin Medical University, No. 154 Anshandao Road, Heping District, Tianjin, 300052, China
| | - Tian Zhang
- Department of Hematology, General Hospital, Tianjin Medical University, No. 154 Anshandao Road, Heping District, Tianjin, 300052, China
| | - Qiuying Cao
- Department of Hematology, General Hospital, Tianjin Medical University, No. 154 Anshandao Road, Heping District, Tianjin, 300052, China
| | - Mengyuan Liu
- Department of Hematology, General Hospital, Tianjin Medical University, No. 154 Anshandao Road, Heping District, Tianjin, 300052, China
| | - Yumei Liu
- Department of Hematology, General Hospital, Tianjin Medical University, No. 154 Anshandao Road, Heping District, Tianjin, 300052, China
| | - Li Yan
- Department of Hematology, General Hospital, Tianjin Medical University, No. 154 Anshandao Road, Heping District, Tianjin, 300052, China
| | - Weiwei Qi
- Department of Hematology, General Hospital, Tianjin Medical University, No. 154 Anshandao Road, Heping District, Tianjin, 300052, China
| | - Ting Wang
- Department of Hematology, General Hospital, Tianjin Medical University, No. 154 Anshandao Road, Heping District, Tianjin, 300052, China
| | - Chunyan Liu
- Department of Hematology, General Hospital, Tianjin Medical University, No. 154 Anshandao Road, Heping District, Tianjin, 300052, China
| | - Lijuan Li
- Department of Hematology, General Hospital, Tianjin Medical University, No. 154 Anshandao Road, Heping District, Tianjin, 300052, China
| | - Limin Xing
- Department of Hematology, General Hospital, Tianjin Medical University, No. 154 Anshandao Road, Heping District, Tianjin, 300052, China
| | - Huaquan Wang
- Department of Hematology, General Hospital, Tianjin Medical University, No. 154 Anshandao Road, Heping District, Tianjin, 300052, China.
| | - Zonghong Shao
- Department of Hematology, General Hospital, Tianjin Medical University, No. 154 Anshandao Road, Heping District, Tianjin, 300052, China.
| | - Rong Fu
- Department of Hematology, General Hospital, Tianjin Medical University, No. 154 Anshandao Road, Heping District, Tianjin, 300052, China.
| |
Collapse
|
11
|
He W, Yu W, Huang Y, Liao S, Zhang G, Wang Q, Li R, Yang L, Yao R, Zhang Z, Zhong B, Liu Y, Wang Q. [Effectiveness of comprehensive echinococcosis control measures with emphasis on management of infectious source in Sichuan Province from 2010 to 2022]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2024; 35:614-620. [PMID: 38413022 DOI: 10.16250/j.32.1374.2023116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/29/2024]
Abstract
OBJECTIVE To evaluate the effectiveness of comprehensive echinococcosis control measures with emphasis on management of infectious source in Sichuan Province from 2010 to 2022, so as to provide insights into formulation of future control interventions. METHODS Data pertaining to comprehensive echinococcosis control measures with emphasis on management of infectious source and echinococcosis surveillance in Sichuan Province from 2010 to 2022 were collected. The effectiveness of comprehensive echinococcosis control measures with emphasis on management of infectious source was evaluated with prevalence of human echinococcosis, detection of newly diagnosed echinococcosis patients, prevalence of Echinococcus infection in domestic dogs, prevalence of cystic echinococcosis in livestock, prevalence of alveolar echinococcosis in small mammals and awareness of echinococcosis control knowledge, and Spearman's rank correlation analysis. RESULTS The prevalence of human echinococcosis reduced from 1.08% in 2010 to 0.40% in 2022 in Sichuan Province (χ2 = 1 482.97, P < 0.05), with a reduction from 0.30% to 0.02% in the detection of newly diagnosed echinococcosis cases (χ2 = 2 776.41, P < 0.05), a reduction from 15.87% to 0.46% in the prevalence of Echinococcus infection in domestic dogs (χ2 = 20 823.96, P < 0.05), a reduction from 8.05% to 1.07% in the prevalence of cystic echinococcosis in livestock (χ2 = 1 296.02, P < 0.05), and the awareness of echinococcosis control knowledge increased from 50.65% to 95.24% (χ2 = 34 938.63, P < 0.05); in addition, there was a year-specific prevalence rate of alveolar echinococcosis in small mammals (χ2 = 164.07, P < 0.05). Spearman's rank correlation analysis revealed that the detection of newly diagnosed echinococcosis cases correlated positively with the prevalence of Echinococcus infections in domestic dogs (rs = 0.823, P < 0.05) and the prevalence of cystic echinococcosis in livestock (rs = 0.795, P < 0.05), and correlated negatively with the awareness of echinococcosis control knowledge (rs = - 0.918, P < 0.05), and the prevalence of Echinococcus infection in domestic dogs correlated positively with the prevalence of cystic echinococcosis in livestock (rs = 0.753, P < 0.05) and negatively with the awareness of echinococcosis control knowledge (rs = -0.747, P < 0.05); however, there was no correlation between the prevalence of Echinococcus infections in domestic dogs and the prevalence of alveolar echinococcosis in small mammals (rs = -0.750, P > 0.05). CONCLUSIONS The comprehensive echinococcosis control measures with emphasis on management of infectious source had achieved remarkable effectiveness in Sichuan Province; however, the transmission chain of echinococcosis has not been interrupted. Reinforced comprehensive echinococcosis control measures with emphasis on management of infectious source and sustained tracking evaluation of the effectiveness are recommended in Sichuan Province.
Collapse
Affiliation(s)
- W He
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - W Yu
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - Y Huang
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - S Liao
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - G Zhang
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - Q Wang
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - R Li
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - L Yang
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - R Yao
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - Z Zhang
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - B Zhong
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - Y Liu
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| | - Q Wang
- Institute of Parasitic Diseases, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan 610041, China
| |
Collapse
|
12
|
Chen J, Yang D, Zhang Y, Yang L, Wang Q, Jiang M, Pan L. A novel bi-functional cold-adaptive chitinase from Chitinilyticum aquatile CSC-1 for efficient synthesis of N-acetyl-D-glucosaminidase. Int J Biol Macromol 2024; 259:129063. [PMID: 38159710 DOI: 10.1016/j.ijbiomac.2023.129063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2023] [Revised: 12/21/2023] [Accepted: 12/25/2023] [Indexed: 01/03/2024]
Abstract
In order to better utilize chitinolytic enzymes to produce high-value N-acetyl-D-glucosamine (GlcNAc) from chitinous waste, there is an urgent need to explore bi-functional chitinases with exceptional properties of temperature, pH and metal tolerance. In this study, we cloned and characterized a novel bi-functional cold-adaptive chitinase called CaChi18A from a newly isolated strain, Chitinilyticum aquatile CSC-1, in Bama longevity village of Guangxi Province, China. The activity of CaChi18A at 50 °C was 4.07 U/mg. However, it exhibited significant catalytic activity even at 5 °C. Its truncated variant CaChi18A_ΔChBDs, containing only catalytic domain, demonstrated significant activity levels, exceeding 40 %, over a temperature range of 5-60 °C and a pH range of 3 to 10. It was noteworthy that it displayed tolerance towards most metal ions at a final concentration of 0.1 mM, including Fe3+ and Cu2+ ions, retaining 122.52 ± 0.17 % and 116.42 ± 1.52 % activity, respectively. Additionally, it exhibited favorable tolerance towards organic solvents with the exception of formic acid. Interestedly, CaChi18A and CaChi18A_ΔChBDs had a low Km value towards colloidal chitin (CC), 0.94 mg mL-1 and 2.13 mg mL-1, respectively. Both enzymes exhibited chitobiosidase and N-acetyl-D-glucosaminidase activities, producing GlcNAc as the primary product when hydrolyzing CC. The high activities across a broader temperature and pH range, strong environmental adaptability, and hydrolytic properties of CaChi18A_ΔChBDs suggested that it could be a promising candidate for GlcNAc production.
Collapse
Affiliation(s)
- Jianrong Chen
- National Key Laboratory of Non-food Biomass Energy Technology, Guangxi Key Laboratory of Marine Natural Products and Combinatorial Biosynthesis Chemistry, Institute of Biology, Guangxi Academy of Sciences, Nanning 530007, China; College of Life Science and Technology, Guangxi University, Nanning 530004, Guangxi, China
| | - Dengfeng Yang
- National Key Laboratory of Non-food Biomass Energy Technology, Guangxi Key Laboratory of Marine Natural Products and Combinatorial Biosynthesis Chemistry, Institute of Biology, Guangxi Academy of Sciences, Nanning 530007, China
| | - Yunkai Zhang
- College of Life Science and Technology, Guangxi University, Nanning 530004, Guangxi, China
| | - Liyan Yang
- National Key Laboratory of Non-food Biomass Energy Technology, Guangxi Key Laboratory of Marine Natural Products and Combinatorial Biosynthesis Chemistry, Institute of Biology, Guangxi Academy of Sciences, Nanning 530007, China
| | - Qingyan Wang
- National Key Laboratory of Non-food Biomass Energy Technology, Guangxi Key Laboratory of Marine Natural Products and Combinatorial Biosynthesis Chemistry, Institute of Biology, Guangxi Academy of Sciences, Nanning 530007, China
| | - Mingguo Jiang
- Guangxi Key Laboratory for Polysaccharide Materials and Modifications, School of Marine Sciences and Biotechnology, Guangxi Minzu University, Nanning 530008, China
| | - Lixia Pan
- National Key Laboratory of Non-food Biomass Energy Technology, Guangxi Key Laboratory of Marine Natural Products and Combinatorial Biosynthesis Chemistry, Institute of Biology, Guangxi Academy of Sciences, Nanning 530007, China; College of Food and Quality Engineering, Nanning University, Nanning 530200, China.
| |
Collapse
|
13
|
Yang L, Tao W, Xie C, Chen Q, Zhao Y, Zhang L, Xiao X, Wang S, Zheng X. Interleukin-37 ameliorates periodontitis development by inhibiting NLRP3 inflammasome activation and modulating M1/M2 macrophage polarization. J Periodontal Res 2024; 59:128-139. [PMID: 37947055 DOI: 10.1111/jre.13196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 09/04/2023] [Accepted: 10/12/2023] [Indexed: 11/12/2023]
Abstract
OBJECTIVE Our study was designed to explore the role of IL-37 in M1/M2 macrophage polarization imbalance in the pathogenesis of periodontitis. BACKGROUND Periodontitis is a chronic progressive inflammatory disease featured by gingival inflammation and alveolar bone resorption. Recent research has revealed that regulating macrophage polarization is a viable method to ameliorate periodontal inflammation. IL-37 is an anti-inflammatory cytokine, which has been reported to inhibit innate and adaptive immunity. METHODS For in vitro experiment, mouse macrophage RAW264.7 cells were pretreated with 0.1 ng/mL recombinant human IL-37. M1 and M2 polarizations of RAW264.7 cells were induced by 100 ng/mL LPS and 20 ng/mL IL-4, respectively. The expression of M1 (iNOS, TNF-α, and IL-6) and M2 (CD206, Arg1, and IL-10) phenotype markers in RAW264.7 cells was detected by RT-qPCR, western blotting, and immunofluorescence staining. For in vivo experiment, experimental periodontitis mouse models were established by sterile silk ligation (5-0) around the bilateral maxillary second molar of mice for 1 week. H&E staining of the maxillary alveolar bone was used to show the resorption of root cementum and dentin. Alveolar bone loss in mouse models was evaluated through micro-CT analysis. The expression of iNOS and CD206 in gingival tissues was assessed by immunohistochemistry staining. NLRP3 inflammasome activation was confirmed by western blotting. RESULTS IL-37 pretreatment reduced iNOS, TNF-α, and IL-6 expression in LPS-treated RAW264.7 cells but increased CD206, Arg1, and IL-10 in IL-4-treated RAW264.7 cells. LPS-induced upregulation in NLRP3, GSDMD, cleaved-IL-1β, and cleaved-caspase-1 expression was antagonized by IL-37 treatment. In addition, IL-37 administration ameliorated the resorption of root cementum and dentin in periodontitis mouse models. IL-37 prominently decreased iNOS+ cell population but increased CD206+ cell population in gingival tissues of periodontitis mice. The enhancement in NLRP3, GSDMD, cleaved-IL-1β, and cleaved-caspase-1 expression in the gingival tissues of periodontitis mice was offset by IL-37 administration. CONCLUSION IL-37 prevents the progression of periodontitis by suppressing NLRP3 inflammasome activation and mediating M1/M2 macrophage polarization.
Collapse
Affiliation(s)
- Liyan Yang
- Department of Stomatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China
| | - Wei Tao
- Department of Stomatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China
| | - Chen Xie
- School of Stomatology, Hainan Medical University, Haikou, China
| | - Qiuye Chen
- Department of Stomatology, Hainan Cancer Hospital, Haikou, China
| | - Yunshan Zhao
- Integrated Department, Hainan Stomatological Hospital, Haikou, China
| | - Li Zhang
- School of Stomatology, Hainan Medical University, Haikou, China
| | - Xu Xiao
- Department of Stomatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China
| | - Shilu Wang
- Department of Anesthesiology, The First Affiliated Hospital of Hainan Medical University, Haikou, China
| | - Xu Zheng
- Department of Stomatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China
- School of Stomatology, Hainan Medical University, Haikou, China
| |
Collapse
|
14
|
Yan XQ, Ye MJ, Zou Q, Chen P, He ZS, Wu B, He DL, He CH, Xue XY, Ji ZG, Chen H, Zhang S, Liu YP, Zhang XD, Fu C, Xu DF, Qiu MX, Lv JJ, Huang J, Ren XB, Cheng Y, Qin WJ, Zhang X, Zhou FJ, Ma LL, Guo JM, Ding DG, Wei SZ, He Y, Guo HQ, Shi BK, Liu L, Liu F, Hu ZQ, Jin XM, Yang L, Zhu SX, Liu JH, Huang YH, Xu T, Liu B, Sun T, Wang ZJ, Jiang HW, Yu DX, Zhou AP, Jiang J, Luan GD, Jin CL, Xu J, Hu JX, Huang YR, Guo J, Zhai W, Sheng XN. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Ann Oncol 2024; 35:190-199. [PMID: 37872020 DOI: 10.1016/j.annonc.2023.09.3108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2023] [Revised: 09/21/2023] [Accepted: 09/21/2023] [Indexed: 10/25/2023] Open
Abstract
BACKGROUND Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors are standard treatments for advanced clear cell renal cell carcinoma (RCC). This phase III RENOTORCH study compared the efficacy and safety of toripalimab plus axitinib versus sunitinib for the first-line treatment of patients with intermediate-/poor-risk advanced RCC. PATIENTS AND METHODS Patients with intermediate-/poor-risk unresectable or metastatic RCC were randomized in a ratio of 1 : 1 to receive toripalimab (240 mg intravenously once every 3 weeks) plus axitinib (5 mg orally twice daily) or sunitinib [50 mg orally once daily for 4 weeks (6-week cycle) or 2 weeks (3-week cycle)]. The primary endpoint was progression-free survival (PFS) assessed by an independent review committee (IRC). The secondary endpoints were investigator-assessed PFS, overall response rate (ORR), overall survival (OS), and safety. RESULTS A total of 421 patients were randomized to receive toripalimab plus axitinib (n = 210) or sunitinib (n = 211). With a median follow-up of 14.6 months, toripalimab plus axitinib significantly reduced the risk of disease progression or death by 35% compared with sunitinib as assessed by an IRC [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.49-0.86; P = 0.0028]. The median PFS was 18.0 months in the toripalimab-axitinib group, whereas it was 9.8 months in the sunitinib group. The IRC-assessed ORR was significantly higher in the toripalimab-axitinib group compared with the sunitinib group (56.7% versus 30.8%; P < 0.0001). An OS trend favoring toripalimab plus axitinib was also observed (HR 0.61, 95% CI 0.40-0.92). Treatment-related grade ≥3 adverse events occurred in 61.5% of patients in the toripalimab-axitinib group and 58.6% of patients in the sunitinib group. CONCLUSION In patients with previously untreated intermediate-/poor-risk advanced RCC, toripalimab plus axitinib provided significantly longer PFS and higher ORR than sunitinib and had a manageable safety profile TRIAL REGISTRATION: ClinicalTrials.gov NCT04394975.
Collapse
Affiliation(s)
- X Q Yan
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing
| | - M J Ye
- Department of Urology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha
| | - Q Zou
- Department of Urology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University, Nanjing
| | - P Chen
- Department of Urology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi
| | - Z S He
- Department of Urology, First Hospital of Peking University, Beijing
| | - B Wu
- Department of Urology, Shengjing Hospital of China Medical University, Shenyang
| | - D L He
- Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
| | - C H He
- Department of Urology, Cancer Hospital of Henan Province, Zhengzhou
| | - X Y Xue
- Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou
| | - Z G Ji
- Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
| | - H Chen
- Department of Urology, Harbin Medical University Cancer Hospital, Harbin
| | - S Zhang
- Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu
| | - Y P Liu
- Department of Oncology, The First Hospital of China Medical University, Shenyang
| | - X D Zhang
- Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing
| | - C Fu
- Department of Urology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang
| | - D F Xu
- Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai
| | - M X Qiu
- Department of Urology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu
| | - J J Lv
- Department of Urology, Provincial Hospital Affiliated to Shandong First Medical University, Jinan
| | - J Huang
- Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
| | - X B Ren
- Department of Immunology and Biotherapy, Cancer Institute & Hospital, Tianjin Medical University, Tianjin
| | - Y Cheng
- Department of Medical Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun
| | - W J Qin
- Department of Urology, Xijing Hospital of Air Force Military Medical University, Xi'an
| | - X Zhang
- Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing
| | - F J Zhou
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
| | - L L Ma
- Department of Urology, Peking University Third Hospital, Beijing
| | - J M Guo
- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai
| | - D G Ding
- Department of Urology, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou
| | - S Z Wei
- Department of Urology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
| | - Y He
- Department of Urology, The Affiliated Hospital of Jiaxing University, Jiaxing
| | - H Q Guo
- Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing
| | - B K Shi
- Department of Urology, Qilu Hospital of Shandong University, Jinan
| | - L Liu
- Department of Urology, Qilu Hospital of Shandong University, Jinan
| | - F Liu
- Department of Urology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou
| | - Z Q Hu
- Department of Urology, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan
| | - X M Jin
- Department of Oncology, General Hospital of Ningxia Medical University, Yinchuan
| | - L Yang
- Department of Urology, The Second Hospital of Lanzhou University, Lanzhou
| | - S X Zhu
- Department of Urology, Fujian Medical University Union Hospital, Fuzhou
| | - J H Liu
- Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming
| | - Y H Huang
- Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou
| | - T Xu
- Department of Urology, Peking University People's Hospital, Beijing
| | - B Liu
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
| | - T Sun
- Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang
| | - Z J Wang
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing
| | - H W Jiang
- Department of Urology, Huashan Hospital, Fudan University, Shanghai
| | - D X Yu
- Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei
| | - A P Zhou
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
| | - J Jiang
- Department of Urology, The PLA General Hospital Army Characteristic Medical Center, Chongqing
| | - G D Luan
- Shanghai Junshi Biosciences Co., Ltd., Shanghai
| | - C L Jin
- Shanghai Junshi Biosciences Co., Ltd., Shanghai
| | - J Xu
- Shanghai Junshi Biosciences Co., Ltd., Shanghai
| | - J X Hu
- Shanghai Junshi Biosciences Co., Ltd., Shanghai
| | - Y R Huang
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - J Guo
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing
| | - W Zhai
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
| | - X N Sheng
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing.
| |
Collapse
|
15
|
Yang F, Yang L, Ning X, Liu J, Wang J. Effect of dry eye on the reliability of keratometry for cataract surgery planning. J Fr Ophtalmol 2024; 47:103999. [PMID: 37919153 DOI: 10.1016/j.jfo.2023.04.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Revised: 04/04/2023] [Accepted: 04/05/2023] [Indexed: 11/04/2023]
Abstract
PURPOSE This study aimed to evaluate the effects of dry eye on the reproducibility of keratometry (K) measurements in patients presenting for cataract surgery. METHODS A non-randomized controlled clinical study was performed. Eighty-three eyes of eighty-three patients with cataracts who were enrolled in our hospital from March 2020 to July 2020 were studied. The mean non-invasive tear film break-up time (NIBUT), corneal fluorescein staining score, and ocular surface disease (OSD) SPEED II questionnaire were measured and recorded prior to surgery, and the patients were assigned to a "dry eye" group (n=35) or a "non-dry eye" group (n=48). The K of the patients was measured twice by a Tomey OA-2000 (an average of three times each). The difference of the mean K (ΔKm) and astigmatism vector (ΔKvector) between the two measurements was calculated. The ΔKm and ΔKvector between the two groups were compared. The relationship between the measurement parameters of dry eyes and the accuracy of the preoperative K values was analyzed. RESULTS ΔKm was 0.09 D [0.03; 0.19] in the non-dry eye control group and 0.28 D [0.18; 0.50] in the dry eye group, with a statistical difference between the two groups (P=0.005). The ΔKvector of the non-dry eye control group was 0.22 D [0.14; 0.42], and that of the dry eye group was 0.50 D [0.28; 1.06]. There was a significant difference between the two groups (P=0.010). Between the two groups, the percentage of the ΔKm and ΔKvector values greater than 0.5 D were statistically different (P<0.05). There was no significant difference in ΔKm between the groups with NIBUT>5s and NIBUT≤5s (P=0.537). There was no significant difference in ΔKm between groups≥2 and<2 on the OSD SPEED II questionnaire scores (P=0.442). CONCLUSION Dry eye can affect the reliability of keratometry measurements before cataract surgery, thereby affecting the accuracy of intraocular lens power calculations. In cataract surgery planning, it is necessary to detect subjective and objective indicators of dry eye in patients and carry out effective intervention so as to avoid refractive errors caused by inaccurate keratometry measurements.
Collapse
Affiliation(s)
- F Yang
- Affiliated to Shanxi Medical University, Shanxi Eye Hospital, 030002 Taiyuan, China.
| | - L Yang
- Changzhi Aier Eye Hospital, Department of ophthalmology, 046000 Changzhi, China
| | - X Ning
- Affiliated to Shanxi Medical University, Shanxi Eye Hospital, 030002 Taiyuan, China
| | - J Liu
- Affiliated to Shanxi Medical University, Shanxi Eye Hospital, 030002 Taiyuan, China
| | - J Wang
- Affiliated to Shanxi Medical University, Shanxi Eye Hospital, 030002 Taiyuan, China
| |
Collapse
|
16
|
Liao XY, Bao YG, Liu ZH, Yang L, Qiu S, Liu LR, Han P, Wei Q. [Functional outcomes of robot-assisted radical prostatectomy with preservation of pelvic stabilized structure and early elevated retrograde liberation of neurovascular bundle]. Zhonghua Wai Ke Za Zhi 2024; 62:128-134. [PMID: 38310380 DOI: 10.3760/cma.j.cn112139-20230718-00014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/05/2024]
Abstract
Objectives: To examine the functional outcomes of robot-assisted radical prostatectomy (RARP) with preservation of pelvic floor stabilized structure and early elevated retrograde liberation of the neurovascular bundle (PEEL). Methods: This study was a retrospective cohort study. Between June 1, 2022, and March 20, 2023, 27 cases of RARP with PEEL and 153 cases of RARP with preservation of pelvic floor stabilized structure (PPSS) were included in this study. All patients were males, aged (62.5±5.2) years (range: 50 to 73 years). There were 18 cases of ≤T2b stage and 9 cases of T2c stage. After 1∶1 propensity score matching, the postoperative functional outcomes of 27 cases of RARP with PEEL and 27 cases of RARP with PPSS were compared. All surgeries were performed by a single surgeon and included patients were clinically staged as cT1-2N0M0 without preoperative urinary incontinence or erectile dysfunction. In RARP with PEEL, the prostate was cut near the midline at the front when dissecting the neurovascular bundle, dissection was performed between the visceral layer of the pelvic fascia and the prostatic fascia, preserving the parietal layer and the visceral layer of the pelvic fascia, and the neurovascular bundle was retrogradely released from the apex. The cumulative probability curve was plotted using the Kaplan-Meier method and the Log-rank test was used to compare the differences in functional outcomes between the two groups. Univariate and multivariate analysis with the Cox proportional hazards model was used to compare postoperative urinary continence and sexual function. Results: The recovery time of continence and potency was significantly longer in the PPSS group than in the PEEL group (all P<0.05). The continence rate of the PEEL group was significantly higher than that of the PPSS group (92.59% vs. 68.10%, P=0.026) at 3 months after surgery. The potency rate of the PEEL group was also significantly higher than that of the PPSS group (40.70% vs. 15.10%, P=0.037) at 3 months after surgery. In the univariate analysis, compared to the PPSS technique, the PEEL technique was associated with a shorter recovery time of continence (HR=1.94, 95%CI: 1.08 to 3.48, P=0.027) and a shorter recovery time of potency (HR=2.06, 95%CI: 1.03 to 4.13, P=0.042). In the multivariate analysis, the PEEL technique was an independent prognosis factor for postoperative recovery of continence (HR=2.05, 95%CI: 1.01 to 4.17, P=0.047) and potency (HR=3.57, 95%CI: 1.43 to 8.92, P=0.007). All the cases of the PPSS group and the PEEL group were performed successfully with negative surgical margins. Conclusion: Compared with PPSS, PEEL may be more conducive to the recovery of urinary continence and sexual function after RARP.
Collapse
Affiliation(s)
- X Y Liao
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Y G Bao
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Z H Liu
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - L Yang
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - S Qiu
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - L R Liu
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - P Han
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Q Wei
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
| |
Collapse
|
17
|
Pan X, Wang W, Shao Q, Wei J, Li H, Zhang F, Cao M, Yang L. Compound drought and heat waves variation and association with SST modes across China. Sci Total Environ 2024; 907:167934. [PMID: 37863227 DOI: 10.1016/j.scitotenv.2023.167934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 10/05/2023] [Accepted: 10/17/2023] [Indexed: 10/22/2023]
Abstract
Compound drought and heatwaves (CDH) have garnered increasing attention because concurrent extreme events can exacerbate the harmful impacts caused by univariate extremes. However, various severities in CDH events and their relationships with sea surface temperature (SST) variations in China remain little understood. Here, we accurately identify CDH events and multi-aspect of characteristics using the standardized precipitation evapotranspiration index (SPEI) and the excess heat factor (EHF) during the extended summer (May-September) of 1961-2017. The evolution of multifaceted characteristics of CDH and their association with SST variation are further explored. The results suggest that the number, frequency, duration and intensity of regional CDH events show heterogeneous spatial patterns, with a significant increasing trend. A consistent abrupt transition in CDH characteristics averaged over China occurred in the period of 1993-1996. Mild and moderate CDHs occur more commonly in Northwest and North China, whereas severe CDHs are mainly found in central and eastern regions. Mild and moderate CDHs are more susceptible to SST modes than severe CDH, and there are strong positive correlations between mild and moderate CDH characteristics and SST variations in the northwest and northern regions. Compared to El Niño-Southern Oscillation (ENSO), Indian Ocean Dipole (IOD) plays a dominant role in the intensifications of mild and moderate CDH events. Regionally, the northwest and north have experienced longer, more frequent and severe CDH events during the positive phase of IOD. These findings reveal the divergent evolutions in CDH characteristics with various severities and inconsistent impacts of different SST modes on the compound events.
Collapse
Affiliation(s)
- Xiaolong Pan
- The National Key Laboratory of Water Disaster Prevention, Hohai University, Nanjing 210098, China; College of Hydrology and Water Resources, Hohai University, Nanjing 210098, China
| | - Weiguang Wang
- The National Key Laboratory of Water Disaster Prevention, Hohai University, Nanjing 210098, China; College of Hydrology and Water Resources, Hohai University, Nanjing 210098, China.
| | - Quanxi Shao
- CSIRO Data 61, Australian Resources Research Centre, Bentley, WA, Australia
| | - Jia Wei
- The National Key Laboratory of Water Disaster Prevention, Hohai University, Nanjing 210098, China; College of Hydrology and Water Resources, Hohai University, Nanjing 210098, China.
| | - Hongbin Li
- The National Key Laboratory of Water Disaster Prevention, Hohai University, Nanjing 210098, China; College of Hydrology and Water Resources, Hohai University, Nanjing 210098, China
| | - Fengyan Zhang
- College of Hydrology and Water Resources, Hohai University, Nanjing 210098, China
| | - Mingzhu Cao
- The National Key Laboratory of Water Disaster Prevention, Hohai University, Nanjing 210098, China; College of Hydrology and Water Resources, Hohai University, Nanjing 210098, China
| | - Liyan Yang
- The National Key Laboratory of Water Disaster Prevention, Hohai University, Nanjing 210098, China; College of Hydrology and Water Resources, Hohai University, Nanjing 210098, China
| |
Collapse
|
18
|
Sharifi N, Smith H, Madden D, Kehoe T, Wu G, Yang L, Welbourn RJL, G Fernandez E, Clarke SM. Diamond-Like Carbon: A Surface for Extreme, High-Wear Environments. Langmuir 2024; 40:52-61. [PMID: 38113451 PMCID: PMC10786025 DOI: 10.1021/acs.langmuir.3c01438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/28/2023] [Revised: 11/14/2023] [Accepted: 12/04/2023] [Indexed: 12/21/2023]
Abstract
In this study, we present an in-depth characterization of a diamond-like carbon (DLC) film, using a range of techniques to understand the structure and chemistry of the film both in the interior and particularly at the DLC/air surface and DLC/liquid interface. The DLC film is found to be a combination of sp2 and sp3 carbon, with significant oxygen present at the surface. The oxygen seems to be present as OH groups, making the DLC somewhat hydrophilic. Quartz-Crystal Microbalance (QCM) isotherms and complementary neutron reflectivity data indicate significant adsorption of a model additive, bis(2-ethylhexyl) sulfosuccinate sodium salt (AOT) surfactant, onto the DLC from water solutions and indicate the adsorbed film is a bilayer. This initial study of the structure and composition of a model surfactant is intended to give a clearer insight into how DLC and additives function as antiwear systems.
Collapse
Affiliation(s)
- N. Sharifi
- Institute
for Energy and Environmental Flows and Yusuf Hamied Department of
Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.
| | - H. Smith
- Institute
for Energy and Environmental Flows and Yusuf Hamied Department of
Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.
| | - D. Madden
- Institute
for Energy and Environmental Flows and Yusuf Hamied Department of
Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.
| | - T. Kehoe
- Institute
for Energy and Environmental Flows and Yusuf Hamied Department of
Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.
| | - G. Wu
- Institute
of Functional Surfaces, School of Mechanical Engineering, University of Leeds, Leeds LS2 9JT, U.K.
| | - L. Yang
- Institute
of Functional Surfaces, School of Mechanical Engineering, University of Leeds, Leeds LS2 9JT, U.K.
| | - R. J. L. Welbourn
- Rutherford
Appleton Laboratory, STFC, Chilton, ISIS
Neutron & Muon Source, Didcot, Oxon OX11 0QX, U.K.
| | - E. G Fernandez
- XMaS/BM28-ESRF, 71 Avenue Des Martyrs, F-38043 Grenoble, Cedex, France
- Department
of Physics, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, U.K.
| | - S. M. Clarke
- Institute
for Energy and Environmental Flows and Yusuf Hamied Department of
Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.
| |
Collapse
|
19
|
Staplin N, Haynes R, Judge PK, Wanner C, Green JB, Emberson J, Preiss D, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu WJ, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Seidi S, Landray MJ, Baigent C, Herrington WG, Abat S, Abd Rahman R, Abdul Cader R, Abdul Hafidz MI, Abdul Wahab MZ, Abdullah NK, Abdul-Samad T, Abe M, Abraham N, Acheampong S, Achiri P, Acosta JA, Adeleke A, Adell V, Adewuyi-Dalton R, Adnan N, Africano A, Agharazii M, Aguilar F, Aguilera A, Ahmad M, Ahmad MK, Ahmad NA, Ahmad NH, Ahmad NI, Ahmad Miswan N, Ahmad Rosdi H, Ahmed I, Ahmed S, Ahmed S, Aiello J, Aitken A, AitSadi R, Aker S, Akimoto S, Akinfolarin A, Akram S, Alberici F, Albert C, Aldrich L, Alegata M, Alexander L, Alfaress S, Alhadj Ali M, Ali A, Ali A, Alicic R, Aliu A, Almaraz R, Almasarwah R, Almeida J, Aloisi A, Al-Rabadi L, Alscher D, Alvarez P, Al-Zeer B, Amat M, Ambrose C, Ammar H, An Y, Andriaccio L, Ansu K, Apostolidi A, Arai N, Araki H, Araki S, Arbi A, Arechiga O, Armstrong S, Arnold T, Aronoff S, Arriaga W, Arroyo J, Arteaga D, Asahara S, Asai A, Asai N, Asano S, Asawa M, Asmee MF, Aucella F, Augustin M, Avery A, Awad A, Awang IY, Awazawa M, Axler A, Ayub W, Azhari Z, Baccaro R, Badin C, Bagwell B, Bahlmann-Kroll E, Bahtar AZ, Baigent C, Bains D, Bajaj H, Baker R, Baldini E, Banas B, Banerjee D, Banno S, Bansal S, Barberi S, Barnes S, Barnini C, Barot C, Barrett K, Barrios R, Bartolomei Mecatti B, Barton I, Barton J, Basily W, Bavanandan S, Baxter A, Becker L, Beddhu S, Beige J, Beigh S, Bell S, Benck U, Beneat A, Bennett A, Bennett D, Benyon S, Berdeprado J, Bergler T, Bergner A, Berry M, Bevilacqua M, Bhairoo J, Bhandari S, Bhandary N, Bhatt A, Bhattarai M, Bhavsar M, Bian W, Bianchini F, Bianco S, Bilous R, Bilton J, Bilucaglia D, Bird C, Birudaraju D, Biscoveanu M, Blake C, Bleakley N, Bocchicchia K, Bodine S, Bodington R, Boedecker S, Bolduc M, Bolton S, Bond C, Boreky F, Boren K, Bouchi R, Bough L, Bovan D, Bowler C, Bowman L, Brar N, Braun C, Breach A, Breitenfeldt M, Brenner S, Brettschneider B, Brewer A, Brewer G, Brindle V, Brioni E, Brown C, Brown H, Brown L, Brown R, Brown S, Browne D, Bruce K, Brueckmann M, Brunskill N, Bryant M, Brzoska M, Bu Y, Buckman C, Budoff M, Bullen M, Burke A, Burnette S, Burston C, Busch M, Bushnell J, Butler S, Büttner C, Byrne C, Caamano A, Cadorna J, Cafiero C, Cagle M, Cai J, Calabrese K, Calvi C, Camilleri B, Camp S, Campbell D, Campbell R, Cao H, Capelli I, Caple M, Caplin B, Cardone A, Carle J, Carnall V, Caroppo M, Carr S, Carraro G, Carson M, Casares P, Castillo C, Castro C, Caudill B, Cejka V, Ceseri M, Cham L, Chamberlain A, Chambers J, Chan CBT, Chan JYM, Chan YC, Chang E, Chang E, Chant T, Chavagnon T, Chellamuthu P, Chen F, Chen J, Chen P, Chen TM, Chen Y, Chen Y, Cheng C, Cheng H, Cheng MC, Cherney D, Cheung AK, Ching CH, Chitalia N, Choksi R, Chukwu C, Chung K, Cianciolo G, Cipressa L, Clark S, Clarke H, Clarke R, Clarke S, Cleveland B, Cole E, Coles H, Condurache L, Connor A, Convery K, Cooper A, Cooper N, Cooper Z, Cooperman L, Cosgrove L, Coutts P, Cowley A, Craik R, Cui G, Cummins T, Dahl N, Dai H, Dajani L, D'Amelio A, Damian E, Damianik K, Danel L, Daniels C, Daniels T, Darbeau S, Darius H, Dasgupta T, Davies J, Davies L, Davis A, Davis J, Davis L, Dayanandan R, Dayi S, Dayrell R, De Nicola L, Debnath S, Deeb W, Degenhardt S, DeGoursey K, Delaney M, Deo R, DeRaad R, Derebail V, Dev D, Devaux M, Dhall P, Dhillon G, Dienes J, Dobre M, Doctolero E, Dodds V, Domingo D, Donaldson D, Donaldson P, Donhauser C, Donley V, Dorestin S, Dorey S, Doulton T, Draganova D, Draxlbauer K, Driver F, Du H, Dube F, Duck T, Dugal T, Dugas J, Dukka H, Dumann H, Durham W, Dursch M, Dykas R, Easow R, Eckrich E, Eden G, Edmerson E, Edwards H, Ee LW, Eguchi J, Ehrl Y, Eichstadt K, Eid W, Eilerman B, Ejima Y, Eldon H, Ellam T, Elliott L, Ellison R, Emberson J, Epp R, Er A, Espino-Obrero M, Estcourt S, Estienne L, Evans G, Evans J, Evans S, Fabbri G, Fajardo-Moser M, Falcone C, Fani F, Faria-Shayler P, Farnia F, Farrugia D, Fechter M, Fellowes D, Feng F, Fernandez J, Ferraro P, Field A, Fikry S, Finch J, Finn H, Fioretto P, Fish R, Fleischer A, Fleming-Brown D, Fletcher L, Flora R, Foellinger C, Foligno N, Forest S, Forghani Z, Forsyth K, Fottrell-Gould D, Fox P, Frankel A, Fraser D, Frazier R, Frederick K, Freking N, French H, Froment A, Fuchs B, Fuessl L, Fujii H, Fujimoto A, Fujita A, Fujita K, Fujita Y, Fukagawa M, Fukao Y, Fukasawa A, Fuller T, Funayama T, Fung E, Furukawa M, Furukawa Y, Furusho M, Gabel S, Gaidu J, Gaiser S, Gallo K, Galloway C, Gambaro G, Gan CC, Gangemi C, Gao M, Garcia K, Garcia M, Garofalo C, Garrity M, Garza A, Gasko S, Gavrila M, Gebeyehu B, Geddes A, Gentile G, George A, George J, Gesualdo L, Ghalli F, Ghanem A, Ghate T, Ghavampour S, Ghazi A, Gherman A, Giebeln-Hudnell U, Gill B, Gillham S, Girakossyan I, Girndt M, Giuffrida A, Glenwright M, Glider T, Gloria R, Glowski D, Goh BL, Goh CB, Gohda T, Goldenberg R, Goldfaden R, Goldsmith C, Golson B, Gonce V, Gong Q, Goodenough B, Goodwin N, Goonasekera M, Gordon A, Gordon J, Gore A, Goto H, Goto S, Goto S, Gowen D, Grace A, Graham J, Grandaliano G, Gray M, Green JB, Greene T, Greenwood G, Grewal B, Grifa R, Griffin D, Griffin S, Grimmer P, Grobovaite E, Grotjahn S, Guerini A, Guest C, Gunda S, Guo B, Guo Q, Haack S, Haase M, Haaser K, Habuki K, Hadley A, Hagan S, Hagge S, Haller H, Ham S, Hamal S, Hamamoto Y, Hamano N, Hamm M, Hanburry A, Haneda M, Hanf C, Hanif W, Hansen J, Hanson L, Hantel S, Haraguchi T, Harding E, Harding T, Hardy C, Hartner C, Harun Z, Harvill L, Hasan A, Hase H, Hasegawa F, Hasegawa T, Hashimoto A, Hashimoto C, Hashimoto M, Hashimoto S, Haskett S, Hauske SJ, Hawfield A, Hayami T, Hayashi M, Hayashi S, Haynes R, Hazara A, Healy C, Hecktman J, Heine G, Henderson H, Henschel R, Hepditch A, Herfurth K, Hernandez G, Hernandez Pena A, Hernandez-Cassis C, Herrington WG, Herzog C, Hewins S, Hewitt D, Hichkad L, Higashi S, Higuchi C, Hill C, Hill L, Hill M, Himeno T, Hing A, Hirakawa Y, Hirata K, Hirota Y, Hisatake T, Hitchcock S, Hodakowski A, Hodge W, Hogan R, Hohenstatt U, Hohenstein B, Hooi L, Hope S, Hopley M, Horikawa S, Hosein D, Hosooka T, Hou L, Hou W, Howie L, Howson A, Hozak M, Htet Z, Hu X, Hu Y, Huang J, Huda N, Hudig L, Hudson A, Hugo C, Hull R, Hume L, Hundei W, Hunt N, Hunter A, Hurley S, Hurst A, Hutchinson C, Hyo T, Ibrahim FH, Ibrahim S, Ihana N, Ikeda T, Imai A, Imamine R, Inamori A, Inazawa H, Ingell J, Inomata K, Inukai Y, Ioka M, Irtiza-Ali A, Isakova T, Isari W, Iselt M, Ishiguro A, Ishihara K, Ishikawa T, Ishimoto T, Ishizuka K, Ismail R, Itano S, Ito H, Ito K, Ito M, Ito Y, Iwagaitsu S, Iwaita Y, Iwakura T, Iwamoto M, Iwasa M, Iwasaki H, Iwasaki S, Izumi K, Izumi K, Izumi T, Jaafar SM, Jackson C, Jackson Y, Jafari G, Jahangiriesmaili M, Jain N, Jansson K, Jasim H, Jeffers L, Jenkins A, Jesky M, Jesus-Silva J, Jeyarajah D, Jiang Y, Jiao X, Jimenez G, Jin B, Jin Q, Jochims J, Johns B, Johnson C, Johnson T, Jolly S, Jones L, Jones L, Jones S, Jones T, Jones V, Joseph M, Joshi S, Judge P, Junejo N, Junus S, Kachele M, Kadowaki T, Kadoya H, Kaga H, Kai H, Kajio H, Kaluza-Schilling W, Kamaruzaman L, Kamarzarian A, Kamimura Y, Kamiya H, Kamundi C, Kan T, Kanaguchi Y, Kanazawa A, Kanda E, Kanegae S, Kaneko K, Kaneko K, Kang HY, Kano T, Karim M, Karounos D, Karsan W, Kasagi R, Kashihara N, Katagiri H, Katanosaka A, Katayama A, Katayama M, Katiman E, Kato K, Kato M, Kato N, Kato S, Kato T, Kato Y, Katsuda Y, Katsuno T, Kaufeld J, Kavak Y, Kawai I, Kawai M, Kawai M, Kawase A, Kawashima S, Kazory A, Kearney J, Keith B, Kellett J, Kelley S, Kershaw M, Ketteler M, Khai Q, Khairullah Q, Khandwala H, Khoo KKL, Khwaja A, Kidokoro K, Kielstein J, Kihara M, Kimber C, Kimura S, Kinashi H, Kingston H, Kinomura M, Kinsella-Perks E, Kitagawa M, Kitajima M, Kitamura S, Kiyosue A, Kiyota M, Klauser F, Klausmann G, Kmietschak W, Knapp K, Knight C, Knoppe A, Knott C, Kobayashi M, Kobayashi R, Kobayashi T, Koch M, Kodama S, Kodani N, Kogure E, Koizumi M, Kojima H, Kojo T, Kolhe N, Komaba H, Komiya T, Komori H, Kon SP, Kondo M, Kondo M, Kong W, Konishi M, Kono K, Koshino M, Kosugi T, Kothapalli B, Kozlowski T, Kraemer B, Kraemer-Guth A, Krappe J, Kraus D, Kriatselis C, Krieger C, Krish P, Kruger B, Ku Md Razi KR, Kuan Y, Kubota S, Kuhn S, Kumar P, Kume S, Kummer I, Kumuji R, Küpper A, Kuramae T, Kurian L, Kuribayashi C, Kurien R, Kuroda E, Kurose T, Kutschat A, Kuwabara N, Kuwata H, La Manna G, Lacey M, Lafferty K, LaFleur P, Lai V, Laity E, Lambert A, Landray MJ, Langlois M, Latif F, Latore E, Laundy E, Laurienti D, Lawson A, Lay M, Leal I, Leal I, Lee AK, Lee J, Lee KQ, Lee R, Lee SA, Lee YY, Lee-Barkey Y, Leonard N, Leoncini G, Leong CM, Lerario S, Leslie A, Levin A, Lewington A, Li J, Li N, Li X, Li Y, Liberti L, Liberti ME, Liew A, Liew YF, Lilavivat U, Lim SK, Lim YS, Limon E, Lin H, Lioudaki E, Liu H, Liu J, Liu L, Liu Q, Liu WJ, Liu X, Liu Z, Loader D, Lochhead H, Loh CL, Lorimer A, Loudermilk L, Loutan J, Low CK, Low CL, Low YM, Lozon Z, Lu Y, Lucci D, Ludwig U, Luker N, Lund D, Lustig R, Lyle S, Macdonald C, MacDougall I, Machicado R, MacLean D, Macleod P, Madera A, Madore F, Maeda K, Maegawa H, Maeno S, Mafham M, Magee J, Maggioni AP, Mah DY, Mahabadi V, Maiguma M, Makita Y, Makos G, Manco L, Mangiacapra R, Manley J, Mann P, Mano S, Marcotte G, Maris J, Mark P, Markau S, Markovic M, Marshall C, Martin M, Martinez C, Martinez S, Martins G, Maruyama K, Maruyama S, Marx K, Maselli A, Masengu A, Maskill A, Masumoto S, Masutani K, Matsumoto M, Matsunaga T, Matsuoka N, Matsushita M, Matthews M, Matthias S, Matvienko E, Maurer M, Maxwell P, Mayne KJ, Mazlan N, Mazlan SA, Mbuyisa A, McCafferty K, McCarroll F, McCarthy T, McClary-Wright C, McCray K, McDermott P, McDonald C, McDougall R, McHaffie E, McIntosh K, McKinley T, McLaughlin S, McLean N, McNeil L, Measor A, Meek J, Mehta A, Mehta R, Melandri M, Mené P, Meng T, Menne J, Merritt K, Merscher S, Meshykhi C, Messa P, Messinger L, Miftari N, Miller R, Miller Y, Miller-Hodges E, Minatoguchi M, Miners M, Minutolo R, Mita T, Miura Y, Miyaji M, Miyamoto S, Miyatsuka T, Miyazaki M, Miyazawa I, Mizumachi R, Mizuno M, Moffat S, Mohamad Nor FS, Mohamad Zaini SN, Mohamed Affandi FA, Mohandas C, Mohd R, Mohd Fauzi NA, Mohd Sharif NH, Mohd Yusoff Y, Moist L, Moncada A, Montasser M, Moon A, Moran C, Morgan N, Moriarty J, Morig G, Morinaga H, Morino K, Morisaki T, Morishita Y, Morlok S, Morris A, Morris F, Mostafa S, Mostefai Y, Motegi M, Motherwell N, Motta D, Mottl A, Moys R, Mozaffari S, Muir J, Mulhern J, Mulligan S, Munakata Y, Murakami C, Murakoshi M, Murawska A, Murphy K, Murphy L, Murray S, Murtagh H, Musa MA, Mushahar L, Mustafa R, Mustafar R, Muto M, Nadar E, Nagano R, Nagasawa T, Nagashima E, Nagasu H, Nagelberg S, Nair H, Nakagawa Y, Nakahara M, Nakamura J, Nakamura R, Nakamura T, Nakaoka M, Nakashima E, Nakata J, Nakata M, Nakatani S, Nakatsuka A, Nakayama Y, Nakhoul G, Nangaku M, Naverrete G, Navivala A, Nazeer I, Negrea L, Nethaji C, Newman E, Ng SYA, Ng TJ, Ngu LLS, Nimbkar T, Nishi H, Nishi M, Nishi S, Nishida Y, Nishiyama A, Niu J, Niu P, Nobili G, Nohara N, Nojima I, Nolan J, Nosseir H, Nozawa M, Nunn M, Nunokawa S, Oda M, Oe M, Oe Y, Ogane K, Ogawa W, Ogihara T, Oguchi G, Ohsugi M, Oishi K, Okada Y, Okajyo J, Okamoto S, Okamura K, Olufuwa O, Oluyombo R, Omata A, Omori Y, Ong LM, Ong YC, Onyema J, Oomatia A, Oommen A, Oremus R, Orimo Y, Ortalda V, Osaki Y, Osawa Y, Osmond Foster J, O'Sullivan A, Otani T, Othman N, Otomo S, O'Toole J, Owen L, Ozawa T, Padiyar A, Page N, Pajak S, Paliege A, Pandey A, Pandey R, Pariani H, Park J, Parrigon M, Passauer J, Patecki M, Patel M, Patel R, Patel T, Patel Z, Paul R, Paul R, Paulsen L, Pavone L, Peixoto A, Peji J, Peng BC, Peng K, Pennino L, Pereira E, Perez E, Pergola P, Pesce F, Pessolano G, Petchey W, Petr EJ, Pfab T, Phelan P, Phillips R, Phillips T, Phipps M, Piccinni G, Pickett T, Pickworth S, Piemontese M, Pinto D, Piper J, Plummer-Morgan J, Poehler D, Polese L, Poma V, Pontremoli R, Postal A, Pötz C, Power A, Pradhan N, Pradhan R, Preiss D, Preiss E, Preston K, Prib N, Price L, Provenzano C, Pugay C, Pulido R, Putz F, Qiao Y, Quartagno R, Quashie-Akponeware M, Rabara R, Rabasa-Lhoret R, Radhakrishnan D, Radley M, Raff R, Raguwaran S, Rahbari-Oskoui F, Rahman M, Rahmat K, Ramadoss S, Ramanaidu S, Ramasamy S, Ramli R, Ramli S, Ramsey T, Rankin A, Rashidi A, Raymond L, Razali WAFA, Read K, Reiner H, Reisler A, Reith C, Renner J, Rettenmaier B, Richmond L, Rijos D, Rivera R, Rivers V, Robinson H, Rocco M, Rodriguez-Bachiller I, Rodriquez R, Roesch C, Roesch J, Rogers J, Rohnstock M, Rolfsmeier S, Roman M, Romo A, Rosati A, Rosenberg S, Ross T, Rossello X, Roura M, Roussel M, Rovner S, Roy S, Rucker S, Rump L, Ruocco M, Ruse S, Russo F, Russo M, Ryder M, Sabarai A, Saccà C, Sachson R, Sadler E, Safiee NS, Sahani M, Saillant A, Saini J, Saito C, Saito S, Sakaguchi K, Sakai M, Salim H, Salviani C, Sammons E, Sampson A, Samson F, Sandercock P, Sanguila S, Santorelli G, Santoro D, Sarabu N, Saram T, Sardell R, Sasajima H, Sasaki T, Satko S, Sato A, Sato D, Sato H, Sato H, Sato J, Sato T, Sato Y, Satoh M, Sawada K, Schanz M, Scheidemantel F, Schemmelmann M, Schettler E, Schettler V, Schlieper GR, Schmidt C, Schmidt G, Schmidt U, Schmidt-Gurtler H, Schmude M, Schneider A, Schneider I, Schneider-Danwitz C, Schomig M, Schramm T, Schreiber A, Schricker S, Schroppel B, Schulte-Kemna L, Schulz E, Schumacher B, Schuster A, Schwab A, Scolari F, Scott A, Seeger W, Seeger W, Segal M, Seifert L, Seifert M, Sekiya M, Sellars R, Seman MR, Shah S, Shah S, Shainberg L, Shanmuganathan M, Shao F, Sharma K, Sharpe C, Sheikh-Ali M, Sheldon J, Shenton C, Shepherd A, Shepperd M, Sheridan R, Sheriff Z, Shibata Y, Shigehara T, Shikata K, Shimamura K, Shimano H, Shimizu Y, Shimoda H, Shin K, Shivashankar G, Shojima N, Silva R, Sim CSB, Simmons K, Sinha S, Sitter T, Sivanandam S, Skipper M, Sloan K, Sloan L, Smith R, Smyth J, Sobande T, Sobata M, Somalanka S, Song X, Sonntag F, Sood B, Sor SY, Soufer J, Sparks H, Spatoliatore G, Spinola T, Squyres S, Srivastava A, Stanfield J, Staplin N, Staylor K, Steele A, Steen O, Steffl D, Stegbauer J, Stellbrink C, Stellbrink E, Stevens W, Stevenson A, Stewart-Ray V, Stickley J, Stoffler D, Stratmann B, Streitenberger S, Strutz F, Stubbs J, Stumpf J, Suazo N, Suchinda P, Suckling R, Sudin A, Sugamori K, Sugawara H, Sugawara K, Sugimoto D, Sugiyama H, Sugiyama H, Sugiyama T, Sullivan M, Sumi M, Suresh N, Sutton D, Suzuki H, Suzuki R, Suzuki Y, Suzuki Y, Suzuki Y, Swanson E, Swift P, Syed S, Szerlip H, Taal M, Taddeo M, Tailor C, Tajima K, Takagi M, Takahashi K, Takahashi K, Takahashi M, Takahashi T, Takahira E, Takai T, Takaoka M, Takeoka J, Takesada A, Takezawa M, Talbot M, Taliercio J, Talsania T, Tamori Y, Tamura R, Tamura Y, Tan CHH, Tan EZZ, Tanabe A, Tanabe K, Tanaka A, Tanaka A, Tanaka N, Tang S, Tang Z, Tanigaki K, Tarlac M, Tatsuzawa A, Tay JF, Tay LL, Taylor J, Taylor K, Taylor K, Te A, Tenbusch L, Teng KS, Terakawa A, Terry J, Tham ZD, Tholl S, Thomas G, Thong KM, Tietjen D, Timadjer A, Tindall H, Tipper S, Tobin K, Toda N, Tokuyama A, Tolibas M, Tomita A, Tomita T, Tomlinson J, Tonks L, Topf J, Topping S, Torp A, Torres A, Totaro F, Toth P, Toyonaga Y, Tripodi F, Trivedi K, Tropman E, Tschope D, Tse J, Tsuji K, Tsunekawa S, Tsunoda R, Tucky B, Tufail S, Tuffaha A, Turan E, Turner H, Turner J, Turner M, Tuttle KR, Tye YL, Tyler A, Tyler J, Uchi H, Uchida H, Uchida T, Uchida T, Udagawa T, Ueda S, Ueda Y, Ueki K, Ugni S, Ugwu E, Umeno R, Unekawa C, Uozumi K, Urquia K, Valleteau A, Valletta C, van Erp R, Vanhoy C, Varad V, Varma R, Varughese A, Vasquez P, Vasseur A, Veelken R, Velagapudi C, Verdel K, Vettoretti S, Vezzoli G, Vielhauer V, Viera R, Vilar E, Villaruel S, Vinall L, Vinathan J, Visnjic M, Voigt E, von-Eynatten M, Vourvou M, Wada J, Wada J, Wada T, Wada Y, Wakayama K, Wakita Y, Wallendszus K, Walters T, Wan Mohamad WH, Wang L, Wang W, Wang X, Wang X, Wang Y, Wanner C, Wanninayake S, Watada H, Watanabe K, Watanabe K, Watanabe M, Waterfall H, Watkins D, Watson S, Weaving L, Weber B, Webley Y, Webster A, Webster M, Weetman M, Wei W, Weihprecht H, Weiland L, Weinmann-Menke J, Weinreich T, Wendt R, Weng Y, Whalen M, Whalley G, Wheatley R, Wheeler A, Wheeler J, Whelton P, White K, Whitmore B, Whittaker S, Wiebel J, Wiley J, Wilkinson L, Willett M, Williams A, Williams E, Williams K, Williams T, Wilson A, Wilson P, Wincott L, Wines E, Winkelmann B, Winkler M, Winter-Goodwin B, Witczak J, Wittes J, Wittmann M, Wolf G, Wolf L, Wolfling R, Wong C, Wong E, Wong HS, Wong LW, Wong YH, Wonnacott A, Wood A, Wood L, Woodhouse H, Wooding N, Woodman A, Wren K, Wu J, Wu P, Xia S, Xiao H, Xiao X, Xie Y, Xu C, Xu Y, Xue H, Yahaya H, Yalamanchili H, Yamada A, Yamada N, Yamagata K, Yamaguchi M, Yamaji Y, Yamamoto A, Yamamoto S, Yamamoto S, Yamamoto T, Yamanaka A, Yamano T, Yamanouchi Y, Yamasaki N, Yamasaki Y, Yamasaki Y, Yamashita C, Yamauchi T, Yan Q, Yanagisawa E, Yang F, Yang L, Yano S, Yao S, Yao Y, Yarlagadda S, Yasuda Y, Yiu V, Yokoyama T, Yoshida S, Yoshidome E, Yoshikawa H, Young A, Young T, Yousif V, Yu H, Yu Y, Yuasa K, Yusof N, Zalunardo N, Zander B, Zani R, Zappulo F, Zayed M, Zemann B, Zettergren P, Zhang H, Zhang L, Zhang L, Zhang N, Zhang X, Zhao J, Zhao L, Zhao S, Zhao Z, Zhong H, Zhou N, Zhou S, Zhu D, Zhu L, Zhu S, Zietz M, Zippo M, Zirino F, Zulkipli FH. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes Endocrinol 2024; 12:39-50. [PMID: 38061371 PMCID: PMC7615591 DOI: 10.1016/s2213-8587(23)00321-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 10/24/2023] [Accepted: 10/25/2023] [Indexed: 12/23/2023]
Abstract
BACKGROUND Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce progression of chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range of patients. However, their effects on kidney disease progression in some patients with chronic kidney disease are unclear because few clinical kidney outcomes occurred among such patients in the completed trials. In particular, some guidelines stratify their level of recommendation about who should be treated with SGLT2 inhibitors based on diabetes status and albuminuria. We aimed to assess the effects of empagliflozin on progression of chronic kidney disease both overall and among specific types of participants in the EMPA-KIDNEY trial. METHODS EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA), and included individuals aged 18 years or older with an estimated glomerular filtration rate (eGFR) of 20 to less than 45 mL/min per 1·73 m2, or with an eGFR of 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher. We explored the effects of 10 mg oral empagliflozin once daily versus placebo on the annualised rate of change in estimated glomerular filtration rate (eGFR slope), a tertiary outcome. We studied the acute slope (from randomisation to 2 months) and chronic slope (from 2 months onwards) separately, using shared parameter models to estimate the latter. Analyses were done in all randomly assigned participants by intention to treat. EMPA-KIDNEY is registered at ClinicalTrials.gov, NCT03594110. FINDINGS Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and then followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroups of eGFR included 2282 (34·5%) participants with an eGFR of less than 30 mL/min per 1·73 m2, 2928 (44·3%) with an eGFR of 30 to less than 45 mL/min per 1·73 m2, and 1399 (21·2%) with an eGFR 45 mL/min per 1·73 m2 or higher. Prespecified subgroups of uACR included 1328 (20·1%) with a uACR of less than 30 mg/g, 1864 (28·2%) with a uACR of 30 to 300 mg/g, and 3417 (51·7%) with a uACR of more than 300 mg/g. Overall, allocation to empagliflozin caused an acute 2·12 mL/min per 1·73 m2 (95% CI 1·83-2·41) reduction in eGFR, equivalent to a 6% (5-6) dip in the first 2 months. After this, it halved the chronic slope from -2·75 to -1·37 mL/min per 1·73 m2 per year (relative difference 50%, 95% CI 42-58). The absolute and relative benefits of empagliflozin on the magnitude of the chronic slope varied significantly depending on diabetes status and baseline levels of eGFR and uACR. In particular, the absolute difference in chronic slopes was lower in patients with lower baseline uACR, but because this group progressed more slowly than those with higher uACR, this translated to a larger relative difference in chronic slopes in this group (86% [36-136] reduction in the chronic slope among those with baseline uACR <30 mg/g compared with a 29% [19-38] reduction for those with baseline uACR ≥2000 mg/g; ptrend<0·0001). INTERPRETATION Empagliflozin slowed the rate of progression of chronic kidney disease among all types of participant in the EMPA-KIDNEY trial, including those with little albuminuria. Albuminuria alone should not be used to determine whether to treat with an SGLT2 inhibitor. FUNDING Boehringer Ingelheim and Eli Lilly.
Collapse
|
20
|
Zhang L, Yang F, Ma J, Hu Y, Li M, Wang C, Chang X, Yang L. The Impact of Testosterone on Alzheimer's Disease Are Mediated by Lipid Metabolism and Obesity: A Mendelian Randomization Study. J Prev Alzheimers Dis 2024; 11:507-513. [PMID: 38374757 DOI: 10.14283/jpad.2023.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2024]
Abstract
BACKGROUND To investigate the causal relationship between testosterone (BT) levels and Alzheimer's disease (AD) risk and to quantify the role of obesity and lipid metabolism as potential mediators. METHODS We used a two-sample, two-step MR to determine:1) the causal effect of BT levels on AD; 2) the causal effect of two lipid metabolites, obesity and LDLc on AD; and 3) the mediating effects of these metabolites. Pooled data for BT levels and lipid metabolism were obtained from the UK Biobank. AD data were obtained from the Alzheimer's Disease Project International Genomics Consortium, FinnGen Consortium, and UK Biobank study. Effect estimates from external genome-wide association study (GWAS) pooled statistics were obtained using inverse variance-weighted (IVW) MR analysis. RESULTS Higher levels of BT were associated with a reduced risk of AD (odds ratio [OR] 0.9992, 95% CI 0.9985-0.9998, P = 0.019), and there was a negative correlation with LDLc (OR 0.9208, 95% CI 0.8569-0.9895, P = 0.024) and obesity class 2 (OC2) (OR 0.7445, 95% CI 0.5873-0.9437, P = 0.014). Conversely, there was a positive correlation between LDLc (OR 1.0014, 95% CI 1.0000-1.0029, P = 0.043) and OC2 (OR 1.0005, 95% CI 1.0001-1.0009, P = 0.003) and AD. Mediation analysis showed that the indirect effect of BT levels on AD was achieved through LDLc and OC2, which accounted for 17% and 17% of the total effect, respectively. CONCLUSION Our study identified a causal role of BT levels in LDLc and OC2. BT levels may affect AD through LDLc and OC2 metabolic processes.
Collapse
Affiliation(s)
- L Zhang
- Lin Yang, Xi'an Hospital of Traditional Chinese Medicine, Shaanxi, China,
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Huang N, Liu X, Liu Q, Zhang J, Fu Y, Zhu Z, Guo J, Li X, Yang L. Does COVID-19 vaccination affect post-traumatic stress symptoms via risk perception? A large cross-sectional study among the Chinese population. Public Health 2024; 226:107-113. [PMID: 38052112 DOI: 10.1016/j.puhe.2023.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 10/07/2023] [Accepted: 11/02/2023] [Indexed: 12/07/2023]
Abstract
OBJECTIVES Although infection rates may increase after relaxation of the zero COVID strategy, the extensive vaccination campaign in China could potentially curb the spread of COVID-19, which may be associated with a low level of risk perception and post-traumatic stress symptoms (PTSS). However, the relationship between vaccination, risk perception and PTSS has not been studied extensively. This study aims to examine the associations between the number of COVID-19 vaccine doses, consistency in the type of each dose and time since vaccination with PTSS, and the mediating role of risk perception on such relationships in China. STUDY DESIGN Cross-sectional sampling with a self-report questionnaire was used to measure vaccination, PTSS and risk perception. METHODS The survey was conducted in Beijing, China, from 13 January to 9 February 2023. Linear regression analyses were conducted to test the relationship between vaccination, risk perception and PTSS. RESULTS The analysis included 55,803 individuals. In total, 72.86 % of participants received two doses of the COVID-19 vaccine. Regression results indicated that people with two doses of the COVID-19 vaccine had a lower level of PTSS (β = -1.232, 95 % confidence interval [CI]: -1.930, -0.534) than those who had not received any doses of the COVID-19 vaccine. Only the negative relationship between two-dose vaccination and PTSS was mediated by risk perception, while the negative relationship between the time since vaccination and PTSS was suppressed by risk perception. CONCLUSIONS This study showed that receiving the COVID-19 vaccine reduced PTSS by decreasing perceived risk. Vaccination time was negatively associated with PTSS, but this relationship was suppressed by risk perception.
Collapse
Affiliation(s)
- N Huang
- Department of Health Policy and Management, School of Public Health, Peking University, Beijing, PR China
| | - X Liu
- Department of Health Policy and Management, School of Public Health, Peking University, Beijing, PR China
| | - Q Liu
- Department of General Practice, Second Outpatient Section, Peking University Third Hospital, Beijing, PR China
| | - J Zhang
- Department of Health Policy and Management, School of Public Health, Peking University, Beijing, PR China
| | - Y Fu
- Department of Health Policy and Management, School of Public Health, Peking University, Beijing, PR China
| | - Z Zhu
- Department of Health Policy and Management, School of Public Health, Peking University, Beijing, PR China
| | - J Guo
- Department of Health Policy and Management, School of Public Health, Peking University, Beijing, PR China.
| | - X Li
- Department of Infectious Diseases, Peking University Third Hospital, Beijing, PR China.
| | - L Yang
- Department of Health Policy and Management, School of Public Health, Peking University, Beijing, PR China.
| |
Collapse
|
22
|
Niu H, Zhang M, Liu M, Yang L, Yang L, Ren J, Yu Y, Liu Y, Xing L, Shao Z, Wang H. Thymocyte selection-associated high mobility box protein regulates T lymphocytes exhaustion in patients with myelodysplastic syndromes by inhibiting PI3K/AKT/mTOR pathway. Hematol Oncol 2024; 42:e3224. [PMID: 37712442 DOI: 10.1002/hon.3224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 08/31/2023] [Accepted: 09/02/2023] [Indexed: 09/16/2023]
Abstract
Myelodysplastic syndromes (MDS) patients often experience CD8+ T lymphocytes exhaustion, which plays a crucial role in the development of MDS. However, the specific role of thymocyte selection-associated high mobility box protein (TOX) in the CD8+ T lymphocytes exhaustion in MDS patients remains unclear. In this study, we investigated the role of TOX in CD8+ T lymphocytes exhaustion in patients with MDS. The expression of TOX, inhibitory receptors (IRs), and functional molecules in peripheral blood T lymphocytes of MDS patients and normal controls were detected using flow cytometry. Lentiviral transduction was used to create stable TOX-knockdown CD8+ T lymphocytes, and small interfering RNA (si-RNA) was used to knock down TOX in Jurkat cells. The expression of TOX was found to be significantly higher in CD8+ T lymphocytes of MDS patients compared to normal controls. This was associated with upregulated IRs and reduced expression of functional molecules such as Granzyme and Perforin. Myelodysplastic syndromes patients with higher TOX expression had poor clinical indicators and shorter survival. Knockdown of TOX using sh-RNA partially reverses the exhausted phenotype and enhances the lethality of CD8+ T lymphocytes. Moreover, the knockdown of TOX using si-RNA in Jurkat cells improved cell proliferation activity, down-regulated IRs and activated PI3K/AKT/mTOR signaling pathway. TOX promotes the exhaustion of CD8+ T lymphocytes by inhibiting PI3K/AKT/mTOR pathway, and targeted inhibition of TOX could partially restore the effector functions and activity of CD8+ T lymphocytes.
Collapse
Affiliation(s)
- Haiyue Niu
- Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China
| | - Mengying Zhang
- Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China
| | - Mengyuan Liu
- Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China
| | - Liyan Yang
- Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China
| | - Liping Yang
- Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China
| | - Jie Ren
- Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China
| | - Yating Yu
- Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China
| | - Yumei Liu
- Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China
| | - Limin Xing
- Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China
| | - Zonghong Shao
- Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China
| | - Huaquan Wang
- Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China
| |
Collapse
|
23
|
Nian Z, Zhao Q, He Y, Xie R, Liu W, Chen T, Huang S, Dong L, Huang R, Yang L. Efficacy and Safety of First-line Therapies for Advanced Unresectable Oesophageal Squamous Cell Cancer: a Systematic Review and Network Meta-analysis. Clin Oncol (R Coll Radiol) 2024; 36:30-38. [PMID: 37827946 DOI: 10.1016/j.clon.2023.09.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 08/27/2023] [Accepted: 09/21/2023] [Indexed: 10/14/2023]
Abstract
AIM To compare the clinical efficacy and safety of first-line treatments for advanced unresectable oesophageal squamous cell cancer. MATERIALS AND METHODS A systematic review and network meta-analysis was carried out by retrieving and retaining relevant literature from databases. The studies were randomised controlled trials comparing first-line treatments for advanced unresectable oesophageal squamous cell cancer. A Bayesian network meta-analysis was used to assess clinical outcomes. RESULTS Nine studies including 4499 patients receiving first-line treatments were analysed. For all populations, toripalimab plus chemotherapy tended to provide the best overall survival (hazard ratio 0.58, 95% confidence intervals 0.43-0.78) and sintilimab plus chemotherapy provided the best progression-free survival (0.56, 0.46-0.68). Nivolumab plus chemotherapy presented the best objective response rate (odds ratio 2.45, 1.78-3.42) and camrelizumab plus chemotherapy (0.47, 0.29-0.74) appeared to be the safest. Sintilimab plus chemotherapy (0.55, 0.40-0.75) and nivolumab (0.54, 0.37-0.80) plus chemotherapy had the best overall survival in programmed death ligand 1 (PD-L1) tumour proportion score <1% and ≥1% subgroups. Toripalimab plus chemotherapy (0.61, 0.40-0.93) and pembrolizumab (0.57, 0.43-0.75) were the best in overall survival in combined positive score <10 and ≥10 subgroups, respectively. Toripalimab plus chemotherapy showed the best overall survival in the Asian group; pembrolizumab presented better overall survival in the Asian population than the non-Asian group. CONCLUSION Most immunotherapy combined with chemotherapy showed superior clinical benefits and sintilimab plus chemotherapy, toripalimab plus chemotherapy and tislelizumab plus chemotherapy had better comprehensive clinical efficacy. PD-L1 expression detection and ethnicity differences are still of great significance and most suitable regimens varied from each subgroup.
Collapse
Affiliation(s)
- Z Nian
- School of Pharmacy, Fujian Medical University, Fuzhou, China
| | - Q Zhao
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - Y He
- School of Pharmacy, Fujian Medical University, Fuzhou, China
| | - R Xie
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - W Liu
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - T Chen
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - S Huang
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - L Dong
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - R Huang
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - L Yang
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
| |
Collapse
|
24
|
Judge PK, Staplin N, Mayne KJ, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Ng SYA, Roddick AJ, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu WJ, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Landray MJ, Baigent C, Haynes R, Herrington WG, Abat S, Abd Rahman R, Abdul Cader R, Abdul Hafidz MI, Abdul Wahab MZ, Abdullah NK, Abdul-Samad T, Abe M, Abraham N, Acheampong S, Achiri P, Acosta JA, Adeleke A, Adell V, Adewuyi-Dalton R, Adnan N, Africano A, Agharazii M, Aguilar F, Aguilera A, Ahmad M, Ahmad MK, Ahmad NA, Ahmad NH, Ahmad NI, Ahmad Miswan N, Ahmad Rosdi H, Ahmed I, Ahmed S, Ahmed S, Aiello J, Aitken A, AitSadi R, Aker S, Akimoto S, Akinfolarin A, Akram S, Alberici F, Albert C, Aldrich L, Alegata M, Alexander L, Alfaress S, Alhadj Ali M, Ali A, Ali A, Alicic R, Aliu A, Almaraz R, Almasarwah R, Almeida J, Aloisi A, Al-Rabadi L, Alscher D, Alvarez P, Al-Zeer B, Amat M, Ambrose C, Ammar H, An Y, Andriaccio L, Ansu K, Apostolidi A, Arai N, Araki H, Araki S, Arbi A, Arechiga O, Armstrong S, Arnold T, Aronoff S, Arriaga W, Arroyo J, Arteaga D, Asahara S, Asai A, Asai N, Asano S, Asawa M, Asmee MF, Aucella F, Augustin M, Avery A, Awad A, Awang IY, Awazawa M, Axler A, Ayub W, Azhari Z, Baccaro R, Badin C, Bagwell B, Bahlmann-Kroll E, Bahtar AZ, Baigent C, Bains D, Bajaj H, Baker R, Baldini E, Banas B, Banerjee D, Banno S, Bansal S, Barberi S, Barnes S, Barnini C, Barot C, Barrett K, Barrios R, Bartolomei Mecatti B, Barton I, Barton J, Basily W, Bavanandan S, Baxter A, Becker L, Beddhu S, Beige J, Beigh S, Bell S, Benck U, Beneat A, Bennett A, Bennett D, Benyon S, Berdeprado J, Bergler T, Bergner A, Berry M, Bevilacqua M, Bhairoo J, Bhandari S, Bhandary N, Bhatt A, Bhattarai M, Bhavsar M, Bian W, Bianchini F, Bianco S, Bilous R, Bilton J, Bilucaglia D, Bird C, Birudaraju D, Biscoveanu M, Blake C, Bleakley N, Bocchicchia K, Bodine S, Bodington R, Boedecker S, Bolduc M, Bolton S, Bond C, Boreky F, Boren K, Bouchi R, Bough L, Bovan D, Bowler C, Bowman L, Brar N, Braun C, Breach A, Breitenfeldt M, Brenner S, Brettschneider B, Brewer A, Brewer G, Brindle V, Brioni E, Brown C, Brown H, Brown L, Brown R, Brown S, Browne D, Bruce K, Brueckmann M, Brunskill N, Bryant M, Brzoska M, Bu Y, Buckman C, Budoff M, Bullen M, Burke A, Burnette S, Burston C, Busch M, Bushnell J, Butler S, Büttner C, Byrne C, Caamano A, Cadorna J, Cafiero C, Cagle M, Cai J, Calabrese K, Calvi C, Camilleri B, Camp S, Campbell D, Campbell R, Cao H, Capelli I, Caple M, Caplin B, Cardone A, Carle J, Carnall V, Caroppo M, Carr S, Carraro G, Carson M, Casares P, Castillo C, Castro C, Caudill B, Cejka V, Ceseri M, Cham L, Chamberlain A, Chambers J, Chan CBT, Chan JYM, Chan YC, Chang E, Chang E, Chant T, Chavagnon T, Chellamuthu P, Chen F, Chen J, Chen P, Chen TM, Chen Y, Chen Y, Cheng C, Cheng H, Cheng MC, Cherney D, Cheung AK, Ching CH, Chitalia N, Choksi R, Chukwu C, Chung K, Cianciolo G, Cipressa L, Clark S, Clarke H, Clarke R, Clarke S, Cleveland B, Cole E, Coles H, Condurache L, Connor A, Convery K, Cooper A, Cooper N, Cooper Z, Cooperman L, Cosgrove L, Coutts P, Cowley A, Craik R, Cui G, Cummins T, Dahl N, Dai H, Dajani L, D'Amelio A, Damian E, Damianik K, Danel L, Daniels C, Daniels T, Darbeau S, Darius H, Dasgupta T, Davies J, Davies L, Davis A, Davis J, Davis L, Dayanandan R, Dayi S, Dayrell R, De Nicola L, Debnath S, Deeb W, Degenhardt S, DeGoursey K, Delaney M, Deo R, DeRaad R, Derebail V, Dev D, Devaux M, Dhall P, Dhillon G, Dienes J, Dobre M, Doctolero E, Dodds V, Domingo D, Donaldson D, Donaldson P, Donhauser C, Donley V, Dorestin S, Dorey S, Doulton T, Draganova D, Draxlbauer K, Driver F, Du H, Dube F, Duck T, Dugal T, Dugas J, Dukka H, Dumann H, Durham W, Dursch M, Dykas R, Easow R, Eckrich E, Eden G, Edmerson E, Edwards H, Ee LW, Eguchi J, Ehrl Y, Eichstadt K, Eid W, Eilerman B, Ejima Y, Eldon H, Ellam T, Elliott L, Ellison R, Emberson J, Epp R, Er A, Espino-Obrero M, Estcourt S, Estienne L, Evans G, Evans J, Evans S, Fabbri G, Fajardo-Moser M, Falcone C, Fani F, Faria-Shayler P, Farnia F, Farrugia D, Fechter M, Fellowes D, Feng F, Fernandez J, Ferraro P, Field A, Fikry S, Finch J, Finn H, Fioretto P, Fish R, Fleischer A, Fleming-Brown D, Fletcher L, Flora R, Foellinger C, Foligno N, Forest S, Forghani Z, Forsyth K, Fottrell-Gould D, Fox P, Frankel A, Fraser D, Frazier R, Frederick K, Freking N, French H, Froment A, Fuchs B, Fuessl L, Fujii H, Fujimoto A, Fujita A, Fujita K, Fujita Y, Fukagawa M, Fukao Y, Fukasawa A, Fuller T, Funayama T, Fung E, Furukawa M, Furukawa Y, Furusho M, Gabel S, Gaidu J, Gaiser S, Gallo K, Galloway C, Gambaro G, Gan CC, Gangemi C, Gao M, Garcia K, Garcia M, Garofalo C, Garrity M, Garza A, Gasko S, Gavrila M, Gebeyehu B, Geddes A, Gentile G, George A, George J, Gesualdo L, Ghalli F, Ghanem A, Ghate T, Ghavampour S, Ghazi A, Gherman A, Giebeln-Hudnell U, Gill B, Gillham S, Girakossyan I, Girndt M, Giuffrida A, Glenwright M, Glider T, Gloria R, Glowski D, Goh BL, Goh CB, Gohda T, Goldenberg R, Goldfaden R, Goldsmith C, Golson B, Gonce V, Gong Q, Goodenough B, Goodwin N, Goonasekera M, Gordon A, Gordon J, Gore A, Goto H, Goto S, Goto S, Gowen D, Grace A, Graham J, Grandaliano G, Gray M, Green JB, Greene T, Greenwood G, Grewal B, Grifa R, Griffin D, Griffin S, Grimmer P, Grobovaite E, Grotjahn S, Guerini A, Guest C, Gunda S, Guo B, Guo Q, Haack S, Haase M, Haaser K, Habuki K, Hadley A, Hagan S, Hagge S, Haller H, Ham S, Hamal S, Hamamoto Y, Hamano N, Hamm M, Hanburry A, Haneda M, Hanf C, Hanif W, Hansen J, Hanson L, Hantel S, Haraguchi T, Harding E, Harding T, Hardy C, Hartner C, Harun Z, Harvill L, Hasan A, Hase H, Hasegawa F, Hasegawa T, Hashimoto A, Hashimoto C, Hashimoto M, Hashimoto S, Haskett S, Hauske SJ, Hawfield A, Hayami T, Hayashi M, Hayashi S, Haynes R, Hazara A, Healy C, Hecktman J, Heine G, Henderson H, Henschel R, Hepditch A, Herfurth K, Hernandez G, Hernandez Pena A, Hernandez-Cassis C, Herrington WG, Herzog C, Hewins S, Hewitt D, Hichkad L, Higashi S, Higuchi C, Hill C, Hill L, Hill M, Himeno T, Hing A, Hirakawa Y, Hirata K, Hirota Y, Hisatake T, Hitchcock S, Hodakowski A, Hodge W, Hogan R, Hohenstatt U, Hohenstein B, Hooi L, Hope S, Hopley M, Horikawa S, Hosein D, Hosooka T, Hou L, Hou W, Howie L, Howson A, Hozak M, Htet Z, Hu X, Hu Y, Huang J, Huda N, Hudig L, Hudson A, Hugo C, Hull R, Hume L, Hundei W, Hunt N, Hunter A, Hurley S, Hurst A, Hutchinson C, Hyo T, Ibrahim FH, Ibrahim S, Ihana N, Ikeda T, Imai A, Imamine R, Inamori A, Inazawa H, Ingell J, Inomata K, Inukai Y, Ioka M, Irtiza-Ali A, Isakova T, Isari W, Iselt M, Ishiguro A, Ishihara K, Ishikawa T, Ishimoto T, Ishizuka K, Ismail R, Itano S, Ito H, Ito K, Ito M, Ito Y, Iwagaitsu S, Iwaita Y, Iwakura T, Iwamoto M, Iwasa M, Iwasaki H, Iwasaki S, Izumi K, Izumi K, Izumi T, Jaafar SM, Jackson C, Jackson Y, Jafari G, Jahangiriesmaili M, Jain N, Jansson K, Jasim H, Jeffers L, Jenkins A, Jesky M, Jesus-Silva J, Jeyarajah D, Jiang Y, Jiao X, Jimenez G, Jin B, Jin Q, Jochims J, Johns B, Johnson C, Johnson T, Jolly S, Jones L, Jones L, Jones S, Jones T, Jones V, Joseph M, Joshi S, Judge P, Junejo N, Junus S, Kachele M, Kadowaki T, Kadoya H, Kaga H, Kai H, Kajio H, Kaluza-Schilling W, Kamaruzaman L, Kamarzarian A, Kamimura Y, Kamiya H, Kamundi C, Kan T, Kanaguchi Y, Kanazawa A, Kanda E, Kanegae S, Kaneko K, Kaneko K, Kang HY, Kano T, Karim M, Karounos D, Karsan W, Kasagi R, Kashihara N, Katagiri H, Katanosaka A, Katayama A, Katayama M, Katiman E, Kato K, Kato M, Kato N, Kato S, Kato T, Kato Y, Katsuda Y, Katsuno T, Kaufeld J, Kavak Y, Kawai I, Kawai M, Kawai M, Kawase A, Kawashima S, Kazory A, Kearney J, Keith B, Kellett J, Kelley S, Kershaw M, Ketteler M, Khai Q, Khairullah Q, Khandwala H, Khoo KKL, Khwaja A, Kidokoro K, Kielstein J, Kihara M, Kimber C, Kimura S, Kinashi H, Kingston H, Kinomura M, Kinsella-Perks E, Kitagawa M, Kitajima M, Kitamura S, Kiyosue A, Kiyota M, Klauser F, Klausmann G, Kmietschak W, Knapp K, Knight C, Knoppe A, Knott C, Kobayashi M, Kobayashi R, Kobayashi T, Koch M, Kodama S, Kodani N, Kogure E, Koizumi M, Kojima H, Kojo T, Kolhe N, Komaba H, Komiya T, Komori H, Kon SP, Kondo M, Kondo M, Kong W, Konishi M, Kono K, Koshino M, Kosugi T, Kothapalli B, Kozlowski T, Kraemer B, Kraemer-Guth A, Krappe J, Kraus D, Kriatselis C, Krieger C, Krish P, Kruger B, Ku Md Razi KR, Kuan Y, Kubota S, Kuhn S, Kumar P, Kume S, Kummer I, Kumuji R, Küpper A, Kuramae T, Kurian L, Kuribayashi C, Kurien R, Kuroda E, Kurose T, Kutschat A, Kuwabara N, Kuwata H, La Manna G, Lacey M, Lafferty K, LaFleur P, Lai V, Laity E, Lambert A, Landray MJ, Langlois M, Latif F, Latore E, Laundy E, Laurienti D, Lawson A, Lay M, Leal I, Leal I, Lee AK, Lee J, Lee KQ, Lee R, Lee SA, Lee YY, Lee-Barkey Y, Leonard N, Leoncini G, Leong CM, Lerario S, Leslie A, Levin A, Lewington A, Li J, Li N, Li X, Li Y, Liberti L, Liberti ME, Liew A, Liew YF, Lilavivat U, Lim SK, Lim YS, Limon E, Lin H, Lioudaki E, Liu H, Liu J, Liu L, Liu Q, Liu WJ, Liu X, Liu Z, Loader D, Lochhead H, Loh CL, Lorimer A, Loudermilk L, Loutan J, Low CK, Low CL, Low YM, Lozon Z, Lu Y, Lucci D, Ludwig U, Luker N, Lund D, Lustig R, Lyle S, Macdonald C, MacDougall I, Machicado R, MacLean D, Macleod P, Madera A, Madore F, Maeda K, Maegawa H, Maeno S, Mafham M, Magee J, Maggioni AP, Mah DY, Mahabadi V, Maiguma M, Makita Y, Makos G, Manco L, Mangiacapra R, Manley J, Mann P, Mano S, Marcotte G, Maris J, Mark P, Markau S, Markovic M, Marshall C, Martin M, Martinez C, Martinez S, Martins G, Maruyama K, Maruyama S, Marx K, Maselli A, Masengu A, Maskill A, Masumoto S, Masutani K, Matsumoto M, Matsunaga T, Matsuoka N, Matsushita M, Matthews M, Matthias S, Matvienko E, Maurer M, Maxwell P, Mayne KJ, Mazlan N, Mazlan SA, Mbuyisa A, McCafferty K, McCarroll F, McCarthy T, McClary-Wright C, McCray K, McDermott P, McDonald C, McDougall R, McHaffie E, McIntosh K, McKinley T, McLaughlin S, McLean N, McNeil L, Measor A, Meek J, Mehta A, Mehta R, Melandri M, Mené P, Meng T, Menne J, Merritt K, Merscher S, Meshykhi C, Messa P, Messinger L, Miftari N, Miller R, Miller Y, Miller-Hodges E, Minatoguchi M, Miners M, Minutolo R, Mita T, Miura Y, Miyaji M, Miyamoto S, Miyatsuka T, Miyazaki M, Miyazawa I, Mizumachi R, Mizuno M, Moffat S, Mohamad Nor FS, Mohamad Zaini SN, Mohamed Affandi FA, Mohandas C, Mohd R, Mohd Fauzi NA, Mohd Sharif NH, Mohd Yusoff Y, Moist L, Moncada A, Montasser M, Moon A, Moran C, Morgan N, Moriarty J, Morig G, Morinaga H, Morino K, Morisaki T, Morishita Y, Morlok S, Morris A, Morris F, Mostafa S, Mostefai Y, Motegi M, Motherwell N, Motta D, Mottl A, Moys R, Mozaffari S, Muir J, Mulhern J, Mulligan S, Munakata Y, Murakami C, Murakoshi M, Murawska A, Murphy K, Murphy L, Murray S, Murtagh H, Musa MA, Mushahar L, Mustafa R, Mustafar R, Muto M, Nadar E, Nagano R, Nagasawa T, Nagashima E, Nagasu H, Nagelberg S, Nair H, Nakagawa Y, Nakahara M, Nakamura J, Nakamura R, Nakamura T, Nakaoka M, Nakashima E, Nakata J, Nakata M, Nakatani S, Nakatsuka A, Nakayama Y, Nakhoul G, Nangaku M, Naverrete G, Navivala A, Nazeer I, Negrea L, Nethaji C, Newman E, Ng SYA, Ng TJ, Ngu LLS, Nimbkar T, Nishi H, Nishi M, Nishi S, Nishida Y, Nishiyama A, Niu J, Niu P, Nobili G, Nohara N, Nojima I, Nolan J, Nosseir H, Nozawa M, Nunn M, Nunokawa S, Oda M, Oe M, Oe Y, Ogane K, Ogawa W, Ogihara T, Oguchi G, Ohsugi M, Oishi K, Okada Y, Okajyo J, Okamoto S, Okamura K, Olufuwa O, Oluyombo R, Omata A, Omori Y, Ong LM, Ong YC, Onyema J, Oomatia A, Oommen A, Oremus R, Orimo Y, Ortalda V, Osaki Y, Osawa Y, Osmond Foster J, O'Sullivan A, Otani T, Othman N, Otomo S, O'Toole J, Owen L, Ozawa T, Padiyar A, Page N, Pajak S, Paliege A, Pandey A, Pandey R, Pariani H, Park J, Parrigon M, Passauer J, Patecki M, Patel M, Patel R, Patel T, Patel Z, Paul R, Paul R, Paulsen L, Pavone L, Peixoto A, Peji J, Peng BC, Peng K, Pennino L, Pereira E, Perez E, Pergola P, Pesce F, Pessolano G, Petchey W, Petr EJ, Pfab T, Phelan P, Phillips R, Phillips T, Phipps M, Piccinni G, Pickett T, Pickworth S, Piemontese M, Pinto D, Piper J, Plummer-Morgan J, Poehler D, Polese L, Poma V, Pontremoli R, Postal A, Pötz C, Power A, Pradhan N, Pradhan R, Preiss D, Preiss E, Preston K, Prib N, Price L, Provenzano C, Pugay C, Pulido R, Putz F, Qiao Y, Quartagno R, Quashie-Akponeware M, Rabara R, Rabasa-Lhoret R, Radhakrishnan D, Radley M, Raff R, Raguwaran S, Rahbari-Oskoui F, Rahman M, Rahmat K, Ramadoss S, Ramanaidu S, Ramasamy S, Ramli R, Ramli S, Ramsey T, Rankin A, Rashidi A, Raymond L, Razali WAFA, Read K, Reiner H, Reisler A, Reith C, Renner J, Rettenmaier B, Richmond L, Rijos D, Rivera R, Rivers V, Robinson H, Rocco M, Rodriguez-Bachiller I, Rodriquez R, Roesch C, Roesch J, Rogers J, Rohnstock M, Rolfsmeier S, Roman M, Romo A, Rosati A, Rosenberg S, Ross T, Rossello X, Roura M, Roussel M, Rovner S, Roy S, Rucker S, Rump L, Ruocco M, Ruse S, Russo F, Russo M, Ryder M, Sabarai A, Saccà C, Sachson R, Sadler E, Safiee NS, Sahani M, Saillant A, Saini J, Saito C, Saito S, Sakaguchi K, Sakai M, Salim H, Salviani C, Sammons E, Sampson A, Samson F, Sandercock P, Sanguila S, Santorelli G, Santoro D, Sarabu N, Saram T, Sardell R, Sasajima H, Sasaki T, Satko S, Sato A, Sato D, Sato H, Sato H, Sato J, Sato T, Sato Y, Satoh M, Sawada K, Schanz M, Scheidemantel F, Schemmelmann M, Schettler E, Schettler V, Schlieper GR, Schmidt C, Schmidt G, Schmidt U, Schmidt-Gurtler H, Schmude M, Schneider A, Schneider I, Schneider-Danwitz C, Schomig M, Schramm T, Schreiber A, Schricker S, Schroppel B, Schulte-Kemna L, Schulz E, Schumacher B, Schuster A, Schwab A, Scolari F, Scott A, Seeger W, Seeger W, Segal M, Seifert L, Seifert M, Sekiya M, Sellars R, Seman MR, Shah S, Shah S, Shainberg L, Shanmuganathan M, Shao F, Sharma K, Sharpe C, Sheikh-Ali M, Sheldon J, Shenton C, Shepherd A, Shepperd M, Sheridan R, Sheriff Z, Shibata Y, Shigehara T, Shikata K, Shimamura K, Shimano H, Shimizu Y, Shimoda H, Shin K, Shivashankar G, Shojima N, Silva R, Sim CSB, Simmons K, Sinha S, Sitter T, Sivanandam S, Skipper M, Sloan K, Sloan L, Smith R, Smyth J, Sobande T, Sobata M, Somalanka S, Song X, Sonntag F, Sood B, Sor SY, Soufer J, Sparks H, Spatoliatore G, Spinola T, Squyres S, Srivastava A, Stanfield J, Staplin N, Staylor K, Steele A, Steen O, Steffl D, Stegbauer J, Stellbrink C, Stellbrink E, Stevens W, Stevenson A, Stewart-Ray V, Stickley J, Stoffler D, Stratmann B, Streitenberger S, Strutz F, Stubbs J, Stumpf J, Suazo N, Suchinda P, Suckling R, Sudin A, Sugamori K, Sugawara H, Sugawara K, Sugimoto D, Sugiyama H, Sugiyama H, Sugiyama T, Sullivan M, Sumi M, Suresh N, Sutton D, Suzuki H, Suzuki R, Suzuki Y, Suzuki Y, Suzuki Y, Swanson E, Swift P, Syed S, Szerlip H, Taal M, Taddeo M, Tailor C, Tajima K, Takagi M, Takahashi K, Takahashi K, Takahashi M, Takahashi T, Takahira E, Takai T, Takaoka M, Takeoka J, Takesada A, Takezawa M, Talbot M, Taliercio J, Talsania T, Tamori Y, Tamura R, Tamura Y, Tan CHH, Tan EZZ, Tanabe A, Tanabe K, Tanaka A, Tanaka A, Tanaka N, Tang S, Tang Z, Tanigaki K, Tarlac M, Tatsuzawa A, Tay JF, Tay LL, Taylor J, Taylor K, Taylor K, Te A, Tenbusch L, Teng KS, Terakawa A, Terry J, Tham ZD, Tholl S, Thomas G, Thong KM, Tietjen D, Timadjer A, Tindall H, Tipper S, Tobin K, Toda N, Tokuyama A, Tolibas M, Tomita A, Tomita T, Tomlinson J, Tonks L, Topf J, Topping S, Torp A, Torres A, Totaro F, Toth P, Toyonaga Y, Tripodi F, Trivedi K, Tropman E, Tschope D, Tse J, Tsuji K, Tsunekawa S, Tsunoda R, Tucky B, Tufail S, Tuffaha A, Turan E, Turner H, Turner J, Turner M, Tuttle KR, Tye YL, Tyler A, Tyler J, Uchi H, Uchida H, Uchida T, Uchida T, Udagawa T, Ueda S, Ueda Y, Ueki K, Ugni S, Ugwu E, Umeno R, Unekawa C, Uozumi K, Urquia K, Valleteau A, Valletta C, van Erp R, Vanhoy C, Varad V, Varma R, Varughese A, Vasquez P, Vasseur A, Veelken R, Velagapudi C, Verdel K, Vettoretti S, Vezzoli G, Vielhauer V, Viera R, Vilar E, Villaruel S, Vinall L, Vinathan J, Visnjic M, Voigt E, von-Eynatten M, Vourvou M, Wada J, Wada J, Wada T, Wada Y, Wakayama K, Wakita Y, Wallendszus K, Walters T, Wan Mohamad WH, Wang L, Wang W, Wang X, Wang X, Wang Y, Wanner C, Wanninayake S, Watada H, Watanabe K, Watanabe K, Watanabe M, Waterfall H, Watkins D, Watson S, Weaving L, Weber B, Webley Y, Webster A, Webster M, Weetman M, Wei W, Weihprecht H, Weiland L, Weinmann-Menke J, Weinreich T, Wendt R, Weng Y, Whalen M, Whalley G, Wheatley R, Wheeler A, Wheeler J, Whelton P, White K, Whitmore B, Whittaker S, Wiebel J, Wiley J, Wilkinson L, Willett M, Williams A, Williams E, Williams K, Williams T, Wilson A, Wilson P, Wincott L, Wines E, Winkelmann B, Winkler M, Winter-Goodwin B, Witczak J, Wittes J, Wittmann M, Wolf G, Wolf L, Wolfling R, Wong C, Wong E, Wong HS, Wong LW, Wong YH, Wonnacott A, Wood A, Wood L, Woodhouse H, Wooding N, Woodman A, Wren K, Wu J, Wu P, Xia S, Xiao H, Xiao X, Xie Y, Xu C, Xu Y, Xue H, Yahaya H, Yalamanchili H, Yamada A, Yamada N, Yamagata K, Yamaguchi M, Yamaji Y, Yamamoto A, Yamamoto S, Yamamoto S, Yamamoto T, Yamanaka A, Yamano T, Yamanouchi Y, Yamasaki N, Yamasaki Y, Yamasaki Y, Yamashita C, Yamauchi T, Yan Q, Yanagisawa E, Yang F, Yang L, Yano S, Yao S, Yao Y, Yarlagadda S, Yasuda Y, Yiu V, Yokoyama T, Yoshida S, Yoshidome E, Yoshikawa H, Young A, Young T, Yousif V, Yu H, Yu Y, Yuasa K, Yusof N, Zalunardo N, Zander B, Zani R, Zappulo F, Zayed M, Zemann B, Zettergren P, Zhang H, Zhang L, Zhang L, Zhang N, Zhang X, Zhao J, Zhao L, Zhao S, Zhao Z, Zhong H, Zhou N, Zhou S, Zhu D, Zhu L, Zhu S, Zietz M, Zippo M, Zirino F, Zulkipli FH. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol 2024; 12:51-60. [PMID: 38061372 DOI: 10.1016/s2213-8587(23)00322-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 10/24/2023] [Accepted: 10/25/2023] [Indexed: 12/23/2023]
Abstract
BACKGROUND The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. METHODS EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. FINDINGS Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62-0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16-1·59), representing a 50% (42-58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). INTERPRETATION In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. FUNDING Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council.
Collapse
|
25
|
Zhai ZY, Yang L, Li H, Li LW, Shen ZH, Zhang XB, Wang ZQ, Wang JL. [Effects of preoperative diagnostic hysteroscopy on peritoneal cytology and prognosis in patients with non-endometrioid carcinoma]. Zhonghua Fu Chan Ke Za Zhi 2023; 58:903-910. [PMID: 38123196 DOI: 10.3760/cma.j.cn112141-20230831-00080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 12/23/2023]
Abstract
Objective: To explore the effects of preoperative hysteroscopic guided biopsy and segmental diagnosis and curettage on the risk of abdominal dissemination and prognosis of non-endometrioid carcinoma. Methods: The clinical and pathological data of 97 patients who underwent surgical treatment and were pathologically confirmed as non-endometrioid carcinoma (including serous carcinoma, clear cell carcinoma, mixed adenocarcinoma, and undifferentiated carcinoma, etc.) from October 2008 to December 2021 in Peking University People's Hospital, were collected for retrospective analysis. According to preoperative diagnostic methods, they were divided into hysteroscopic group (n=44) and non-hysteroscopic group (n=53). The impact of hysteroscopy examination on peritoneal cytology and prognosis was analyzed. Results: (1) There were no statistical differences in age, body mass index, tumor size, pathological characteristics, and treatment methods between the hysteroscopic group and the non-hysteroscopic group (all P>0.05), but the proportion of stage Ⅰ-Ⅱ patients in the hysteroscopic group was significantly higher than that in the non-hysteroscopic group [68% (30/44) vs 47% (25/53); χ2=4.32, P=0.038]. (2) Among 97 patients, 25 (26%, 25/97) of them were cytologically positive for ascites. The hysteroscopic group had a lower positive rate of peritoneal cytology than that in the non-hysteroscopy group, which was significantly different [11% (5/44) vs 38% (20/53); χ2=8.74, P=0.003]. Stratification according to surgical and pathological stages showed that the positive rate of peritoneal cytology in the hysteroscopic group (3%, 1/30) was lower than that in the non-hysteroscopic group (12%, 3/25) in the 55 patients with stage Ⅰ-Ⅱ, and that in the hysteroscopic group (4/14) was also lower than that in the non-hysteroscopic group (61%, 17/28) in the 42 patients with stage Ⅲ-Ⅳ. There were no significant differences (all P>0.05). (3) The 5-year disease-free survival (DFS) rate of the hysteroscopic group and the non-hysteroscopic group were respectively 72.7% and 60.4%, and there was no significant difference between the two groups (P=0.186). After stratification according to staging, the 5-year DFS rate were respectively 90.0% and 72.0% (P=0.051) between the hysteroscopic and non-hysteroscopic groups of patients in stage Ⅰ-Ⅱ, and 35.7% and 50.0% (P=0.218) between the hysteroscopic and non-hysteroscopic groups of patients in stage Ⅲ-Ⅳ, in which there were not statistically significant differences. The 5-year overall survival (OS) rate were respectively 86.4% and 81.1% between the hysteroscopic group and the non-hysteroscopic group, with no significant difference between the two groups (P=0.388). The 5-year OS rate were respectively 93.3% and 96.0% in the hysteroscopic group and non-hysteroscopic group for patients with stage Ⅰ-Ⅱ(P=0.872), and 71.4% and 67.9% in the hysteroscopic group and non-hysteroscopic group in patients with stage Ⅲ-Ⅳ (P=0.999), with no statistical significance. Conclusions: Diagnostic hysteroscopy do not increase the rate of positive peritoneal cytology result at the time of surgery in this cohort, and no significant correlation between preoperative hysteroscopy examination and poor prognosis of non-endometrioid carcinoma is observed. Therefore, preoperative hysteroscopic guided biopsy and segmental diagnosis and curettage in non-endometrioid carcinoma maybe safe.
Collapse
Affiliation(s)
- Z Y Zhai
- Department of Gynecology, Peking University People's Hospital, Beijing 100044, China
| | - L Yang
- Department of Gynecology, Peking University People's Hospital, Beijing 100044, China
| | - H Li
- Department of Gynecology, Peking University People's Hospital, Beijing 100044, China
| | - L W Li
- Department of Gynecology, Peking University People's Hospital, Beijing 100044, China
| | - Z H Shen
- Department of Gynecology, Peking University People's Hospital, Beijing 100044, China
| | - X B Zhang
- Department of Pathology, Peking University People's Hospital, Beijing 100044, China
| | - Z Q Wang
- Department of Gynecology, Peking University People's Hospital, Beijing 100044, China
| | - J L Wang
- Department of Gynecology, Peking University People's Hospital, Beijing 100044, China
| |
Collapse
|
26
|
Yin Q, Yang CH, Strelkova OS, Wu J, Sun Y, Gopalan S, Yang L, Dekker J, Fazzio TG, Li XZ, Gibcus J, Rando OJ. Revisiting chromatin packaging in mouse sperm. Genome Res 2023; 33:gr.277845.123. [PMID: 38129076 PMCID: PMC10760523 DOI: 10.1101/gr.277845.123] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2023] [Accepted: 10/31/2023] [Indexed: 12/23/2023]
Abstract
Mammalian sperm show an unusual and heavily compacted genomic packaging state. In addition to its role in organizing the compact and hydrodynamic sperm head, it has been proposed that sperm chromatin architecture helps to program gene expression in the early embryo. Scores of genome-wide surveys in sperm have reported patterns of chromatin accessibility, nucleosome localization, histone modification, and chromosome folding. Here, we revisit these studies in light of recent reports that sperm obtained from the mouse epididymis are contaminated with low levels of cell-free chromatin. In the absence of proper sperm lysis, we readily recapitulate multiple prominent genome-wide surveys of sperm chromatin, suggesting that these profiles primarily reflect contaminating cell-free chromatin. Removal of cell-free DNA, and appropriate lysis conditions, are together required to reveal a sperm chromatin state distinct from most previous reports. Using ATAC-seq to explore relatively accessible genomic loci, we identify a landscape of open loci associated with early development and transcriptional control. Histone modification and chromosome folding profiles also strongly support the hypothesis that prior studies suffer from contamination, but technical challenges associated with reliably preserving the architecture of the compacted sperm head prevent us from confidently assaying true localization patterns for these epigenetic marks. Together, our studies show that our knowledge of chromosome packaging in mammalian sperm remains largely incomplete, and motivate future efforts to more accurately characterize genome organization in mature sperm.
Collapse
Affiliation(s)
- Qiangzong Yin
- Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, USA
| | - Chih-Hsiang Yang
- Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, USA
| | - Olga S Strelkova
- Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, USA
| | - Jingyi Wu
- Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA
- Gene Regulation Observatory, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA
- Departments of Cell Biology and Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Yu Sun
- Center for RNA Biology: From Genome to Therapeutics, Department of Biochemistry and Biophysics, Department of Urology, University of Rochester Medical Center, Rochester, New York 14642, USA
| | - Sneha Gopalan
- Department of Molecular Cellular and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, USA
| | - Liyan Yang
- Department of Systems Biology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, USA
| | - Job Dekker
- Department of Systems Biology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, USA
- Howard Hughes Medical Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, USA
| | - Thomas G Fazzio
- Department of Molecular Cellular and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, USA
| | - Xin Zhiguo Li
- Center for RNA Biology: From Genome to Therapeutics, Department of Biochemistry and Biophysics, Department of Urology, University of Rochester Medical Center, Rochester, New York 14642, USA
| | - Johan Gibcus
- Department of Systems Biology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, USA
| | - Oliver J Rando
- Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, USA;
| |
Collapse
|
27
|
Ye H, Liu Q, Xu X, Song M, Lu Y, Yang L, Wang W, Wang Y, Li M, Wang D. Construction Strategy for Flexible and Breathable SiO 2/Al/NFs/PET Composite Fabrics with Dual Shielding against Microwave and Infrared-Thermal Radiations for Wearable Protective Clothing. Polymers (Basel) 2023; 16:6. [PMID: 38201671 PMCID: PMC10781071 DOI: 10.3390/polym16010006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Revised: 12/04/2023] [Accepted: 12/08/2023] [Indexed: 01/12/2024] Open
Abstract
Microwave and infrared-thermal radiation-compatible shielding fabrics represent an important direction in the development of wearable protective fabrics. Nevertheless, effectively and conveniently integrating compatible shielding functions into fabrics while maintaining breathability and moisture permeability remains a significant challenge. Here, we take hydrophilic PVA-co-PE nanofibrous film-coated PET fabric (NFs/PET) as a flexible substrate and deposit a dielectric/conductive (SiO2/Al) bilayer film via magnetron sputtering. This strategy endows the fabric surface with high electrical conductivity, nanoscale roughness comparable to visible and infrared waves, and a dielectric-metal contact interface possessing localized plasmon resonance and Mie scattering effects. The results demonstrate that the optimized SiO2/Al/NFs/PET composite conductive fabric (referred to as S4-1) possesses favorable X-band electromagnetic interference (EMI) shielding effectiveness (50 dB) as well as excellent long-wave infrared (LWIR) shielding or IR stealth performance (IR emissivity of 0.60). Notably, the S4-1 fabric has a cooling effect of about 12.4 °C for a heat source (80 °C) and an insulating effect of about 17.2 °C for a cold source (-20 °C), showing excellent shielding capability for heat conduction and heat radiations. Moreover, the moisture permeability of the S4-1 fabric is about 300 g/(m2·h), which is better than the requirement concerning moisture permeability for wearable fabrics (≥2500-5000 g/(m2·24 h)), indicating excellent heat and moisture comfort. In short, our fabrics have lightweight, thin, moisture-permeable and excellent shielding performance, which provides novel ideas for the development of wearable multi-band shielding fabrics applied to complex electromagnetic environments.
Collapse
Affiliation(s)
- Hui Ye
- Key Laboratory of Textile Fiber and Products, Ministry of Education, Wuhan Textile University, Wuhan 430200, China; (H.Y.); (X.X.); (M.S.); (Y.L.); (L.Y.); (W.W.); (Y.W.); (M.L.)
- Hubei International Science and Technology Cooperation Base for Intelligent Textile Material Innovation & Application, Wuhan Textile University, Wuhan 430200, China
| | - Qiongzhen Liu
- Key Laboratory of Textile Fiber and Products, Ministry of Education, Wuhan Textile University, Wuhan 430200, China; (H.Y.); (X.X.); (M.S.); (Y.L.); (L.Y.); (W.W.); (Y.W.); (M.L.)
- Hubei International Science and Technology Cooperation Base for Intelligent Textile Material Innovation & Application, Wuhan Textile University, Wuhan 430200, China
| | - Xiao Xu
- Key Laboratory of Textile Fiber and Products, Ministry of Education, Wuhan Textile University, Wuhan 430200, China; (H.Y.); (X.X.); (M.S.); (Y.L.); (L.Y.); (W.W.); (Y.W.); (M.L.)
- Hubei International Science and Technology Cooperation Base for Intelligent Textile Material Innovation & Application, Wuhan Textile University, Wuhan 430200, China
| | - Mengya Song
- Key Laboratory of Textile Fiber and Products, Ministry of Education, Wuhan Textile University, Wuhan 430200, China; (H.Y.); (X.X.); (M.S.); (Y.L.); (L.Y.); (W.W.); (Y.W.); (M.L.)
- Hubei International Science and Technology Cooperation Base for Intelligent Textile Material Innovation & Application, Wuhan Textile University, Wuhan 430200, China
| | - Ying Lu
- Key Laboratory of Textile Fiber and Products, Ministry of Education, Wuhan Textile University, Wuhan 430200, China; (H.Y.); (X.X.); (M.S.); (Y.L.); (L.Y.); (W.W.); (Y.W.); (M.L.)
- Hubei International Science and Technology Cooperation Base for Intelligent Textile Material Innovation & Application, Wuhan Textile University, Wuhan 430200, China
| | - Liyan Yang
- Key Laboratory of Textile Fiber and Products, Ministry of Education, Wuhan Textile University, Wuhan 430200, China; (H.Y.); (X.X.); (M.S.); (Y.L.); (L.Y.); (W.W.); (Y.W.); (M.L.)
- Hubei International Science and Technology Cooperation Base for Intelligent Textile Material Innovation & Application, Wuhan Textile University, Wuhan 430200, China
| | - Wen Wang
- Key Laboratory of Textile Fiber and Products, Ministry of Education, Wuhan Textile University, Wuhan 430200, China; (H.Y.); (X.X.); (M.S.); (Y.L.); (L.Y.); (W.W.); (Y.W.); (M.L.)
- Hubei International Science and Technology Cooperation Base for Intelligent Textile Material Innovation & Application, Wuhan Textile University, Wuhan 430200, China
| | - Yuedan Wang
- Key Laboratory of Textile Fiber and Products, Ministry of Education, Wuhan Textile University, Wuhan 430200, China; (H.Y.); (X.X.); (M.S.); (Y.L.); (L.Y.); (W.W.); (Y.W.); (M.L.)
- Hubei International Science and Technology Cooperation Base for Intelligent Textile Material Innovation & Application, Wuhan Textile University, Wuhan 430200, China
| | - Mufang Li
- Key Laboratory of Textile Fiber and Products, Ministry of Education, Wuhan Textile University, Wuhan 430200, China; (H.Y.); (X.X.); (M.S.); (Y.L.); (L.Y.); (W.W.); (Y.W.); (M.L.)
- Hubei International Science and Technology Cooperation Base for Intelligent Textile Material Innovation & Application, Wuhan Textile University, Wuhan 430200, China
| | - Dong Wang
- Key Laboratory of Textile Fiber and Products, Ministry of Education, Wuhan Textile University, Wuhan 430200, China; (H.Y.); (X.X.); (M.S.); (Y.L.); (L.Y.); (W.W.); (Y.W.); (M.L.)
- Hubei International Science and Technology Cooperation Base for Intelligent Textile Material Innovation & Application, Wuhan Textile University, Wuhan 430200, China
| |
Collapse
|
28
|
You D, Nie K, Wu X, Weng M, Yang L, Chen Y, Cui J, Wan J. C3a/C3aR synergies with TGF-β to promote epithelial-mesenchymal transition of renal tubular epithelial cells via the activation of the NLRP3 inflammasome. J Transl Med 2023; 21:904. [PMID: 38082306 PMCID: PMC10714586 DOI: 10.1186/s12967-023-04764-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2023] [Accepted: 11/25/2023] [Indexed: 12/18/2023] Open
Abstract
BACKGROUND Complement component 3a and its receptor (C3a/C3aR) and the nucleotide-binding oligomerization domain-like receptor protein-3 (NLRP3) inflammasome contribute to epithelial-mesenchymal transition (EMT). However, the relationship between C3a/C3aR and the NLRP3 inflammasome in EMT remains unclear. This study aimed to elucidate the roles of C3a/C3aR and the NLRP3 inflammasome involved in TGF-β-induced EMT. METHOD Mouse renal tubular epithelial cells (TCMK-1) were exposed to C3a and TGF-β for 48 h. C3aR antagonist, MCC950, an inhibitor of the NLRP3 inflammasome and PD98059, an inhibitor of ERK signaling, were respectively applied to pretreat the cells at 30 min before C3a and TGF-β administration.The cells were collected for western blot, immunofluorescence staining and ELISA. Unilateral ureteral obstruction (UUO) models were established using male C57BL/6 wild-type (WT) mice and age-matched C3aR-deficient mice. MCC950 was intraperitoneally injected in UUO mice. Kidney samples were collected for immunohistochemistry staining. RESULTS In vitro, C3a synergized with TGF-β to promote EMT and the activation of the NLRP3 inflammasome. Inhibition of C3aR attenuated EMT and the activation of the NLRP3 inflammasome. Inhibition of the NLRP3 inflammasome alleviated EMT but didn't affect the expression of C3aR. Inhibition of ERK signaling inhibited the activation of the NLRP3 inflammasome. In vivo, the expression of IL-1β was significantly higher in UUO mice compared to the sham-operated mice. C3aR deficiency and inhibition of the NLRP3 Inflammasome contributed to decreased IL-1β in UUO mice. CONCLUSION Our data revealed that C3a/C3aR synergies with TGF-β to activate the NLRP3 inflammasome to promote epithelial-mesenchymal transition of renal tubular epithelial cells through ERK signaling, and the way in which C3aR activates the inflammasome is to promote the assembly of the NLRP3 inflammasome.
Collapse
Affiliation(s)
- Danyu You
- Department of Nephrology, Blood Purification Research Center, The First Affiliated Hospital of Fujian Medical University, Chazhong Road 20, Fuzhou, 350005, China
- Fujian Clinical Research Center for Metabolic Chronic Kidney Disease, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China
- Department of Nephrology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, China
| | - Kun Nie
- Department of Nephrology, Blood Purification Research Center, The First Affiliated Hospital of Fujian Medical University, Chazhong Road 20, Fuzhou, 350005, China
- Fujian Clinical Research Center for Metabolic Chronic Kidney Disease, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China
- Department of Nephrology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, China
| | - Xiaoting Wu
- Department of Nephrology, Blood Purification Research Center, The First Affiliated Hospital of Fujian Medical University, Chazhong Road 20, Fuzhou, 350005, China
- Fujian Clinical Research Center for Metabolic Chronic Kidney Disease, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China
- Department of Nephrology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, China
| | - Mengjie Weng
- Department of Nephrology, Blood Purification Research Center, The First Affiliated Hospital of Fujian Medical University, Chazhong Road 20, Fuzhou, 350005, China
- Fujian Clinical Research Center for Metabolic Chronic Kidney Disease, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China
- Department of Nephrology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, China
| | - Liyan Yang
- Department of Nephrology, Blood Purification Research Center, The First Affiliated Hospital of Fujian Medical University, Chazhong Road 20, Fuzhou, 350005, China
- Fujian Clinical Research Center for Metabolic Chronic Kidney Disease, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China
- Department of Nephrology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, China
| | - Yi Chen
- Department of Nephrology, Blood Purification Research Center, The First Affiliated Hospital of Fujian Medical University, Chazhong Road 20, Fuzhou, 350005, China
- Fujian Clinical Research Center for Metabolic Chronic Kidney Disease, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China
- Department of Nephrology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, China
| | - Jiong Cui
- Department of Nephrology, Blood Purification Research Center, The First Affiliated Hospital of Fujian Medical University, Chazhong Road 20, Fuzhou, 350005, China
- Fujian Clinical Research Center for Metabolic Chronic Kidney Disease, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China
- Department of Nephrology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, China
| | - Jianxin Wan
- Department of Nephrology, Blood Purification Research Center, The First Affiliated Hospital of Fujian Medical University, Chazhong Road 20, Fuzhou, 350005, China.
- Fujian Clinical Research Center for Metabolic Chronic Kidney Disease, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China.
- Department of Nephrology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, China.
| |
Collapse
|
29
|
Zhou R, Yin MG, Yang L, Wang XT, Chao YG, He W. [Analysis and treatment workflow of modified seven-step approach for acute respiratory and circulatory disorders]. Zhonghua Nei Ke Za Zhi 2023; 62:1423-1429. [PMID: 38044068 DOI: 10.3760/cma.j.cn112138-20230405-00183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/05/2023]
Abstract
Acute respiratory and circulatory disorders are the most common critical syndromes, the essence of which is damage to the organs/systems of the heart and lungs. These comprise the essential manifestation of disease and injury progression to the severe stage. Its development involves the following components: individual specificity, primary disease strike, dysregulation of the host's response, and systemic disorders. Admission for acute respiratory and circulatory disorders is a clinical challenge. Based on a previously proposed flow, a critical care ultrasound-based stepwise approach (PIEPEAR) as a standard procedure to manage patients with acute cardiorespiratory compromise and practical experience in recent years, a modified seven-step analysis and treatment process has been developed to help guide clinicians with rational thinking and standardized treatment when faced with acute respiratory and circulatory disorders. The process consists of seven steps: problem-based clinical analysis, intentional information acquisition, evaluation of core disorder based on critical care ultrasound, pathophysiology and host response phenotype identification, etiology diagnosis, act treatment through pathophysiology-host response and etiology, and re-check. The modified seven-step approach is guided by a "modular analysis" style of thinking and visual monitoring. This approach can strengthen the identification of clinical problems and facilitate a three-in-one analysis. It focuses on pathophysiological disorders, body reactions, and primary causes to more accurately understand the condition's key points, and make treatment more straight forward, to finally achieve the aim of "comprehensive cognition and refined treatment".
Collapse
Affiliation(s)
- R Zhou
- Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
| | - M G Yin
- Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
| | - L Yang
- Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
| | - X T Wang
- Department of Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
| | - Y G Chao
- Department of Critical Care Medicine, the First Affiliated Hospital of Tsinghua University, Beijing 100016, China
| | - W He
- Department of Critical Care Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing 100041, China
| |
Collapse
|
30
|
Yang L, Chen W, Zeng J, Pan S. Regional differences in spatial determinants of land urbanization in China. Environ Sci Pollut Res Int 2023; 30:119260-119274. [PMID: 37925374 DOI: 10.1007/s11356-023-30765-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Accepted: 10/26/2023] [Indexed: 11/06/2023]
Abstract
China has entered a critical stage of urbanization transition but still faces unbalanced regional development and uncoordinated urban-rural integration. Studying the regional differences in spatial determinants of land urbanization (LU) is crucial to achieving coordinated regional development of urbanization. However, the spatial determinants of LU remain unclear, especially in terms of their regional differences. Therefore, this study introduced dynamic distribution and spatial analysis to measure regional differences in spatial determinants of LU in China. During 1990-2020, the imbalance of LU in China was constantly decreasing, and the differences in LU among different regions were also decreasing. LU in China had significant spatial dependence and spatial spillover effects, and the trend of group development was gradually becoming obvious. LU in eastern region was more affected by natural factors than in central and western regions, while central and western regions were more affected by socioeconomic factors than in eastern region. This study can provide a scientific reference for understanding the spatial disequilibrium of LU and promoting the regional implementation of LU coordinated development.
Collapse
Affiliation(s)
- Liyan Yang
- Department of Geography, School of Geography and Information Engineering, China University of Geosciences, Wuhan, 430074, China
| | - Wanxu Chen
- Department of Geography, School of Geography and Information Engineering, China University of Geosciences, Wuhan, 430074, China.
- Institute of Geographic Sciences and Natural Resources Research, Chinese Academy of Sciences, Beijing, 100101, China.
| | - Jie Zeng
- Department of Geography, School of Geography and Information Engineering, China University of Geosciences, Wuhan, 430074, China
| | - Sipei Pan
- College of Land Management, Nanjing Agricultural University, Nanjing, 210095, China
| |
Collapse
|
31
|
Yang L, Yang Y, Yu W, Wang Q, Zhong B, Hua K, Liu Y, Huang Y. [Prevalence of Echinococcus infections in wild carnivores based on copro - DNA tests in Serthar County of Sichuan Province]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2023; 35:492-496. [PMID: 38148538 DOI: 10.16250/j.32.1374.2023063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 12/28/2023]
Abstract
OBJECTIVE To investigate the prevalence of Echinococcus infections in wild carnivores in Serthar County, Sichuan Province, so as to provide insights into echinococcosis control in local areas. METHODS Stool samples were collected from wild carnivores in Serthar County, Sichuan Province in May 2021, and the host sources of stool samples and Echinococcus infections were identified using PCR assays. The prevalence of E. multilocularis, E. granulosus and E. shiquicus infections was estimated in different hosts. RESULTS A total of 583 stool samples were collected from wild carnivores, including 147 stool samples from fox, 154 from wolf, 227 from wild dogs and 11 from lynx. The overall prevalence of E. multilocularis, E. granulosus and E. shiquicus infections was 5.68%, 0.19% and 14.20% in canine stool samples, and no E. granulosus infection was detected in fox stool samples, while the prevalence of E. multilocularis and E. shiquicus infections was 0.68% and 47.62% in fox stool samples (χ2 = 88.41, P < 0.001). No E. granulosus or E. shiquicus infection was detected in wolf stool samples, and the prevalence of E. multilocularis infection was 10.39% in wolf stool samples. The prevalence of E. multilocularis, E. granulosus and E. shiquicus infections was 5.73%, 0.44% and 2.20% in canine stool samples (χ2 = 12.13, P < 0.01). In addition, the prevalence of E. multilocularis infections was significantly higher in wolf stool samples than in canine and fox stool samples (χ2 = 13.23, P < 0.01), and the prevalence of E. shiquicus infections was significantly higher in fox stool samples than in canine and wolf stool samples (χ2 = 187.01, P < 0.001). No Echinococcus infection was identified in 11 lynx stool samples. CONCLUSIONS The prevalence of Echinococcus infections is high in wild canines in Serthar County, Sichuan Province. Wolf, wild dog and fox all participate in the wild life cycle of E. multilocularis in Serthar County, and wolf and wild dogs may play a more important role.
Collapse
Affiliation(s)
- L Yang
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuang 610041, China
| | - Y Yang
- Serthar County Center for Disease Control and Prevention, Garze Tibetan Autonomous Prefecture, Sichuan Province, China
| | - W Yu
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuang 610041, China
| | - Q Wang
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuang 610041, China
| | - B Zhong
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuang 610041, China
| | - K Hua
- Serthar County Center for Disease Control and Prevention, Garze Tibetan Autonomous Prefecture, Sichuan Province, China
| | - Y Liu
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuang 610041, China
| | - Y Huang
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuang 610041, China
| |
Collapse
|
32
|
Peng Q, Wu N, Huang Y, Zhao SJ, Tang W, Liang M, Ran YL, Xiao T, Yang L, Liang X. [Diagnostic values of conventional tumor markers and their combination with chest CT for patients with stageⅠA lung cancer]. Zhonghua Zhong Liu Za Zhi 2023; 45:934-941. [PMID: 37968078 DOI: 10.3760/cma.j.cn112152-20220208-00082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/17/2023]
Abstract
Objective: To investigate the diagnostic efficiency of conventional serum tumor markers and their combination with chest CT for stage ⅠA lung cancer. Methods: A total of 1 155 patients with stage ⅠA lung cancer and 200 patients with benign lung lesions (confirmed by surgery) treated at the Cancer Hospital, Chinese Academy of Medical Sciences from January 2016 to October 2020 were retrospectively enrolled in this study. Six conventional serum tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), squamous cell carcinoma associated antigen (SCCA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), and gastrin-releasing peptide precursor (ProGRP)] and chest thin-slice CT were performed on all patients one month before surgery. Pathology was taken as the gold standard to analyze the difference of positivity rates of tumor markers between the lung cancer group and the benign group, the moderate/poor differentiation group and the well differentiation group, the adenocarcinoma group and the squamous cell carcinoma group, the lepidic and non-lepidic predominant adenocarcinoma groups, the solid nodule group and the subsolid nodule group based on thin-slice CT, and subgroups of ⅠA1 to ⅠA3 lung cancers. The diagnostic performance of tumor markers and tumor markers combined with chest CT was analyzed using the receiver operating characteristic curve. Results: The positivity rates of six serum tumor markers in the lung cancer group and the benign group were 2.32%-20.08% and 0-13.64%, respectively; only the SCCA positivity rate in the lung cancer group was higher than that in the benign group (10.81% and 0, P=0.022). There were no significant differences in the positivity rates of other serum tumor markers between the two groups (all P>0.05). The combined detection of six tumor markers showed that the positivity rate of the lung cancer group was higher than that of the benign group (40.93% and 18.18%, P=0.004), and the positivity rate of the adenocarcinoma group was lower than that of the squamous cell carcinoma group (35.66% and 47.41%, P=0.045). The positivity rates in the poorly differentiated group and moderately differentiated group were higher than that in the well differentiated group (46.48%, 43.75% and 22.73%, P=0.025). The positivity rate in the non-lepidic adenocarcinoma group was higher than that in lepidic adenocarcinoma group (39.51% and 21.74%, P=0.001). The positivity rate of subsolid nodules was lower than that of solid nodules (30.01% vs 58.71%, P=0.038), and the positivity rates of stageⅠA1, ⅠA2 and ⅠA3 lung cancers were 33.33%, 48.96% and 69.23%, respectively, showing an increasing trend (P=0.005). The sensitivity and specificity of the combined detection of six tumor markers in the diagnosis of stage ⅠA lung cancer were 74.00% and 56.30%, respectively, and the area under the curve (AUC) was 0.541. The sensitivity and specificity of the combined detection of six serum tumor markers with CT in the diagnosis of stage ⅠA lung cancer were 83.0% and 78.3%, respectively, and the AUC was 0.721. Conclusions: For stage ⅠA lung cancer, the positivity rates of commonly used clinical tumor markers are generally low. The combined detection of six markers can increase the positivity rate. The positivity rate of markers tends to be higher in poorly differentiated lung cancer, squamous cell carcinoma, or solid nodules. Tumor markers combined with thin-slice CT showed limited improvement in diagnostic efficiency for early lung cancer.
Collapse
Affiliation(s)
- Q Peng
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - N Wu
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Y Huang
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - S J Zhao
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - W Tang
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - M Liang
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Y L Ran
- State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - T Xiao
- State Key Laboratory of Molecular Oncology, Beijing Key Laboratory for Carcinogenesis and Cancer Prevention, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - L Yang
- Department of Pathology Diagnosis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - X Liang
- Medical Statistics Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| |
Collapse
|
33
|
Adhikari G, Carlin N, Choi JJ, Choi S, Ezeribe AC, França LE, Ha C, Hahn IS, Hollick SJ, Jeon EJ, Jo JH, Joo HW, Kang WG, Kauer M, Kim BH, Kim HJ, Kim J, Kim KW, Kim SH, Kim SK, Kim WK, Kim YD, Kim YH, Ko YJ, Lee DH, Lee EK, Lee H, Lee HS, Lee HY, Lee IS, Lee J, Lee JY, Lee MH, Lee SH, Lee SM, Lee YJ, Leonard DS, Luan NT, Manzato BB, Maruyama RH, Neal RJ, Nikkel JA, Olsen SL, Park BJ, Park HK, Park HS, Park KS, Park SD, Pitta RLC, Prihtiadi H, Ra SJ, Rott C, Shin KA, Cavalcante DFFS, Scarff A, Spooner NJC, Thompson WG, Yang L, Yu GH. Search for Boosted Dark Matter in COSINE-100. Phys Rev Lett 2023; 131:201802. [PMID: 38039466 DOI: 10.1103/physrevlett.131.201802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Accepted: 10/30/2023] [Indexed: 12/03/2023]
Abstract
We search for energetic electron recoil signals induced by boosted dark matter (BDM) from the galactic center using the COSINE-100 array of NaI(Tl) crystal detectors at the Yangyang Underground Laboratory. The signal would be an excess of events with energies above 4 MeV over the well-understood background. Because no excess of events are observed in a 97.7 kg·yr exposure, we set limits on BDM interactions under a variety of hypotheses. Notably, we explored the dark photon parameter space, leading to competitive limits compared to direct dark photon search experiments, particularly for dark photon masses below 4 MeV and considering the invisible decay mode. Furthermore, by comparing our results with a previous BDM search conducted by the Super-Kamionkande experiment, we found that the COSINE-100 detector has advantages in searching for low-mass dark matter. This analysis demonstrates the potential of the COSINE-100 detector to search for MeV electron recoil signals produced by the dark sector particle interactions.
Collapse
Affiliation(s)
- G Adhikari
- Department of Physics and Wright Laboratory, Yale University, New Haven, Connecticut 06520, USA
| | - N Carlin
- Physics Institute, University of São Paulo, 05508-090, São Paulo, Brazil
| | - J J Choi
- Department of Physics and Astronomy, Seoul National University, Seoul 08826, Republic of Korea
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - S Choi
- Department of Physics and Astronomy, Seoul National University, Seoul 08826, Republic of Korea
| | - A C Ezeribe
- Department of Physics and Astronomy, University of Sheffield, Sheffield S3 7RH, United Kingdom
| | - L E França
- Physics Institute, University of São Paulo, 05508-090, São Paulo, Brazil
| | - C Ha
- Department of Physics, Chung-Ang University, Seoul 06973, Republic of Korea
| | - I S Hahn
- Department of Science Education, Ewha Womans University, Seoul 03760, Republic of Korea
- Center for Exotic Nuclear Studies, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
| | - S J Hollick
- Department of Physics and Wright Laboratory, Yale University, New Haven, Connecticut 06520, USA
| | - E J Jeon
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - J H Jo
- Department of Physics and Wright Laboratory, Yale University, New Haven, Connecticut 06520, USA
| | - H W Joo
- Department of Physics and Astronomy, Seoul National University, Seoul 08826, Republic of Korea
| | - W G Kang
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - M Kauer
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - B H Kim
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - H J Kim
- Department of Physics, Kyungpook National University, Daegu 41566, Republic of Korea
| | - J Kim
- Department of Physics, Chung-Ang University, Seoul 06973, Republic of Korea
| | - K W Kim
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - S H Kim
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - S K Kim
- Department of Physics and Astronomy, Seoul National University, Seoul 08826, Republic of Korea
| | - W K Kim
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
| | - Y D Kim
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
- Department of Physics, Sejong University, Seoul 05006, Republic of Korea
| | - Y H Kim
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
- Korea Research Institute of Standards and Science, Daejeon 34113, Republic of Korea
| | - Y J Ko
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - D H Lee
- Department of Physics, Kyungpook National University, Daegu 41566, Republic of Korea
| | - E K Lee
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - H Lee
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
| | - H S Lee
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
| | - H Y Lee
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - I S Lee
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - J Lee
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - J Y Lee
- Department of Physics, Kyungpook National University, Daegu 41566, Republic of Korea
| | - M H Lee
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
| | - S H Lee
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
| | - S M Lee
- Department of Physics and Astronomy, Seoul National University, Seoul 08826, Republic of Korea
| | - Y J Lee
- Department of Physics, Chung-Ang University, Seoul 06973, Republic of Korea
| | - D S Leonard
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - N T Luan
- Department of Physics, Kyungpook National University, Daegu 41566, Republic of Korea
| | - B B Manzato
- Physics Institute, University of São Paulo, 05508-090, São Paulo, Brazil
| | - R H Maruyama
- Department of Physics and Wright Laboratory, Yale University, New Haven, Connecticut 06520, USA
| | - R J Neal
- Department of Physics and Astronomy, University of Sheffield, Sheffield S3 7RH, United Kingdom
| | - J A Nikkel
- Department of Physics and Wright Laboratory, Yale University, New Haven, Connecticut 06520, USA
| | - S L Olsen
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - B J Park
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- IBS School, University of Science and Technology (UST), Daejeon 34113, Republic of Korea
| | - H K Park
- Department of Accelerator Science, Korea University, Sejong 30019, Republic of Korea
| | - H S Park
- Korea Research Institute of Standards and Science, Daejeon 34113, Republic of Korea
| | - K S Park
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - S D Park
- Department of Physics, Kyungpook National University, Daegu 41566, Republic of Korea
| | - R L C Pitta
- Physics Institute, University of São Paulo, 05508-090, São Paulo, Brazil
| | - H Prihtiadi
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - S J Ra
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - C Rott
- Department of Physics, Sungkyunkwan University, Suwon 16419, Republic of Korea
- Department of Physics and Astronomy, University of Utah, Salt Lake City, Utah 84112, USA
| | - K A Shin
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - D F F S Cavalcante
- Physics Institute, University of São Paulo, 05508-090, São Paulo, Brazil
| | - A Scarff
- Department of Physics and Astronomy, University of Sheffield, Sheffield S3 7RH, United Kingdom
| | - N J C Spooner
- Department of Physics and Astronomy, University of Sheffield, Sheffield S3 7RH, United Kingdom
| | - W G Thompson
- Department of Physics and Wright Laboratory, Yale University, New Haven, Connecticut 06520, USA
| | - L Yang
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - G H Yu
- Center for Underground Physics, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
- Department of Physics, Sungkyunkwan University, Suwon 16419, Republic of Korea
| |
Collapse
|
34
|
Zhang N, Yue Q, Yang L, Song WH, Wang X, Wu SL, Liu T. [Associations between risk factor control and survival among cancer patients]. Zhonghua Yi Xue Za Zhi 2023; 103:3402-3409. [PMID: 37963738 DOI: 10.3760/cma.j.cn112137-20230905-00397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/16/2023]
Abstract
Objective: This study aimed to evaluate the associations between the number of cardiovascular risk factor goals achieved with all-cause mortality, atherosclerotic cardiovascular diseases (ASCVD)-related mortality, and cancer-related mortality amongst cancer patients. Methods: From 2006 to 2020, a total of 2 079 individuals with newly diagnosed cancer, free of ASCVD, were enrolled in this study from the Kailuan cohort. Patients were classified into three groups (group 1,≤1 risk factor at goal, n=407; group 2, 2 risk factors at goal, n=865; group 3,≥3 risk factors at goal, n=807) according to the control status of blood pressure, fasting blood glucose, low-density lipoprotein cholesterol and high-sensitivity C-reactive protein, using health checkup results of the latest survey after cancer diagnosis. Multivariable Cox regression analyses were performed to examine the associations between the number of risk factors at goals with all-cause mortality, ASCVD-related mortality, and cancer-related mortality. Results: The mean age at diagnosis was (60.4±10.4) years, and 71.2% were male. During a median follow-up of 2.95 (1.38, 5.12) years, 600 cases of all-cause mortality, 63 cases of ASCVD-related mortality, and 314 cases of cancer-related mortality were observed. After adjusting for age, gender, education level, smoking status, alcohol consumption, salt intake, physical activity, body mass index, triglyceride, high-density lipoprotein cholesterol, family history of cardiovascular diseases, antihypertensive drugs, hypoglycemic drugs, lipid-lowering drugs, and anti-cancer medications, compared with cancer patients achieving ≤1 risk factor goal, those achieving ≥3 risk factor goals showed significantly decreased risk of all-cause mortality, ASCVD mortality, and cancer mortality, with HR (95%CI) of 0.68 (0.54-0.86), 0.35 (0.16-0.77), and 0.60 (0.43-0.82), respectively (all P values <0.05). Significant relationships between the number of risk factor goals achieved and decreased mortality of all kinds were observed (all P values for trend<0.05). Results of the subgroup analyses suggested that the associations between the number of risk factor goals achieved and lower mortality of all kinds were more prominent among individuals who were ≥60 years, male, and those with respiratory and reproductive cancers (all P values <0.05). Conclusions: This study suggested a significant association between the number of cardiovascular risk factor goals achieved and survival in cancer patients, especially amongst those who were older, male, with respiratory cancers and reproductive cancers.
Collapse
Affiliation(s)
- N Zhang
- Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Q Yue
- Department of Preventive Medicine, School of Public Health, North China University of Science and Technology, Tangshan 063210, China
| | - L Yang
- Department of Preventive Medicine, School of Public Health, North China University of Science and Technology, Tangshan 063210, China
| | - W H Song
- Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - X Wang
- Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - S L Wu
- Department of Cardiology, Kailuan Hospital, North China University of Science and Technology, Tangshan 063001, China
| | - T Liu
- Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
| |
Collapse
|
35
|
Wei YQ, Wan BN, Shen B, Yang L, Ji F, Wang Y, Chen M, Liu ZJ. An alternating continuous integration system for magnetic measurements for experimental advanced superconducting tokamak. Rev Sci Instrum 2023; 94:115101. [PMID: 37909840 DOI: 10.1063/5.0169108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/23/2023] [Accepted: 10/11/2023] [Indexed: 11/03/2023]
Abstract
Integrators are critical instruments used for magnetic measurement systems (MMSs) in tokamaks, and, currently, the Experimental Advanced Superconducting Tokamak (EAST) has over 600 deployed. However, these integrators, designed with real-time drift compensation, will not be able to support longer pulse operations in the near future due to saturation and drift. To address these issues, this paper proposes a new alternating integration system combining analog integration with drift digital rectification. This system utilizes a microcontroller unit (MCU) to control two parallel analog integrators to work alternatively, compensate their drifts based on their respective error characteristics, and assemble the two integration segments together. The designed architecture provides highly flexible capabilities in operation modes and error correction, which make the system operation and maintenance highly automated. Performance tests on the EAST experiment site show that the prototype integrator can meet the requirements of real-time plasma control for a duration of hour-level.
Collapse
Affiliation(s)
- Y Q Wei
- School of Instrument Science and Optoelectronics Engineering, Hefei University of Technology, Hefei 230009, China
| | - B N Wan
- Institute of Plasma Physics, Chinese Academy of Sciences, Hefei 230031, China
| | - B Shen
- Institute of Plasma Physics, Chinese Academy of Sciences, Hefei 230031, China
| | - L Yang
- School of Instrument Science and Optoelectronics Engineering, Hefei University of Technology, Hefei 230009, China
| | - F Ji
- School of Instrument Science and Optoelectronics Engineering, Hefei University of Technology, Hefei 230009, China
| | - Y Wang
- Institute of Plasma Physics, Chinese Academy of Sciences, Hefei 230031, China
| | - M Chen
- Institute of Plasma Physics, Chinese Academy of Sciences, Hefei 230031, China
| | - Z J Liu
- School of Instrument Science and Optoelectronics Engineering, Hefei University of Technology, Hefei 230009, China
| |
Collapse
|
36
|
Lu G, Su Y, Jiang Y, Yang L, Wang Y, Shi G, Zhang F, Duan X, Hu H. Improving the visualisation of perforator arteries for anterolateral thigh flaps harvest in CT angiography via sublingual glyceryl trinitrate. Clin Radiol 2023; 78:e791-e797. [PMID: 37574403 DOI: 10.1016/j.crad.2023.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 07/05/2023] [Accepted: 07/08/2023] [Indexed: 08/15/2023]
Abstract
AIM To investigate the improvement of image quality and visualisation of the anterolateral thigh (ALT) flap perforators on computed tomography angiography (CTA) after administration of sublingual glyceryl trinitrate (GTN). MATERIALS AND METHODS Sixty patients with oral lesions received thigh CTA examinations were divided randomly into two groups after administration of sublingual GTN (GTN group) or without administration of sublingual GTN (non-GTN group). Two radiologists calculated the signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and assessed the image quality of each vessel. Besides, the grade of thigh artery, the lumen diameter of deep femoral artery, lateral circumflex femoral artery (LCFA), the descending branch of LCFA and its proximal and distal perforators, and the number and type of visible perforators were evaluated quantitatively. RESULTS The SNR and CNR were not significantly different between the two groups (p>0.05). The image quality of CTA in the GTN group was significantly better than that in the non-GTN group (p<0.01). The lumen diameters of the deep femoral artery, LCFA, the descending branch of LCFA and its perforators were significantly larger in the GTN group than those in the non-GTN group (p<0.01). Compared with the non-GTN group, the number of visible perforators and the number of visible septocutaneous perforators were significantly more in the GTN group, and the qualitative grade of visible perforators was significantly higher (p<0.001). CONCLUSIONS The administration of sublingual GTN in preoperative thigh CTA can improve the image quality and visualisation of perforator vessels, thus could help surgeons to select the optimum ALT flaps.
Collapse
Affiliation(s)
- G Lu
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China
| | - Y Su
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China
| | - Y Jiang
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China
| | - L Yang
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China
| | - Y Wang
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China
| | - G Shi
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
| | - F Zhang
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China
| | - X Duan
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
| | - H Hu
- Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China.
| |
Collapse
|
37
|
Li CY, Chen S, Qian WL, Yang L, Zheng Q, Chen AJ, Chen J, Huang K, Fang S, Wang P, Hu L, Liu XR, Zhao XQ, Tan N, Cai T. [Clinical observation on the efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis]. Zhonghua Yu Fang Yi Xue Za Zhi 2023; 57:1590-1595. [PMID: 37859375 DOI: 10.3760/cma.j.cn112150-20221103-01063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 10/21/2023]
Abstract
To investigate the clinical efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis (AD) in China. A small sample self-controlled study before and after treatment was conducted to retrospective analysis patients with moderate to severe AD treated with dupilumab in the department of dermatology of the First Affiliated Hospital of Chongqing Medical University from July 2020 to March 2022. Dupilumab 600 mg was injected subcutaneously at week 0, and then 300 mg was injected subcutaneously every 2 weeks. The condition was evaluated by SCORAD(severity scoring of atopic dermatitis), NRS(numerical rating scale), DLQI(dermatology life quality index) and POEM(patient-oriented eczema measure). The improvement of SCORAD, NRS, DLQI and POEM was analyzed by paired t test and non-parametric paired Wilcoxon. The results showed that a total of 67 patients with moderate to severe AD received dupilumab treatment, of which 41 patients (the course of treatment was more than 6 weeks) had reduced the severity of skin lesions, improved quality of life and reduced pruritus. A total of 23 patients completed 16 weeks of treatment. At 4, 8, 12 and 16 weeks, SCORAD, NRS, DLQI and POEM decreased compared with the baseline, and the differences were statistically significant. SCORAD (50.13±15.19) at baseline, SCORAD (36.08±11.96)(t=6.049,P<0.001) at week 4,SCORAD (28.04±11.10)(t=10.471,P<0.001) at week 8, SCORAD (22.93±9.72)(t=12.428,P<0.001) at week 12, SCORAD (16.84±7.82)(t=14.609,P<0.001) at week 16, NRS 7(6,8) at baseline, NRS 4(3,5)(Z=-3.861,P<0.001) at week 4, NRS 2(1,4)(Z=-4.088,P<0.001) at week 8, NRS 1(0,2)(Z=-4.206,P<0.001) at week 12, NRS 2(0,2)(Z=-4.222,P<0.001) at week 16, DLQI (13.83±5.71) at baseline, DLQI (8.00±4.02)(t=6.325,P<0.001) at week 4, DLQI (5.61±3.50)(t=8.060,P<0.001) at week 8, DLQI (3.96±1.99)(t=8.717,P<0.001) at week 12, DLQI (2.70±1.89)(t=10.355,P<0.001) at week 16, POEM (18.04±6.41) at baseline, POEM (9.70±4.70)(t=7.031,P<0.001) at week 4, POEM (7.74±3.48)(t=8.806,P<0.001) at week 8, POEM (6.35±3.33)(t=10.474,P<0.001) at week 12, POEM (4.26±2.51)(t=11.996,P<0.001) at week 16. In the 16th week, 100%(23 patients), 91.3%(21 patients), 34.8%(8 patients) and 8.7%(2 patients) of 23 patients reached SCORAD30, SCORAD50, SCORAD70, and SCORAD90 statuses, respectively. There were 82.6%(19 patients), 95.7%(22 patients) and 95.7%(22 patients) of 23 patients with NRS, DLQI and POEM improved by≥4 points compared with baseline. Twelve patients with AD who continued to receive dupilumab after 16 weeks showed further improvement in skin lesions. The adverse events were conjunctivitis and injection site reaction. In conclusion, dupilumab is an effective and safe treatment for moderate and severe AD. However, the longer-term efficacy and safety require further studies involving larger sample sizes and a longer follow-up time.
Collapse
Affiliation(s)
- C Y Li
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - S Chen
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - W L Qian
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - L Yang
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - Q Zheng
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - A J Chen
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - J Chen
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - K Huang
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - S Fang
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - P Wang
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - L Hu
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - X R Liu
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - X Q Zhao
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - N Tan
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| | - T Cai
- Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042, China
| |
Collapse
|
38
|
Xu Z, Liang J, Fu R, Yang L, Xin Chen Y, Ren W, Lu Y, Qiu X, Gu Q. Effect of PD-L1 Expression for the PD-1/L1 Inhibitors on Non-small Cell Lung Cancer: A Meta-analysis Based on Randomised Controlled Trials. Clin Oncol (R Coll Radiol) 2023; 35:640-651. [PMID: 37563075 DOI: 10.1016/j.clon.2023.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2023] [Revised: 06/23/2023] [Accepted: 07/28/2023] [Indexed: 08/12/2023]
Abstract
AIMS As PD-L1 expression has been proposed as one of the cancer biomarkers for non-small cell lung cancer (NSCLC), the predictive value of tumour proportional score (TPS) in the effect of immunotherapy [programmed death protein-1/ligand 1 (PD-1/L1) inhibitors] for NSCLC is worth exploring further. Here, we aimed to summarise the outcomes of current NSCLC randomised controlled trials (RCTs) and explore the predictive value of TPS in clinical immunotherapy, including immune checkpoint inhibitors (ICIs) with or without chemotherapy. MATERIALS AND METHODS RCTs published by PubMed, Medline, Embase and Scopus before February 2023 comparing immunotherapy (PD-1/L1 with or without other therapy) versus a control group in advanced or metastatic NSCLC were included to assess the prognosis according to the patients' TPS with 1% and 50% as the thresholds. The primary endpoints were overall survival and progression-free survival. RESULTS In total, 28 RCTs containing 17 266 participants with advanced or metastatic NSCLC were included in this meta-analysis. Statistical results showed that compared with TPS <1%, ≥1% or within 1-49%, patients with TPS ≥50% benefited more significantly from the immunotherapy. A subgroup analysis showed that when TPS was <1%, ≥1% or within 1-49%, ICIs + chemotherapy had better efficacy than ICIs alone; PD-1 (such as pembrolizumab) inhibitors had better efficacy than PD-L1 inhibitors (such as atezolizumab). CONCLUSION The efficacy of immunotherapy (PD-1/L1 inhibitors) for advanced or metastatic NSCLC is influenced by TPS.
Collapse
Affiliation(s)
- Z Xu
- Department of Respiratory and Critical Care Medicine, Linhai Second People's Hospital, Taizhou, Zhejiang, China
| | - J Liang
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - R Fu
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - L Yang
- Emergency Medical Center, Ningbo Yinzhou No. 2 Hospital, Ningbo, Zhejiang, China
| | - Y Xin Chen
- The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - W Ren
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - Y Lu
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - X Qiu
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - Q Gu
- Department of Respiratory and Critical Care Medicine, Linhai Second People's Hospital, Taizhou, Zhejiang, China.
| |
Collapse
|
39
|
Li B, Yang L, Jiang C, Li H, Qin W, Dong T, Wang L. Outcome Supervised Deep Learning Model on Pathological Whole Slide Images for Survival Prediction of Immunotherapy in Non-Small Cell Lung Cancer Patients: A Multicenter Study. Int J Radiat Oncol Biol Phys 2023; 117:e35. [PMID: 37785211 DOI: 10.1016/j.ijrobp.2023.06.724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Although PD-(L)1 inhibitors were marked by durable efficacy in non-small cell lung cancer patients (NSCLC), about 60% of patients still suffer from recurrence and metastasis after PD-(L)1 inhibitors treatment. And there were no robust biomarkers of the response of PD-(L)1 inhibitors. Whole slide images (WSIs) of H&E-stained specimens have been found to characterize the tumor microenvironment, and might be the potential prognostic predictors of NSCLC patients. To accurately predict the response to PD-(L)1 inhibitors, we presented the deep learning model based on WSI of H&E-stained specimens of NSCLC patients. MATERIALS/METHODS Two independent cohorts of NSCLC patients receiving PD-(L)1 inhibitors from two hospitals were enrolled for model training and testing respectively. The WSI images of H&E-stained histological specimens were obtained from these patients, and patched into 1024×1024 pixels. The labels of patched images were determined due to their progression free survival (PFS) with the interval of 4 months. The patch-level model was firstly trained based on Vit to identify the predictive patches in training cohort, and patch-level probability distribution was performed. Then we trained patient-level survival model-based Vit-RNN framework, and tested it in external validation cohort. RESULTS A total of 291 WSI images of H&E-stained histological specimens from 198 NSCLC patients in primary cohort and 62 WSI images from 30 NSCLC patients in testing cohort were included for model training and external validation. All patients were divided into 4 groups due to their PFS after PD-(L)1 inhibitors. There were 246,318 patches from 291 images in primary cohort after image pre-processing, and all images were randomly divided into train cohort and validation cohort with the proportion of 7:3. The patch-level Vit model with the highest accuracy was saved and the predictive patches were selected after 50 epochs training. All patches were ranked by the probability of correct prediction, and the first 50 top-ranked patches from each WSI image are sequentially passed to the patient-level Vit-RNN model. The Vit-RNN survival achieved an accuracy of 88.6% in the validation cohort, and an accuracy of 81% in the testing cohort. The multivariate cox analysis also indicated the Vit-RNN survival model remained a statistically independent predictor of survival from PD-(L)1 inhibitors (P = 0.0085). CONCLUSION The outcome supervised Vit-RNN survival model based on pathological WSIs could be used to predict the efficacy the PD-(L)1 inhibitors in NSCLC patients, laying the foundation for the deployment of computational pathomics in clinical practice of immunotherapy.
Collapse
Affiliation(s)
- B Li
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - L Yang
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - C Jiang
- Department of Otorhinolaryngology & Head and Neck Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - H Li
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - W Qin
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - T Dong
- Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China
| | - L Wang
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| |
Collapse
|
40
|
Wu YY, Tian WF, Cheng CX, Yang L, Ye QQ, Li WH, Jiang JY. Effects of cadmium exposure on metabolism, antioxidant defense, immune function, and the hepatopancreas transcriptome of Cipangopaludina cathayensis. Ecotoxicol Environ Saf 2023; 264:115416. [PMID: 37647801 DOI: 10.1016/j.ecoenv.2023.115416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Revised: 08/24/2023] [Accepted: 08/26/2023] [Indexed: 09/01/2023]
Abstract
Cadmium (Cd) is a common contaminant in aquatic environments. However, little is known about the mechanisms underlying Cd toxicity in the freshwater snail Cipangopaludina cathayensis (Heude, 1890). This study to investigate the toxic effects of Cd on the standard metabolism, antioxidant activities, immune function, and hepatopancreas transcriptome profiles of C. cathayensis. C. cathayensis was exposed to 0.25, 0.5, 1.0, or 1.5 mg/L Cd for 3 h, with results showing that Cd significantly inhibited oxygen consumption and ammonia excretion and disrupted the respiratory metabolism of C. cathayensis. In addition, the O:N ratio dropped below 7, indicating that C. cathayensis may rely exclusively on proteins as an energy source under Cd stress. To understand how Cd impacts the antioxidant activities, immune function, and transcriptional profiles, C. cathayensis were exposed to 0.5 (low exposure, L14) or 1.5 (high exposure, H14) mg/L Cd for 14 days. Our results indicate that Cd exposure leads to oxidative stress and immunosuppression, with the latter effect being larger for exposure to higher Cd concentrations. A total of 2172 differentially expressed genes (DEGs) were identified by transcriptome analysis of the hepatopancreas, of which 885 were upregulated and 1287 were downregulated. Gene ontology and KEGG analyses revealed that the DEGs in the H14 group are enriched for energy generation terms and the "oxidative phosphorylation" pathway, respectively. Therefore, up-regulation of energy metabolism may be an adaptive strategy under Cd stress. Moreover, several genes involved in antioxidant activity were downregulated, whereas genes related to reactive oxygen species generation were upregulated. In addition, many immunity-related genes were identified within the DEGs, indicating that Cd toxicity may affect immune defense. Further, DEGs in the H14 group were enriched for disease-associated pathways. Taken together, our results indicate that Cd exposure leads to metabolic disorders, oxidative stress, and immunosuppression and thus may potentially contribute to disease outbreaks.
Collapse
Affiliation(s)
- Y Y Wu
- Key Laboratory of Ecology of Rare and Endangered Species and Environmental Protection, Guangxi Normal University, Ministry of Education, Guilin 541004, China
| | - W F Tian
- College of Biotechnology, Guilin Medical University, Guilin 541004, China
| | - C X Cheng
- Key Laboratory of Ecology of Rare and Endangered Species and Environmental Protection, Guangxi Normal University, Ministry of Education, Guilin 541004, China
| | - L Yang
- Key Laboratory of Ecology of Rare and Endangered Species and Environmental Protection, Guangxi Normal University, Ministry of Education, Guilin 541004, China
| | - Q Q Ye
- Key Laboratory of Ecology of Rare and Endangered Species and Environmental Protection, Guangxi Normal University, Ministry of Education, Guilin 541004, China
| | - W H Li
- College of Animal Science and Technology, Guangxi University, Nanning 530004, China
| | - J Y Jiang
- Key Laboratory of Ecology of Rare and Endangered Species and Environmental Protection, Guangxi Normal University, Ministry of Education, Guilin 541004, China; Guangxi Key Laboratory of Rare and Endangered Animal Ecology, Gangxi Normal University, Guilin 541004, China; Guangxi Key Laboratory of Veterinary Biotechnology, Guangxi Veterinary Research Institute, Nanning 530001, China.
| |
Collapse
|
41
|
Yang L, Miller ED, Shakya R, Na R, Hu A, Packard R, Williams TM. Investigation of ATR Inhibitor VX970 as a Radiosensitizer in Colorectal Cancer Cells. Int J Radiat Oncol Biol Phys 2023; 117:e271-e272. [PMID: 37785025 DOI: 10.1016/j.ijrobp.2023.06.1239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Colorectal cancer (CRC) is the second leading cause of combined cancer-related mortality in males and females in the U.S. Traditional treatment of locally advanced rectal cancer consists of neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy. Emerging data suggests that higher response rates can be achieved with total neoadjuvant therapy (TNT) where delivery of all chemotherapy and radiation therapy (RT) occurs prior to surgery. In addition, for patients with a complete response to TNT, non-operative management (NOM) can be considered. However, despite the use of TNT, pathologic complete response rates remain below 40% and NOM is only achieved in approximately 50% of rectal cancer patients. A strong need remains for more active anti-cancer therapies in rectal cancer to both reduce pelvic recurrence and facilitate NOM. Here, we tested the hypothesis that inhibition of the ataxia telangiectasia and Rad3-related protein kinase (ATR), a critical regulator of cellular DNA damage response, could increase the sensitivity of CRC to RT. MATERIALS/METHODS VX970, a highly potent and selective ATR inhibitor, was investigated as a radiosensitizer in SW48 and LoVo CRC cell models. In vitro, IC50 of VX970 was assessed by alamarBlue cytotoxicity assay, while radiosensitivity was revealed by radiation clonogenic assays (0, 2, 4, 6, 8 Gy). ATR activity was determined by p-Chk1 using immunoblotting, and cell cycle distribution was analyzed by propidium iodide flow cytometry. CRC xenografts were generated using both LoVo and SW48 cells injected in the left flanks of athymic nude mice to explore the radiosensitizing effects of VX970 in vivo. Tumors were allowed to grow to 100-150 mm3, and the mice were randomized into multiple groups [vehicle alone, RT alone (10 Gy/5 fractions), VX970 alone, and VX970+RT]. Mouse weights and tumor size were measured three times weekly. Comparison of treatment groups was performed using the log-rank test with P<0.05 considered significant. RESULTS The IC50 concentrations of VX970 on SW48 and LoVo cells were about 500 and 100 nM, respectively. VX970 at doses of 3 nM did not alter the viability of CRC cells, but significantly sensitized CRC cells to radiotherapy (P<0.05), with DER of 1.43 and 1.59, respectively, in SW48 and LoVo cells. VX970 efficiently attenuated p-Chk1 expression and significantly abrogated radiation induced G2/M cell cycle arrest (P<0.05). In addition, VX970 in combination with radiotherapy significantly prolonged tumor growth delay of CRC xenografts compared to radiation alone (P<0.05), with minimal toxicity observed. CONCLUSION Inhibition of the ATR-Chk1 pathway by targeting ATR kinase with VX970 sensitizes CRC to radiotherapy in vitro and in vivo. Our findings support that ATR inhibition by VX970 is a promising new approach to improve the therapeutic ratio of radiotherapy for patients with CRC and warrants further clinical testing.
Collapse
Affiliation(s)
- L Yang
- Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA
| | - E D Miller
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - R Shakya
- Target Validation Shared Resource, The Ohio State University, Columbus, OH
| | - R Na
- Target Validation Shared Resource, The Ohio State University, Columbus, OH
| | - A Hu
- The Ohio State University Wexner Medical Center, Columbus, OH
| | - R Packard
- The Ohio State University Wexner Medical Center, Columbus, OH
| | - T M Williams
- Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA
| |
Collapse
|
42
|
Dai J, Zhou FX, Xu H, Jiang CQ, Wang WB, Jiang HG, Wang QY, Wang Y, Xia L, Wu H, Peng J, Wei Y, Luo M, Tang F, Yang L, Hu H, Huang TH, Jiang DZ, Wang DJ, Wang XY. Efficacy and Safety of High-Dose Vitamin C Combined with Total Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer (HCCSC R02 Study). Int J Radiat Oncol Biol Phys 2023; 117:e291-e292. [PMID: 37785075 DOI: 10.1016/j.ijrobp.2023.06.1287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Forpatients with locally advanced rectal cancer (LARC), the standard treatment is fluoropyrimidine (FU) -based neoadjuvant chemoradiotherapy (NCRT) combined with curative surgery. The CAO/ARO/AIO-04 trial and FORWARC trial reported that the addition of oxaliplatin to FU -based NCRT contributed to improve pathologic complete response (pCR), nevertheless, increased the acute therapeutic toxicity. Some studies showed that vitamin C (VitC) had potential benefits on anti-tumor therapy and anti-inflammatory response. Therefore, we conducted this HCCSC R02 study to explore the efficacy and safety of adding a high-dose intravenous VitC to mFOLFOX6/XELOX -based NCRT in LARC. MATERIALS/METHODS HCCSCR02 study was designed as a prospective, single-center phase II trial, which including pts aged 18-75 years with stage II/III rectal adenocarcinoma, distance from anus ≤12cm. The enrollment criteria included: staged with MRI as cT3/cT4 or cN1/2, or mesorectal fascia involvement (MRF+), or difficult to preserve the anus. Patients with glucose-6-phosphate dehydrogenase enzyme(G6PD) deficiency were excluded. Pelvic intensity modulated radiation therapy (IMRT) was given in 45-50.4Gy/25-28 fractions. Concurrently, two cycles of chemotherapy (mFOLFOX6 or XELOX) were administered during IMRT, as well as intravenous VitC (24g) delivered daily after the end of each radiation therapy. Additional 2-3 cycles of mFOLFOX6 / XELOX were adopted between the completion of radiotherapy and surgery. The primary endpoint was pCR rate. The secondary endpoints included radiation-related toxicities, overall survival (OS) and disease-free survival (DFS). This study is still recruiting. RESULTS From May 15, 2021 to Feb 8, 2023, 19 pts were recruited and finished all the scheduled NCRT, of which the proportion of cT4, cT3, cN2, cN1 were 31.6%, 63.2%, 52.6%, 36.8%, respectively. In addition, 10 pts (52.6%) were diagnosed as MRF+ initially, and 8 pts (42.1%) had a lower primary tumor(≤5cm) who were considered difficult for anal preservation before NCRT. All subjects enrolled were confirmed to be proficient mismatch repair (pMMR). As a result, 18 pts underwent a total mesorectal excision (TME) all with R0-resection, and 8 pts were evaluated as pCR (44.4%, 8/18, confidence interval: 0.246-0.663), 11 as major pathological response rate (MPR) (61.6%, 11/18), respectively. The anus preservation rate in patients with lower diseases was 87.5% (7/8). One case accepted a watch-and-wait strategy because of clinical complete response (cCR). Overall, grade 3 toxicities were observed in 4 pts, including 3 leucopenia (15.8%, 3/19), 2 neutropenia (10.5%, 2/19) and 1 diarrhea (5.3%, 1/19). No grade 4 adverse event was observed. CONCLUSION The addition of high-dose VitC to the mFOLFOX6/XELOX-based NCRT in LARC showed a promising pCR, well tolerance, particularly low rate of diarrhea, thus warrants further investigation. CLINICAL TRIAL INFORMATION NCT04801511.
Collapse
Affiliation(s)
- J Dai
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - F X Zhou
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - H Xu
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - C Q Jiang
- Department of Colorectal and Anal Surgery, Low Rectal Cancer Diagnosis and Treatment Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - W B Wang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - H G Jiang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Q Y Wang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Y Wang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - L Xia
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - H Wu
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - J Peng
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Y Wei
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - M Luo
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - F Tang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - L Yang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - H Hu
- Department of Colorectal and Anal Surgery, Low Rectal Cancer Diagnosis and Treatment Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - T H Huang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - D Z Jiang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - D J Wang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - X Y Wang
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
| |
Collapse
|
43
|
Yao Y, Li B, Song R, Yang L, Zou B, Wang L. Thoracic Radiotherapy Improves the Outcomes of Extensive Stage Small-Cell Lung Cancer Patients Receiving First-Line Immunotherapy: A Multicenter Retrospective Analysis. Int J Radiat Oncol Biol Phys 2023; 117:S57. [PMID: 37784528 DOI: 10.1016/j.ijrobp.2023.06.351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Platinum-etoposide chemotherapy combined with immune checkpoint inhibitors has been recommended as the first line standard treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, the role of thoracic radiotherapy (TRT) was still unknown for these patients. The aim of this study was to evaluate the efficacy and safety of TRT for ES-SCLC patients receiving first-line immunotherapy and chemotherapy MATERIALS/METHODS: ES-SCLC patients who received 4 to 6 cycles of chemotherapy and immunotherapy as first-line therapy from two hospitals were included in analysis between July 2018 and January 2023. All patients were divided into two groups based on whether receiving TRT or not during the first-line setting. The primary endpoints were overall survival (OS) and progression-free survival (PFS), and the secondary endpoint was toxic effects. The Kaplan-Meier method was used to estimate overall survival and progression-free survival. All adverse events were graded by the senior doctors according to the Common Terminology Criteria for Adverse Events version 5.0. RESULTS A total of 253 patients from two hospitals were enrolled in analysis. The median age was 62 years and most patients were men (83%), and 36% patients were staged T4 and 52% N3. The most common sites of metastasis were brain (32%), liver (32%) and bone (30%). There were 107 patients (42%) receiving TRT and 146 (58%) without TRT. Baseline characteristics were well balanced between the two groups. The median follow-up time was 16.7 months. Statistically significant benefit was observed for patients receiving TRT compared to patients without TRT (median PFS, 10.4 vs 7.3 months, P< 0.001; median OS, 22.2 vs 13.7 months, P = 0.009). In terms of safety, no significant increase of any grade adverse event (AE) (P = 0.115) and grade 3 or 4 AE (P = 0.631) were observed for patients receiving TRT. The most common grade 3 or 4 AE were neutrophil count decreased, white blood cell count decreased, and nausea in the two groups. In the TRT group, the most common grade 1 or 2 AE related to TRT were esophagitis (40%) and pneumonitis (25%). Grade 3 or 4 esophagitis and pneumonitis were 4% and 8%, respectively. Only one patient developed grade 4 toxic effect of pneumonitis leading to radiotherapy withdrawal. No grade 5 adverse event occurred. CONCLUSION Addition of TRT showed significant survival benefits and well tolerability in ES-SCLC patients receiving platinum-etoposide chemotherapy and immune checkpoint inhibitors, which could be a feasible first-line treatment strategy for ES-SCLC patients.
Collapse
Affiliation(s)
- Y Yao
- Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - B Li
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - R Song
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - L Yang
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - B Zou
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - L Wang
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| |
Collapse
|
44
|
Li D, Yang L, Wang Y, Sui JD, Liu YC, Yang MQ. Eosinophil Dynamics during Chemo-Radiation Correlate to Clinical Outcome in Stage II-IVA Nasopharyngeal Carcinoma Patients: Results from a Large Cohort Study. Int J Radiat Oncol Biol Phys 2023; 117:e596. [PMID: 37785801 DOI: 10.1016/j.ijrobp.2023.06.1952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) We investigated the dynamics of eosinophil depletion and recovery during definitive concurrent chemo-radiotherapy (CCRT) and how they affect the prognosis of stage II-IVA nasopharyngeal carcinoma (NPC) patients. MATERIALS/METHODS A total of 1225 patients with pathologically proven NPC from 2013 to 2019 were enrolled. Fuzzy C-Means Clustering (FCM) was used to assess trends in eosinophil during CCRT longitudinally and to grade eosinophil decline during treatment in combination with absolute eosinophil counts (AECs) at the end of CCRT. Grade G0 refers to patients with no decreasing trend in eosinophils and AECs >0.05×109 cells/L, grade G1 refers to patients with a decreasing trend in eosinophils or AECs between 0-0.05×109 cells/L, grade G2 refers to patients with a decreasing trend in eosinophils and AECs between 0-0.05×109 cells/L. Progression-free survival (PFS) is the primary outcome measure, with overall survival (OS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRFS) as secondary outcome measures. A Cox proportional risk model was used to determine the hazard ratio for adverse prognostic effects in declining grades of eosinophil. RESULTS During a median follow-up of 4.1 years, 376 (30.69%) patients experienced disease progression events. The grade of eosinophil reduction after CCRT was significantly associated with PFS, OS, and DMFS but not with LRFS. After adjusting for demographics, clinical baseline indicators, tumor characteristics, and treatment characteristics, a 1.57-fold (p = 0.001), 1.69-fold (p = 0.007), and 1.51-fold (p = 0.019) increase in the risk of developing PFS, OS, and DMFS was observed for G1 compared with G0, whereas a 2.4-fold (p < 0.001), 2.76-fold (p < 0.001), and 2.31-fold (p < 0.001) increase in the risk of developing PFS, OS, and DMFS was observed for G2. Moreover, among patients with G0, treatment with CCRT with a cumulative dose of platinum-based chemotherapy < 200 mg/m2 resulted in PFS, OS, and DMFS that were not inferior to CCRT with cumulative doses ≥ 200 mg/m2. CONCLUSION Eosinophil is an easily detectable and inexpensive biomarker that may be useful in the clinical setting to aid in assessing the prognosis for standard treatment of NPC.
Collapse
Affiliation(s)
- D Li
- School of Medicine, Chongqing University, Chongqing, China
| | - L Yang
- Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, Chongqing, China
| | - Y Wang
- Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, China
| | - J D Sui
- Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, China
| | - Y C Liu
- College of Bioengineering, Chongqing University, Chongqing, China, China
| | - M Q Yang
- Chongqing University Cancer Hospital, Chongqing, China
| |
Collapse
|
45
|
Liu JM, Zhao JH, Wang Y, Liu W, Zhang XL, Yang L, Zhou L. A Model of Type II Collagen-Induced Spondylitis and Arthritis in F1 Hybrid Male Mice. Bull Exp Biol Med 2023; 175:794-800. [PMID: 37979028 DOI: 10.1007/s10517-023-05949-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Indexed: 11/19/2023]
Abstract
In this study, we tested a new model of ankylosing spondylitis in order to determine its histological and radiological features needed to investigate peripheral arthritis, spondylitis, and formation of the new bone tissues. F1 hybrid male mice (BALB/c×DBA/1), a progeny of spondylitis-susceptible BALB/c male mice and rheumatoid arthritis-susceptible DBA/1 female mice, were immunized intraperitoneally with bovine type II collagen (CII) mixed with adjuvant dimethyldioctadecylammonium bromide. Radiological and histological studies were performed at the peak of swelling, redness, and stiffness. The incidence of peripheral arthritis and spondylitis induced by CII in F1 hybrid mice were 66 and 62%, respectively. X-ray examination revealed bone erosion and spondylitis in the peripheral joints, as well as the formation of new bone tissues in the coccygeal vertebrae and between LIII and LIV vertebrae. The histological study showed lymphocyte and plasma cell infiltration, capillary dilation, congestion, and endochondral ossification of the lumbar vertebrae. This novel model of CII-induced spondylitis in F1 hybrid mice provoked axial and peripheral arthritides inducing chronic inflammation. In this model, the formation of new bone tissue in the stiff spine is characterized by endochondral ossification. The advanced model is an additional and valuable tool for investigation of the autoimmune reactions in spondylitis.
Collapse
Affiliation(s)
- J M Liu
- Allergy and Clinical Immunology Research Centre, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
- Jinzhou Palmtop Cloud Biotechnology Co., Ltd., Jinzhou, Liaoning, China
| | - J H Zhao
- Allergy and Clinical Immunology Research Centre, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
| | - Y Wang
- Allergy and Clinical Immunology Research Centre, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
| | - W Liu
- Allergy and Clinical Immunology Research Centre, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
| | - X L Zhang
- Department of Radiology, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
| | - L Yang
- Department of Pathology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
| | - L Zhou
- Allergy and Clinical Immunology Research Centre, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
| |
Collapse
|
46
|
Kuang H, Yang L, Li Z, Wang J, Zheng K, Mei J, Sun H, Huang Y, Yang C, Luo W. DNA methyltransferase 3A induces the occurrence of oral submucous fibrosis by promoting the methylation of the von Hippel-Lindau. Oral Dis 2023. [PMID: 37743610 DOI: 10.1111/odi.14725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 07/25/2023] [Accepted: 08/15/2023] [Indexed: 09/26/2023]
Abstract
BACKGROUND Oral submucous fibrosis (OSF) is associated with malignant disorders. DNA methyltransferase 3A (DNMT3A) is a DNA methylesterase reported to be upregulated in multiple organs and shown to inhibit fibrosis. However, the detailed effect of DNMT3A on OSF remains unclear. METHODS To mimic OSF in vitro, oral fibroblasts were exposed to arecoline and molecular biological experiments were performed to detect the function of DNMT3A in OSF. RESULTS We found that von Hippel-Lindau (VHL) was downregulated and highly methylated in OSF. Arecoline remarkably increased the viability, invasiveness, and migration of oral fibroblasts, but upregulation of VHL partially reversed these effects. DNMT3A induces DNA hypermethylation in the VHL promoter, and VHL markedly inhibits the level of tenascin-C (TNC) by inducing the ubiquitination of TNC. TNC reversed the inhibitory effect of VHL upregulation on the differentiation of oral fibroblasts into myofibroblasts. CONCLUSION DNMT3A induces OSF by promoting methylation of the VHL promoter. Hence, our study provides novel insights into the discovery of novel strategies that can be employed against OSF.
Collapse
Affiliation(s)
- Huifang Kuang
- Department of Stomatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China
- School of Stomatology, Hainan Medical University, Haikou, China
| | - Liyan Yang
- Department of Stomatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China
- School of Stomatology, Hainan Medical University, Haikou, China
| | - Zhixin Li
- Department of Stomatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China
- School of Stomatology, Hainan Medical University, Haikou, China
| | - Jinrong Wang
- Department of Stomatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China
- School of Stomatology, Hainan Medical University, Haikou, China
| | - Kaiyue Zheng
- Department of Stomatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China
- School of Stomatology, Hainan Medical University, Haikou, China
| | - Jie Mei
- Department of Stomatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China
- School of Stomatology, Hainan Medical University, Haikou, China
| | - Honglan Sun
- Department of Stomatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China
- School of Stomatology, Hainan Medical University, Haikou, China
| | - Yuqi Huang
- Department of Stomatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China
- School of Stomatology, Hainan Medical University, Haikou, China
| | - Chao Yang
- Department of Stomatology, The People's Hospital of Longhua, Shenzhen, China
- Research and Development Department, Shenzhen Uni-Medica Technology Co., Ltd, Shenzhen, China
| | - Wen Luo
- Department of Stomatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China
- School of Stomatology, Hainan Medical University, Haikou, China
| |
Collapse
|
47
|
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An Q, Bai Y, Bakina O, Ferroli RB, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere RA, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen G, Chen HS, Chen ML, Chen SJ, Chen XR, Chen YB, Chen ZJ, Cheng WS, Cibinetto G, Cossio F, Dai HL, Dai JP, Dai XC, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Fritsch M, Fu CD, Gao YN, Gao Y, Gao Y, Garzia I, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu S, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Hao XQ, Harris FA, He KL, Heinsius FHH, Heinz CH, Heng YK, Herold C, Himmelreich M, Holtmann T, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang LQ, Huang XT, Huang YP, Hussain T, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Jiang XS, Jiao JB, Jiao Z, Jin S, Jin Y, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Kolcu OB, Kopf B, Kuemmel M, Kuessner MK, Kupsc A, Kurth MG, Kühn W, Lane JJ, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li HB, Li HJ, Li JQ, Li JW, Li K, Li LK, Li L, Li PL, Li PR, Li SY, Li WD, Li WG, Li XH, Li XL, Li ZY, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JY, Liu K, Liu KY, Liu L, Liu MH, Liu Q, Liu SB, Liu S, Liu T, Liu WM, Liu X, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JD, Lu JG, Lu XL, Lu Y, Lu YP, Luo CL, Luo MX, Luo T, Luo XL, Lusso S, Lyu XR, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XX, Ma XY, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Patteri P, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Pitka A, Poling R, Prasad V, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qiao CF, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Qu SQ, Ravindran K, Redmer CF, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan DC, Shan W, Shan XY, Shao M, Shen CP, Shen PX, Shen XY, Shi HC, Shi RS, Shi X, Shi XD, Song WM, Song YX, Sosio S, Spataro S, Su KX, Sun GX, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun YJ, Sun YK, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Teng JX, Thoren V, Uman I, Wang B, Wang BL, Wang CW, Wang DY, Wang HP, Wang K, Wang LL, Wang M, Wang M, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang YD, Wang YF, Wang YQ, Wang Z, Wang ZY, Wang Z, Wang Z, Wei DH, Weidenkaff P, Weidner F, Wen SP, White DJ, Wiedner UW, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu Z, Xia L, Xiao H, Xiao SY, Xiao ZJ, Xie XH, Xie YG, Xie YH, Xing TY, Xu GF, Xu JJ, Xu QJ, Xu W, Xu XP, Xu YC, Yan F, Yan L, Yan WB, Yan WC, Yan X, Yang HJ, Yang HX, Yang L, Yang SL, Yang YH, Yang Y, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yuan CZ, Yuan L, Yuan W, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng Y, Zhang BX, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JJ, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang L, Zhang SF, Zhang XD, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhong C, Zhou LP, Zhou Q, Zhou X, Zhou XK, Zhou XR, Zhu AN, Zhu J, Zhu K, Zhu KJ, Zhu SH, Zhu WJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. Search for Λ[over ¯]-Λ Baryon-Number-Violating Oscillations in the Decay J/ψ→pK^{-}Λ[over ¯]+c.c. Phys Rev Lett 2023; 131:121801. [PMID: 37802947 DOI: 10.1103/physrevlett.131.121801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Revised: 08/14/2023] [Accepted: 08/29/2023] [Indexed: 10/08/2023]
Abstract
We report on the first search for Λ[over ¯]-Λ oscillations in the decay J/ψ→pK^{-}Λ[over ¯]+c.c. by analyzing 1.31×10^{9} J/ψ events accumulated with the BESIII detector at the BEPCII collider. The J/ψ events are produced using e^{+}e^{-} collisions at a center of mass energy sqrt[s]=3.097 GeV. No evidence for hyperon oscillations is observed. The upper limit for the oscillation rate of Λ[over ¯] to Λ hyperons is determined to be P(Λ)=[B(J/ψ→pK^{-}Λ+c.c.)/B(J/ψ→pK^{-}Λ[over ¯]+c.c.)]<4.4×10^{-6} corresponding to an oscillation parameter δm_{ΛΛ[over ¯]} of less than 3.8×10^{-18} GeV at the 90% confidence level.
Collapse
Affiliation(s)
- M Ablikim
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - M N Achasov
- Budker Institute of Nuclear Physics SB RAS (BINP), Novosibirsk 630090, Russia
| | - P Adlarson
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | - S Ahmed
- Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
| | - M Albrecht
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - R Aliberti
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - A Amoroso
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - Q An
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Y Bai
- Southeast University, Nanjing 211100, People's Republic of China
| | - O Bakina
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - R Baldini Ferroli
- INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044, Frascati, Italy
| | - I Balossino
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
| | - Y Ban
- Peking University, Beijing 100871, People's Republic of China
| | - K Begzsuren
- Institute of Physics and Technology, Peace Avenue 54B, Ulaanbaatar 13330, Mongolia
| | - N Berger
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - M Bertani
- INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044, Frascati, Italy
| | - D Bettoni
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
| | - F Bianchi
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - J Bloms
- University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
| | - A Bortone
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - I Boyko
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - R A Briere
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - H Cai
- Wuhan University, Wuhan 430072, People's Republic of China
| | - X Cai
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - A Calcaterra
- INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044, Frascati, Italy
| | - G F Cao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - N Cao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - S A Cetin
- Turkish Accelerator Center Particle Factory Group, Istinye University, 34010, Istanbul, Turkey
| | - J F Chang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - W L Chang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - G Chelkov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - G Chen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - H S Chen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - M L Chen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - S J Chen
- Nanjing University, Nanjing 210093, People's Republic of China
| | - X R Chen
- Institute of Modern Physics, Lanzhou 730000, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Y B Chen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Z J Chen
- Hunan University, Changsha 410082, People's Republic of China
| | | | - G Cibinetto
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
| | | | - H L Dai
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - J P Dai
- Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China
| | - X C Dai
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - A Dbeyssi
- Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
| | - R E de Boer
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - D Dedovich
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - Z Y Deng
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - A Denig
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - I Denysenko
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - M Destefanis
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - F De Mori
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - Y Ding
- Liaoning University, Shenyang 110036, People's Republic of China
| | - J Dong
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - L Y Dong
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - M Y Dong
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X Dong
- Wuhan University, Wuhan 430072, People's Republic of China
| | - S X Du
- Zhengzhou University, Zhengzhou 450001, People's Republic of China
| | - J Fang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - S S Fang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Y Fang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - R Farinelli
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
| | - L Fava
- University of Eastern Piedmont, I-15121, Alessandria, Italy
- INFN, I-10125, Turin, Italy
| | - F Feldbauer
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - G Felici
- INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044, Frascati, Italy
| | - C Q Feng
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - M Fritsch
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - C D Fu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Y N Gao
- Peking University, Beijing 100871, People's Republic of China
| | - Ya Gao
- University of South China, Hengyang 421001, People's Republic of China
| | - Yang Gao
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - I Garzia
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
- University of Ferrara, I-44122, Ferrara, Italy
| | - E M Gersabeck
- University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
| | - A Gilman
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - K Goetzen
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - L Gong
- Liaoning University, Shenyang 110036, People's Republic of China
| | - W X Gong
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - W Gradl
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - M Greco
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - L M Gu
- Nanjing University, Nanjing 210093, People's Republic of China
| | - M H Gu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - S Gu
- Beihang University, Beijing 100191, People's Republic of China
| | - Y T Gu
- Guangxi University, Nanning 530004, People's Republic of China
| | - C Y Guan
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - A Q Guo
- Indiana University, Bloomington, Indiana 47405, USA
| | - L B Guo
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - R P Guo
- Shandong Normal University, Jinan 250014, People's Republic of China
| | - Y P Guo
- Fudan University, Shanghai 200433, People's Republic of China
| | - A Guskov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - T T Han
- Shandong University, Jinan 250100, People's Republic of China
| | - X Q Hao
- Henan Normal University, Xinxiang 453007, People's Republic of China
| | - F A Harris
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | - K L He
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | | | - C H Heinz
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - Y K Heng
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - C Herold
- Suranaree University of Technology, University Avenue 111, Nakhon Ratchasima 30000, Thailand
| | - M Himmelreich
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - T Holtmann
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - Y R Hou
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Z L Hou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - H M Hu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J F Hu
- South China Normal University, Guangzhou 510006, People's Republic of China
| | - T Hu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Y Hu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - G S Huang
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - L Q Huang
- University of South China, Hengyang 421001, People's Republic of China
| | - X T Huang
- Shandong University, Jinan 250100, People's Republic of China
| | - Y P Huang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - T Hussain
- University of the Punjab, Lahore-54590, Pakistan
| | - W Imoehl
- Indiana University, Bloomington, Indiana 47405, USA
| | - M Irshad
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - S Jaeger
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - S Janchiv
- Institute of Physics and Technology, Peace Avenue 54B, Ulaanbaatar 13330, Mongolia
| | - Q Ji
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Q P Ji
- Henan Normal University, Xinxiang 453007, People's Republic of China
| | - X B Ji
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X L Ji
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - X S Jiang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J B Jiao
- Shandong University, Jinan 250100, People's Republic of China
| | - Z Jiao
- Huangshan College, Huangshan 245000, People's Republic of China
| | - S Jin
- Nanjing University, Nanjing 210093, People's Republic of China
| | - Y Jin
- University of Jinan, Jinan 250022, People's Republic of China
| | - T Johansson
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | | | - X S Kang
- Liaoning University, Shenyang 110036, People's Republic of China
| | - R Kappert
- University of Groningen, NL-9747 AA Groningen, The Netherlands
| | - M Kavatsyuk
- University of Groningen, NL-9747 AA Groningen, The Netherlands
| | - B C Ke
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- Shanxi Normal University, Linfen 041004, People's Republic of China
| | - I K Keshk
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - A Khoukaz
- University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
| | - P Kiese
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - R Kiuchi
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - R Kliemt
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - O B Kolcu
- Turkish Accelerator Center Particle Factory Group, Istinye University, 34010, Istanbul, Turkey
| | - B Kopf
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - M Kuemmel
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | | | - A Kupsc
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | - M G Kurth
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - W Kühn
- Justus-Liebig-Universitaet Giessen, II. Physikalisches Institut, Heinrich-Buff-Ring 16, D-35392 Giessen, Germany
| | - J J Lane
- University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
| | - P Larin
- Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
| | - A Lavania
- Indian Institute of Technology Madras, Chennai 600036, India
| | - L Lavezzi
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - Z H Lei
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H Leithoff
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - M Lellmann
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - T Lenz
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - C Li
- Qufu Normal University, Qufu 273165, People's Republic of China
| | - C H Li
- Liaoning Normal University, Dalian 116029, People's Republic of China
| | - Cheng Li
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - D M Li
- Zhengzhou University, Zhengzhou 450001, People's Republic of China
| | - F Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - G Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - H Li
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H B Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - H J Li
- Fudan University, Shanghai 200433, People's Republic of China
| | - J Q Li
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - J W Li
- Shandong University, Jinan 250100, People's Republic of China
| | - Ke Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - L K Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Lei Li
- Beijing Institute of Petrochemical Technology, Beijing 102617, People's Republic of China
| | - P L Li
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - P R Li
- Lanzhou University, Lanzhou 730000, People's Republic of China
| | - S Y Li
- Tsinghua University, Beijing 100084, People's Republic of China
| | - W D Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - W G Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - X H Li
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - X L Li
- Shandong University, Jinan 250100, People's Republic of China
| | - Z Y Li
- Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
| | - H Liang
- Jilin University, Changchun 130012, People's Republic of China
| | - H Liang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - H Liang
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Y F Liang
- Sichuan University, Chengdu 610064, People's Republic of China
| | - Y T Liang
- Institute of Modern Physics, Lanzhou 730000, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - G R Liao
- Guangxi Normal University, Guilin 541004, People's Republic of China
| | - L Z Liao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J Libby
- Indian Institute of Technology Madras, Chennai 600036, India
| | - A Limphirat
- Suranaree University of Technology, University Avenue 111, Nakhon Ratchasima 30000, Thailand
| | - B J Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - C X Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - D Liu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - F H Liu
- Shanxi University, Taiyuan 030006, People's Republic of China
| | - Fang Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Feng Liu
- Central China Normal University, Wuhan 430079, People's Republic of China
| | - H B Liu
- Guangxi University, Nanning 530004, People's Republic of China
| | - H M Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Huanhuan Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Huihui Liu
- Henan University of Science and Technology, Luoyang 471003, People's Republic of China
| | - J B Liu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - J Y Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - K Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - K Y Liu
- Liaoning University, Shenyang 110036, People's Republic of China
| | - L Liu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - M H Liu
- Fudan University, Shanghai 200433, People's Republic of China
| | - Q Liu
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - S B Liu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Shuai Liu
- Soochow University, Suzhou 215006, People's Republic of China
| | - T Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - W M Liu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - X Liu
- Lanzhou University, Lanzhou 730000, People's Republic of China
| | - Y B Liu
- Nankai University, Tianjin 300071, People's Republic of China
| | - Z A Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Z Q Liu
- Shandong University, Jinan 250100, People's Republic of China
| | - X C Lou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - F X Lu
- Henan Normal University, Xinxiang 453007, People's Republic of China
| | - H J Lu
- Huangshan College, Huangshan 245000, People's Republic of China
| | - J D Lu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J G Lu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - X L Lu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Y Lu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Y P Lu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - C L Luo
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - M X Luo
- Zhejiang University, Hangzhou 310027, People's Republic of China
| | - T Luo
- Fudan University, Shanghai 200433, People's Republic of China
| | - X L Luo
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | | | - X R Lyu
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - F C Ma
- Liaoning University, Shenyang 110036, People's Republic of China
| | - H L Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - L L Ma
- Shandong University, Jinan 250100, People's Republic of China
| | - M M Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Q M Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - R Q Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - R T Ma
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X X Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X Y Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - F E Maas
- Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
| | - M Maggiora
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - S Maldaner
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - S Malde
- University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
| | - Q A Malik
- University of the Punjab, Lahore-54590, Pakistan
| | - A Mangoni
- INFN Sezione di Perugia, I-06100, Perugia, Italy
| | - Y J Mao
- Peking University, Beijing 100871, People's Republic of China
| | - Z P Mao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - S Marcello
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - Z X Meng
- University of Jinan, Jinan 250022, People's Republic of China
| | - J G Messchendorp
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
- University of Groningen, NL-9747 AA Groningen, The Netherlands
| | - G Mezzadri
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
| | - T J Min
- Nanjing University, Nanjing 210093, People's Republic of China
| | - R E Mitchell
- Indiana University, Bloomington, Indiana 47405, USA
| | - X H Mo
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - N Yu Muchnoi
- Budker Institute of Nuclear Physics SB RAS (BINP), Novosibirsk 630090, Russia
| | - H Muramatsu
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - S Nakhoul
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - Y Nefedov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - F Nerling
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - I B Nikolaev
- Budker Institute of Nuclear Physics SB RAS (BINP), Novosibirsk 630090, Russia
| | - Z Ning
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - S Nisar
- COMSATS University Islamabad, Lahore Campus, Defence Road, Off Raiwind Road, 54000 Lahore, Pakistan
| | - S L Olsen
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Q Ouyang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - S Pacetti
- INFN Sezione di Perugia, I-06100, Perugia, Italy
- University of Perugia, I-06100, Perugia, Italy
| | - X Pan
- Fudan University, Shanghai 200433, People's Republic of China
| | - Y Pan
- University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
| | - A Pathak
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - P Patteri
- INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044, Frascati, Italy
| | - M Pelizaeus
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - H P Peng
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - K Peters
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - J L Ping
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - R G Ping
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - A Pitka
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - R Poling
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - V Prasad
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H Qi
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H R Qi
- Tsinghua University, Beijing 100084, People's Republic of China
| | - M Qi
- Nanjing University, Nanjing 210093, People's Republic of China
| | - T Y Qi
- Beihang University, Beijing 100191, People's Republic of China
| | - S Qian
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - W B Qian
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - C F Qiao
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - L Q Qin
- Guangxi Normal University, Guilin 541004, People's Republic of China
| | - X P Qin
- Fudan University, Shanghai 200433, People's Republic of China
| | - X S Qin
- Shandong University, Jinan 250100, People's Republic of China
| | - Z H Qin
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - J F Qiu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - S Q Qu
- Nankai University, Tianjin 300071, People's Republic of China
| | - S Q Qu
- Tsinghua University, Beijing 100084, People's Republic of China
| | - K Ravindran
- Indian Institute of Technology Madras, Chennai 600036, India
| | - C F Redmer
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | | | - V Rodin
- University of Groningen, NL-9747 AA Groningen, The Netherlands
| | - M Rolo
- INFN, I-10125, Turin, Italy
| | - G Rong
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Ch Rosner
- Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
| | - A Sarantsev
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - Y Schelhaas
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - C Schnier
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - K Schoenning
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | - M Scodeggio
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
- University of Ferrara, I-44122, Ferrara, Italy
| | - D C Shan
- Soochow University, Suzhou 215006, People's Republic of China
| | - W Shan
- Hunan Normal University, Changsha 410081, People's Republic of China
| | - X Y Shan
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - M Shao
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - C P Shen
- Fudan University, Shanghai 200433, People's Republic of China
| | - P X Shen
- Nankai University, Tianjin 300071, People's Republic of China
| | - X Y Shen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - H C Shi
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - R S Shi
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X Shi
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - X D Shi
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - W M Song
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- Jilin University, Changchun 130012, People's Republic of China
| | - Y X Song
- Peking University, Beijing 100871, People's Republic of China
| | - S Sosio
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - S Spataro
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - K X Su
- Wuhan University, Wuhan 430072, People's Republic of China
| | - G X Sun
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J F Sun
- Henan Normal University, Xinxiang 453007, People's Republic of China
| | - L Sun
- Wuhan University, Wuhan 430072, People's Republic of China
| | - S S Sun
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - T Sun
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - W Y Sun
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - Y J Sun
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Y K Sun
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Y Z Sun
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Z T Sun
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Y H Tan
- Wuhan University, Wuhan 430072, People's Republic of China
| | - Y X Tan
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - C J Tang
- Sichuan University, Chengdu 610064, People's Republic of China
| | - G Y Tang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J Tang
- Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
| | - J X Teng
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - V Thoren
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | - I Uman
- Near East University, Nicosia, North Cyprus, 99138, Mersin 10, Turkey
| | - B Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - B L Wang
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - C W Wang
- Nanjing University, Nanjing 210093, People's Republic of China
| | - D Y Wang
- Peking University, Beijing 100871, People's Republic of China
| | - H P Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - K Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - L L Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - M Wang
- Shandong University, Jinan 250100, People's Republic of China
| | - Meng Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - W H Wang
- Wuhan University, Wuhan 430072, People's Republic of China
| | - W P Wang
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - X Wang
- Peking University, Beijing 100871, People's Republic of China
| | - X F Wang
- Lanzhou University, Lanzhou 730000, People's Republic of China
| | - X L Wang
- Fudan University, Shanghai 200433, People's Republic of China
| | - Y Wang
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Y D Wang
- North China Electric Power University, Beijing 102206, People's Republic of China
| | - Y F Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Y Q Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Z Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Z Y Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Ziyi Wang
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Zongyuan Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - D H Wei
- Guangxi Normal University, Guilin 541004, People's Republic of China
| | - P Weidenkaff
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - F Weidner
- University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
| | - S P Wen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - D J White
- University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
| | - U W Wiedner
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - G Wilkinson
- University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
| | - M Wolke
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | | | - J F Wu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - L H Wu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - L J Wu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X Wu
- Fudan University, Shanghai 200433, People's Republic of China
| | - Z Wu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - L Xia
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H Xiao
- Fudan University, Shanghai 200433, People's Republic of China
| | - S Y Xiao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Z J Xiao
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - X H Xie
- Peking University, Beijing 100871, People's Republic of China
| | - Y G Xie
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Y H Xie
- Central China Normal University, Wuhan 430079, People's Republic of China
| | - T Y Xing
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - G F Xu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J J Xu
- Nanjing University, Nanjing 210093, People's Republic of China
| | - Q J Xu
- Hangzhou Normal University, Hangzhou 310036, People's Republic of China
| | - W Xu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X P Xu
- Soochow University, Suzhou 215006, People's Republic of China
| | - Y C Xu
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - F Yan
- Fudan University, Shanghai 200433, People's Republic of China
| | - L Yan
- Fudan University, Shanghai 200433, People's Republic of China
| | - W B Yan
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - W C Yan
- Zhengzhou University, Zhengzhou 450001, People's Republic of China
| | - Xu Yan
- Soochow University, Suzhou 215006, People's Republic of China
| | - H J Yang
- Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China
| | - H X Yang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - L Yang
- Shanxi Normal University, Linfen 041004, People's Republic of China
| | - S L Yang
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Y H Yang
- Nanjing University, Nanjing 210093, People's Republic of China
| | - Yifan Yang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - M Ye
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - M H Ye
- China Center of Advanced Science and Technology, Beijing 100190, People's Republic of China
| | - J H Yin
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Z Y You
- Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
| | - B X Yu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - C X Yu
- Nankai University, Tianjin 300071, People's Republic of China
| | - G Yu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J S Yu
- Hunan University, Changsha 410082, People's Republic of China
| | - T Yu
- University of South China, Hengyang 421001, People's Republic of China
| | - C Z Yuan
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - L Yuan
- Beihang University, Beijing 100191, People's Republic of China
| | - W Yuan
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - Y Yuan
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Z Y Yuan
- Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
| | - C X Yue
- Liaoning Normal University, Dalian 116029, People's Republic of China
| | - A A Zafar
- University of the Punjab, Lahore-54590, Pakistan
| | - Y Zeng
- Hunan University, Changsha 410082, People's Republic of China
| | - B X Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - G Y Zhang
- Henan Normal University, Xinxiang 453007, People's Republic of China
| | - H Zhang
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H H Zhang
- Jilin University, Changchun 130012, People's Republic of China
| | - H H Zhang
- Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
| | - H Y Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - J J Zhang
- Shanxi Normal University, Linfen 041004, People's Republic of China
| | - J Q Zhang
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - J W Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J Y Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J Z Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Jianyu Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Jiawei Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Lei Zhang
- Nanjing University, Nanjing 210093, People's Republic of China
| | - S F Zhang
- Nanjing University, Nanjing 210093, People's Republic of China
| | - X D Zhang
- North China Electric Power University, Beijing 102206, People's Republic of China
| | - X Y Zhang
- Shandong University, Jinan 250100, People's Republic of China
| | - Y Zhang
- University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
| | - Y T Zhang
- Zhengzhou University, Zhengzhou 450001, People's Republic of China
| | - Y H Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Yan Zhang
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Yao Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Z Y Zhang
- Wuhan University, Wuhan 430072, People's Republic of China
| | - G Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J Zhao
- Liaoning Normal University, Dalian 116029, People's Republic of China
| | - J Y Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J Z Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Lei Zhao
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Ling Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - M G Zhao
- Nankai University, Tianjin 300071, People's Republic of China
| | - Q Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - S J Zhao
- Zhengzhou University, Zhengzhou 450001, People's Republic of China
| | - Y B Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Y X Zhao
- Institute of Modern Physics, Lanzhou 730000, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Z G Zhao
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - A Zhemchugov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - B Zheng
- University of South China, Hengyang 421001, People's Republic of China
| | - J P Zheng
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Y H Zheng
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - B Zhong
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - C Zhong
- University of South China, Hengyang 421001, People's Republic of China
| | - L P Zhou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Q Zhou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X Zhou
- Wuhan University, Wuhan 430072, People's Republic of China
| | - X K Zhou
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X R Zhou
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - A N Zhu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J Zhu
- Nankai University, Tianjin 300071, People's Republic of China
| | - K Zhu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - K J Zhu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - S H Zhu
- University of Science and Technology Liaoning, Anshan 114051, People's Republic of China
| | - W J Zhu
- Fudan University, Shanghai 200433, People's Republic of China
| | - W J Zhu
- Nankai University, Tianjin 300071, People's Republic of China
| | - Y C Zhu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Z A Zhu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - B S Zou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J H Zou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| |
Collapse
|
48
|
Yang CP, Tang LF, Liu ZJ, Liu SZ, Yang L, Cheng JN, Zhang T, Sun FW, Huang YT, Gao QF, Ju JH. [Clinical effects of anterolateral thigh flap with blood supply source of medial femoral perforator in repairing the wounds on extremities]. Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi 2023; 39:842-848. [PMID: 37805800 DOI: 10.3760/cma.j.cn501225-20220726-00310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 10/09/2023]
Abstract
Objective: To investigate clinical effects of anterolateral thigh flap with blood supply source of medial femoral perforator in repairing the wounds on extremities. Methods: A retrospective observational study was conducted. From October 2018 to June 2021, Suzhou Ruihua Orthopedic Hospital admitted 12 patients (11 males and 1 female, aged 24-64 years) who met the inclusion criteria, and did not have the lateral circumflex femoral artery during anterolateral thigh flap resection, or changed to medial femoral perforator as a source of blood supply due to small perforator to repair the wound with flap transplantation. The wounds were on the upper limbs in 7 cases and on the lower limbs in 5 cases. The wound area after debridement was 8.0 cm×5.0 cm-24.0 cm×6.5 cm, and the applied flap area was 9 cm×6 cm-25 cm×7 cm. During transplantation, the perforating branch or source artery of the flap was anastomosed end to end with the vascular pedicle of the recipient area. Subcutaneous beauty suture was performed on all the donor wounds. After operation, the survival of the flap and vascular crisis were observed; and the wound healing at the donor site was observed. During follow-up, the texture of the flap and complications at the donor site were observed. At the last follow-up, the effect of flap repair was evaluated by using the modified self-made comprehensive efficacy rating table. Results: After operation, all the flaps of patients survived without vascular crisis; the wounds in the donor site healed smoothly. During follow-up of 6 to 26 months, the flaps had good texture; only linear scars remained in the donor area without scar contracture, pain or other discomfort. At the last follow-up, the total score of flap repair effect of 12 patients was 75-95, with an average of 87, of which 5 cases were rated as excellent, 6 cases as good, and 1 case as fair, and the proportion of excellent and good patients was 11/12. Conclusions: The application of anterolateral thigh flap with blood supply from the medial femoral perforator to repair wounds on extremities is an alternative method for the vascular variations such as no descending branch, oblique branch, or small perforator of the lateral circumflex femoral artery during the resection of the anterolateral thigh flap. This operation has the advantages of simple operation, small trauma, and others, which effectively ensures the smooth operation.
Collapse
Affiliation(s)
- C P Yang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - L F Tang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - Z J Liu
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - S Z Liu
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - L Yang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - J N Cheng
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - T Zhang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - F W Sun
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - Y T Huang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - Q F Gao
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - J H Ju
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| |
Collapse
|
49
|
Yuan Z, Miao L, Yang L, Chen P, Jiang C, Fang M, Wang H, Xu D, Lin Z. PM 2.5 and its respiratory tract depositions on blood pressure, anxiety, depression and health risk assessment: A mechanistic study based on urinary metabolome. Environ Res 2023; 233:116481. [PMID: 37364626 DOI: 10.1016/j.envres.2023.116481] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/25/2023] [Revised: 05/28/2023] [Accepted: 06/20/2023] [Indexed: 06/28/2023]
Abstract
Effects of fine particulate matter (PM2.5) and regional respiratory tract depositions on blood pressure (BP), anxiety, depression, health risk and the underlying mechanisms need further investigations. A repeated-measures panel investigation among 40 healthy young adults in Hefei, China was performed to explore the acute impacts of PM2.5 exposure and its deposition doses in 3 regions of respiratory tract over diverse lag times on BP, anxiety, depression, health risk, and the potential mechanisms. We collected PM2.5 concentrations, its deposition doses, BP, the Self-Rating Anxiety Scale (SAS) score and the Self-Rating Depression Scale (SDS) score. An untargeted metabolomics approach was used to detect significant urine metabolites, and the health risk assessment model was used to evaluate the non-carcinogenic risks associated with PM2.5. We applied linear mixed-effects models to assess the relationships of PM2.5 with the aforementioned health indicators We further evaluate the non-carcinogenic risks associated with PM2.5. We found deposited PM2.5 dose in the head accounted for a large proportion. PM2.5 and its three depositions exposures at a specific lag day was significantly related to increased BP levels and higher SAS and SDS scores. Metabolomics analysis showed significant alterations in urinary metabolites (i.e., glucoses, lipids and amino acids) after PM2.5 exposure, simultaneously accompanied by activation of the cAMP signaling pathway. Health risk assessment presented that the risk values for the residents in Hefei were greater than the lower limits of non-cancer risk guidelines. This real-world investigation suggested that acute PM2.5 and its depositions exposures may increase health risks by elevating BP, inducing anxiety and depression, and altering urinary metabolomic profile via activating the cAMP signaling pathway. And the further health risk assessment indicated that there are potential non-carcinogenic risks of PM2.5 via the inhalation route in this area.
Collapse
Affiliation(s)
- Zhi Yuan
- Department of Toxicology, School of Public Health, Key Laboratory of Environmental Toxicology of Anhui Higher Education Institutes, Anhui Medical University, Hefei, 230032, China
| | - Lin Miao
- Department of Toxicology, School of Public Health, Key Laboratory of Environmental Toxicology of Anhui Higher Education Institutes, Anhui Medical University, Hefei, 230032, China
| | - Liyan Yang
- Department of Toxicology, School of Public Health, Key Laboratory of Environmental Toxicology of Anhui Higher Education Institutes, Anhui Medical University, Hefei, 230032, China
| | - Ping Chen
- Department of Toxicology, School of Public Health, Key Laboratory of Environmental Toxicology of Anhui Higher Education Institutes, Anhui Medical University, Hefei, 230032, China
| | - Cunzhong Jiang
- Department of Toxicology, School of Public Health, Key Laboratory of Environmental Toxicology of Anhui Higher Education Institutes, Anhui Medical University, Hefei, 230032, China
| | - Miao Fang
- Department of Toxicology, School of Public Health, Key Laboratory of Environmental Toxicology of Anhui Higher Education Institutes, Anhui Medical University, Hefei, 230032, China
| | - Hua Wang
- Department of Toxicology, School of Public Health, Key Laboratory of Environmental Toxicology of Anhui Higher Education Institutes, Anhui Medical University, Hefei, 230032, China
| | - Dexiang Xu
- Department of Toxicology, School of Public Health, Key Laboratory of Environmental Toxicology of Anhui Higher Education Institutes, Anhui Medical University, Hefei, 230032, China
| | - Zhijing Lin
- Department of Toxicology, School of Public Health, Key Laboratory of Environmental Toxicology of Anhui Higher Education Institutes, Anhui Medical University, Hefei, 230032, China.
| |
Collapse
|
50
|
Yang L, Luo L, Zhang YT, Shi DD, Ci ZG, Xiao BS, Yang SQ. [Clinical implications of thrombolytic therapy for patients with acute intermediate-high risk pulmonary embolism in Tibet plateau, China]. Zhonghua Jie He He Hu Xi Za Zhi 2023; 46:924-929. [PMID: 37670647 DOI: 10.3760/cma.j.cn112147-20230413-00172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 09/07/2023]
Abstract
At present, clinical studies and case reports of systemic thrombolytic therapy for patients with acute pulmonary embolism in Tibet Plateau are very rare. There is little understanding of the risk factors, clinical characteristics, and thrombolytic therapy for patients with acute pulmonary embolism at intermediate-high risk in Tibet Plateau. In this paper, we reported the data of 4 patients with acute intermediate-high risk pulmonary embolism treated with thrombolytic therapy in Lhasa People's Hospital. The demographic characteristics, clinical manifestations, treatment, and outcomes were analyzed. We summarized the clinical features and raised scientific issues. We aimed to provide basic data to improve the standardized diagnosis and treatment of acute pulmonary embolism in plateau, and to point out the direction of future clinical research in this field.
Collapse
Affiliation(s)
- L Yang
- Department of Respiratory and Critical Care Medicine, Lhasa People's Hospital, Lhasa Tibet, 850000, China
| | - L Luo
- Department of Respiratory and Critical Care Medicine, Lhasa People's Hospital, Lhasa Tibet, 850000, China
| | - Y T Zhang
- Department of Respiratory and Critical Care Medicine, Lhasa People's Hospital, Lhasa Tibet, 850000, China
| | - D D Shi
- Department of Respiratory and Critical Care Medicine, Lhasa People's Hospital, Lhasa Tibet, 850000, China
| | - Z G Ci
- Department of Respiratory and Critical Care Medicine, Lhasa People's Hospital, Lhasa Tibet, 850000, China
| | - B S Xiao
- Department of Respiratory and Critical Care Medicine, Lhasa People's Hospital, Lhasa Tibet, 850000, China
| | - S Q Yang
- Department of Pulmonary and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing Institute of Respiratory Medicine, Beijing 100020, China
| |
Collapse
|